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A successful pregnancy and the birth of a healthy baby depends to a great extent on the 
controlled supply of essential nutrients via the placenta. Inspired by clinical observations 
and in close collaborations with clinical obstetricians, we focused on the implementation 
of biochemical and cell biological in vitro models to mimick and investigate physiological 
relationships between the human placenta and gestational diseases.  
This work is structured into two clinically based sections studying solute carrier (SLC)-
mediated materno-fetal transport of amino acids and iron across the placenta. The third 
methodologically oriented part describes the attempt to generate placental SLC knockout 
cells. 
The first clinically oriented part investigated the contribution of amino acid transporters 
of the SLC7 family in transplacental transfer of essential amino acids. Na+-independent 
placental leucine transport is mainly attributed to the System L-transporters LAT1/SLC7A5 
and LAT2/SLC7A8. We determined physiological amino acid gradients of paired maternal 
and fetal serum samples by ion exchange chromatography. Subsequently, we assessed 
their importance by performing Spearman correlation analysis between materno-fetal 
gradients determined in vivo and anthropometric parameters. We found significant 
associations between reduced materno-fetal amino acid gradients with maternal 
gestational weight gain and maternal blood pressure suggesting a potential role of amino 
acid gradients in reduced intrauterine growth or even in hypertensive diseases like 
preeclampsia. Functional effects of a physiological gradient versus equimolar leucine 
concentrations were tested using in vitro uptake and Transwell®-based transfer assays. 
Interestingly, materno-fetal leucine transfer was significantly stimulated against a 
counter-directed gradient. These results suggest a currently underestimated effect of 
transplacental amino acid gradients on leucine transfer efficiency and underline their 
potential impact in pregnancy diseases associated with impaired fetal growth. Moreover, 
we investigated the relevance of SLC7 transporter in placental leucine transfer by applying 
the LAT1-specific inhibitor JPH203 and the System L-specific inhibitor JX009 synthesized 
by our collaborators in the NCCR TransCure network. These studies identified LAT1 as the 
major accumulative transporter in the placenta, but other System L-transporters like LAT2 
as rate-limiting for leucine efflux to the fetus.  
Abstract 
 iii 
The second clinical part of this thesis focused on investigating the molecular mechanisms 
of materno-fetal iron transport. Clinical studies suggest that pregnancies with elevated 
iron levels are more vulnerable to develop gestational diabetes mellitus (GDM), but the 
underlying mechanisms are unknown. We found differential regulation of iron 
transporters (DMT1/FPN1/ZIP8), receptors (TfR1), sensors (IRP1), regulators (HEPC) and 
oxidoreductases (HEPH/Zp) by RT-qPCR and by LC-MS/MS-based protein quantification in 
placental tissue from GDM compared to healthy pregnancies. Newly established 
hyperglycemic and hyperlipidemic trophoblast cell models, but also obesogenic HFHS diet 
in wildtype mice, mimicked to a great extent the expression results found in the clinical 
specimens of GDM patients. By expressional and functional assessment of normo-
glycemic, hyperglycemic and hyperglycemic-hyperlipidemic BeWo choriocarcinoma cells, 
we found altered cellular morphology, differential expression of iron transporters and 
reduced iron uptake confirming the impact of hyperglycemia on iron transport as 
observed in GDM patients. Iron depletion by the iron chelator deferoxamine (DFO) 
revealed a bidirectional relationship between placental glucose and iron homeostasis. 
Pathway analysis and rescue experiments indicated that dysregulated oxidative stress and 
autophagy contribute to reduced placental iron transport under hyperglycemic 
conditions. These adaptations are likely mediated by ferroptosis and could represent a 
protective mechanism preventing oxidative damage for both fetus and placenta caused 
by highly oxidative iron levels or hyperglycemia. Thus, in pregnancies with increased risk 
for GDM, antioxidant treatment and controlled iron supplementation could help to 
protect mother and fetus from impaired iron and glucose homeostasis. 
Within the last methodologically oriented part, we aimed to establish an efficient protocol 
to generate CRISPR/Cas9-mediated trophoblast knockout cell lines. Trophoblast cells 
lacking the function of single nutrient transporters would help to unravel their role in 
physiological nutrient transfer or in gestational diseases affecting fetal growth. To date, 
we were not able to successfully generate knockout cell lines by CRISPR/Cas9-
mutagenesis. However, the achieved optimization of target site validation, BeWo 
transfection and characterization procedures of potential CRISPR/Cas9-mutant 
candidates created an advanced toolbox suitable to successfully continue the 
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Introduction - The role of the placenta in gestational pathologies 
 1 
1 Introduction 
The placenta is a vital tissue during pregnancy as it is the connecting organ between the 
fetus and the ex utero world. Furthermore, it is a fetal organ and temporary enables the 
mutual exchange between the embryo and mother. Besides its main function of 
physiological materno-fetal exchange of nutrients and waste products, the placenta is also 
responsible for the prevention of maternal immune rejection as well as for maintaining 
pregnancy through the secretion of gestational hormones. The placenta maintains the 
balance between nutrition and growth control of the fetus through selective and 
regulated supply of macronutrients such as carbohydrates, protein, lipids and critical 
micronutrients like minerals and vitamins (Roos, Powell, and Jansson 2009). The placental 
nutrient transport does not just play a role in fetal development, but also affects the 
newborn’s life by metabolic programming until adulthood (Burton, Fowden, and 
Thornburg 2016). 
This work was focusing mainly on solute carrier (SLC) -mediated materno-fetal transport 
of essential amino acids like leucine and iron as most abundant trace element in the 
human body. Both parts of the current project (amino acid and iron transport) are 
embedded in and profit from the TransCure scientific network (www.nccr-
transcure.ch/research/), in which we tightly collaborate with chemists, structural 
biologists, and physiologists in the field of membrane transporters. 
1.1 The role of the placenta in gestational pathologies  
The latest report published by the Swiss Federal Statistical Office revealed that, the 
prevalence of pregnancies resulting in abnormal fetal growth has been increased by 1.3% 
from 5.9% in 1979 to 7.2% in 2017 (Figure 1). Such altered fetal development has a 
fundamental impact on lifelong health and wellbeing and may contribute by fetal 
programming to later prevalence for cardiovascular disease and diabetes/adiposity 
(Harder et al. 2007; Eriksson et al. 2003; Boney et al. 2005; Leon et al. 1998). Appropriate 
in utero fetal growth is largely dictated by the availability of nutrients in the maternal 
circulation, which is ensured during pregnancy by the capacity of the placenta to transfer 
these nutrients into the fetal circulation. In the framework of the current work, we 
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focused on gestational diabetes mellitus (GDM). Therefore, the hallmarks and 
consequences of this disease will be introduced in detail (see next chapter).  
 
Figure 1: Prevalence of abnormal weight in life births in Switzerland from 1979 until 2017. 
Source: Federal Statistical Office (Bundesamt für Statistik, BSF) - Statistics of Natural Population 
Movement (Statistik der natürlichen Bevölkerungsbewegung, BEVNAT), 2019 
 
1.2 Link between GDM and iron homeostasis 
GDM, defined as any degree of glucose intolerance with onset or first recognition during 
pregnancy, is one of the most common pregnancy complications and has a prevalence of 
4.8% in Switzerland (Orecchio et al. 2014) and 9.2% in the US (DeSisto, Kim, and Sharma 
2014), respectively. Within a swiss cohort study (n= 1042), GDM was strongly associated 
with short-term complications of fetal development and its early life (Crowther et al. 
2005). They observed high birth complication rate, e.g. 6.3% neonatal hypoglycemia, 9.4% 
respiratory distress syndrome and 9.4% jaundice that was far above the incidence in the 
control group and in the general population. Despite considerable progress in diagnosis 
and treatment of GDM, it has still substantial adverse health effects on the mother and 
her offspring. The etiology of GDM is multifactorial. Well known modifiable risk factors for 
GDM include obesity, high fat diet, high blood pressure, excess weight gain in pregnancy, 
endocrine dysfunction and sedentary life style (Lappas et al. 2011). Several clinical studies 
ascertain a positive association between increased serum iron levels and increased risk to 
develop GDM (Bo et al. 2009; Zein et al. 2015; Rawal et al. 2017; Fu et al. 2016; Afkhami-
Ardekani and Rashidi 2009). Zein et al. found ferritin levels at early pregnancy correlating 
positively with glucose levels in oral glucose tolerance tests (oGTTs) (Zein et al. 2015). 
More recently, Rawal et al. associated in a longitudinal and prospective study increased 
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ferritin levels already in gestational week 10-14 with increased risk to develop GDM 
(Rawal et al. 2017). These findings raise potential concerns for the recommendation of 
routine iron supplementation among iron-replete pregnant women. However, the 
pathophysiological association of GDM and elevated maternal iron plasma levels reported 
in clinical studies as well as the underlying mechanism are still unclear.  
Association of GDM-mediated hyperglycemia and placenta iron homeostasis 
Both the hyperglycemic environment and increased levels of iron may play a role in the 
generation of oxidative stress during pregnancy. Oxidative stress occurs when the delicate 
balance between generation of reactive oxygen species (ROS) and production of 
antioxidant neutralizing species, such as nicotinamide adenine dinucleotide phosphate 
(NADPH) and glutathione (GSH), is disturbed. Hyperglycemia raises oxidative stress levels 
through different metabolic pathways. For example, glucose is converted under 
intracellular hyperglycemic conditions to the polyalcohol sorbitol by utilizing intracellular 
NADPH and GSH. Consequently, hyperglycemia induces an overrepresentation of ROS by 
antioxidant depletion (Brownlee 2001). On the other side, excessive iron supplementation 
might expose women to increased lipid peroxidation and protein carbonylation by 
intracellular generation of ROS (Papanikolaou and Pantopoulos 2005; Ziaei et al. 2007). 
Notably, whether hyperglycemia could alter placental iron homeostasis in the placenta 
and increased antioxidant intake could reduce the complications of GDM in both mother 
and fetus has not been explored yet.  
1.3 Development and structure of human placenta 
The placenta is the first organ to be formed in humans and other mammals (Maltepe and 
Fisher 2014). It has a discoidal, flat and round to oval macroscopic appearance. At term, 
which represents the time at the end of pregnancy, approx. 40 weeks post fertilization, 
the average diameter of a human placenta is 22 cm, reaches a thickness of 2.5 cm and has 
a weight of approx. 470 g (Baergen 2005).  
The development of the placenta begins following the attachment of the blastocyst to the 
uterine endometrium of the uterine wall within 6-7 days after fertilization (Figure 2A). At 
the blastocyst stage, the inner cell mass (ICM) and the blastocoel are enveloped by 
mononucleated trophoblasts also called trophectoderm cells at this stage (Cha, Dey, and 
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Lim 2015). The trophoblasts that get direct contact to the maternal endometrium 
immediately start to fuse with the neighboring uterine cells to form the first 
multinucleated syncytiotrophoblasts (STB) (Figure 2A). This process continues until day 
11 after fertilization (Figure 2B), when a complete syncytium surrounds the fully 
implanted blastocyst (Figure 2C) (Sadovsky and Jansson 2015; Turco and Moffett 2019). 
At this stage of human embryonic development, the lacunar stage starts with the 
formation of fluid-filled spaces (lacunas) within the STB cell mass (Figure 2C). These 
lacunas will form the intervillous spaces after further proliferation, branching and filling 
with maternal blood. In parallel, the endometrium proliferates to cover the entire 
implantation site and the ICM cells differentiate to form the embryonal germ layers such 
as the ectoderm, the mesoderm and endoderm that will ultimately form the developing 
fetus, but also the extraembryonic layer of cells that will form stromal structures of the 
placenta (Figure 2D).  
 
Figure 2: The early stages of human placental development. The development of the human 
placenta starts with the implantation of the blastocyst at pre-lacunar stage at approx. 1 week after 
fertilization (A). During the pre-lacunal stage extraembryonic trophoblasts syncytialize and invade 
the endometrium of the uterine wall (B). Syncytiotrophoblasts (STB) completely surround the 
implanted early embryo, while lacunae, the intervillous space precursors, are formed and uterine 
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glands get invaded for histotroph nutrition in the lacunar stage (C). STB grow further into the 
decidua basalis (basal plate) toward the maternal vessels and get penetrated by cytotrophoblasts 
to form primary villi (D). Modified from Turco and Moffett 2019. 
 
Following implantation, the primary syncytium quickly invades through the surface 
epithelium into the underlying endometrium. These invasive extravillous 
cytotrophoblasts penetrate the uterine glands and cells around and within the spiral 
arteries, forming the endovascular trophoblast and transform the contractile spiral 
arteries into noncontractile, constantly dilated arteries (Sadovsky and Jansson 2015). The 
invaded uterine glands secrete vital nutrients and become the first nutrient source for the 
conceptus during the histotrophic first trimester, before the establishment of maternal 
blood flow to the intervillous space of the placenta occurs (Filant and Spencer 2014). To 
connect the early placenta to the circulation of the mother, the STBs interfere with 
maternal capillaries to form a direct connection between the lacunas and maternal blood 
vessels, but they maintain feto-placental hypoxia until the end of the first trimester 
(Jauniaux et al. 2000). Once fully functional, the intra-arterial plug lyses and the 
intervillous space fills with maternal blood and enables oxygenation and hemotrophic 
nutrient transport from the maternal blood to the fetus at around 4 months after 
conception (Turco and Moffett 2019). With the connection of the lacunas to the maternal 
circulation the lacunar stage ends and placental development progresses to the villous 
stage (Figure 2D). First primary villi are formed by cytotrophoblast (CTB) proliferation at 
the wall of the lacunas. Cells of the extraembryonic mesoderm move out (purple cells, 
Figure 2D) and penetrate the primary villi to form the villous cores (secondary villi). 
Proliferating hemangioblastic progenitors of hematopoietic and endothelial cells (EC) 
differentiate within the extraembryonic mesoderm to form the early first fetal capillaries 
and blood cells (Demir et al. 1989). By the third week of gestation tertiary villi have formed 
consisting of an outer monolayer of STB, invaded by an inner layer of CTB cells and 
vascularized with fetal capillaries (Huppertz 2008). Tertiary villi containing differentiated 
blood vessels will eventually form the placental barrier representing the site of nutrient 
exchange until term. 
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1.4 The human placental barrier  
As soon as a feto-placental circulation is established within the placental villi towards the 
end of the first trimester, fetal and maternal blood come into close contact with each 
other. The two bloodstreams are always separated by the placental barrier (Baergen 
2005). The placental or chorionic villi increase the effective surface area and represent 
the functional unit of the placenta, where most transport, metabolic and endocrine 
activities are localized (Figure 3A left panel). Virtually all materno-fetal and feto-maternal 
exchange takes place across the placental barrier of the chorionic villi (Figure 3A middle 
panel with magnification to the right). The chorionic villi are surrounded by STB, a 
multinuclear epithelial surface layer that is in direct contact with the maternal blood 
(Figure 3A right panel and STB in Figure 3D). Between STB and the basal lamina 
(trophoblastic basement membrane) are the villous CTB. CTB are the stem cells of the 
syncytium, supporting its growth and regeneration (Figure 3A violet cells). The basal 
lamina separates the trophoblast from the villous stroma (Figure 3A orange lamina). The 
stroma (intercellular space, pink in Figure 3A) is composed of connective tissue cells, such 
as first mesenchymal cells that differentiate to fibroblasts in the last trimester, connective 
tissue fibers, tissue macrophages (Hofbauer cells) and fetal vessels (Figure 3D) (Baergen 
2005). Interestingly, it is speculated that Hofbauer cells play a role in iron storage and 
homeostasis as described in 1.5.2 on p.19ff.  
There are two important cell layers in the chorionic villi to coordinate the nutrient 
transfer, namely the fetal capillary EC and the STB. The EC form the fetal vessels, which 
allow the unrestricted diffusion of the molecules like glucose and amino acids (peptides 
<204 Da) through the paracellular channels (Edwards et al. 1993; R. M. Lewis et al. 2013). 
In contrast, STB represent the limiting barrier for charged macro- and microelements due 
to the syncytium composed of two polarized plasma membranes, the microvillous plasma 
membrane (MVM) facing towards the maternal side and the basal membrane (BM) 
directed towards the fetal capillary (Figure 3A). However, strikingly little information has 
been published on the molecular transport mechanisms and regulations involved in 
controlling the crucial interface between mother and fetus. Therefore, this project 
investigated the physiology of fetal nutrition, mainly focusing on the STB-mediated 
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materno-fetal transfer of fundamental macromolecules (amino acids) and the most 
abundant trace element (iron).  
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Figure 3: Simplified representation and histological pictures of the human placenta as 
connection between the developing fetus and the maternal circulation separated through the 
placental barrier. Scheme a developing fetus connected via umbilical cord to the placenta (A, left 
panel). Cross section of the placental disk revealing fetal villous structures and the maternal 
interface connecting the intervillous space via spiral arteries and maternal veins to the uterine 
blood supply. A, right panel, closeup of the placental barrier in a chorionic villous as hemochorial 
interface between the fetal capillaries (fetal blood compartment in red) and the maternal 
circulation (maternal blood compartment in orange). The human placental barrier involves three 
different cell types: endothelial cells (EC) lining the fetal capillaries, single-nucleated 
cytotrophoblasts (CTB, violet) and syncytiotrophoblasts (STB, blue) forming a multi-nucleated 
monolayer. The STB are in direct contact with maternal blood and mainly responsible for materno-
fetal nutrient and feto-maternal CO2 and waste product exchange. B-D, histological pictures of 
haematoxylin and eosin (HE) stained placental tissue at term with increasing magnification as 
indicated by the dashed boxes (placental tissue from Malia Zaugg, *20.12.2019). B, section 
through the chorionic plate at the fetal side with macroscopically visible superficial fetal artery 
(vessel cross section with thicker wall) and vein (larger vessel with thinner wall) still containing 
erythrocytes (purple cells) to the right of the picture. C, with a 5 x magnification the intervillous 
space (IVS) filled with erythrocytes and the hierarchy of chorionic villi becomes visible. There are 
large villi with condensed collagen fibers (fibers in magenta) in the stroma histologically called 
stem villi (upper right structure in C and D) making about 20-25% of the placental volume at term, 
but also small and intermediate villi that are long and slender with numerous capillaries. D, beside 
the large stromal villi to the right with completely fibrotic stromal core (magenta), single placental 
cells are visible with 20 x magnification. There are small and intermediate villi with multinucleated 
STB at the borders and fetal capillaries (nuclei in dark blue), stromal and Hofbauer cells in the 
stromal core, but also numerous erythrocytes in the IVS. Green arrows indicate the apical 
microvillous membrane (MVM), i.e. maternal blood orientated side; arrowheads depict the basal 
membrane (BM) of the STB. As is typical for term placentae, the trophoblastic cover of the stem 
villi is partly replaced by fibrinoid. The stromal core is completely fibrotic. Abbreviations: FV, fetal 
vein; FA fetal artery; MV, microvilli; IVS, intervillous space; STB, syncytiotrophoblast; VC, villous 
core; PMNL, polymorphonuclear leukocytes; H, Hofbauer cell; FC, fetal capillary; SC, stromal core. 
 
1.5 Nutrient transport across the placenta 
Human hemochorial placenta represents the structural barrier and prevents the direct 
contact between maternal and fetal blood as explained before in 1.4, which highlights the 
importance of diffusion, endocytosis/exocytosis and transporter-, channel- or facilitator-
mediated mechanisms for nutrient exchange across the materno-fetal interface (Figure 
4).  
Passive transport 
Nutrients can be transferred across epithelial barriers either between STB cells via 
intercellular water-filled pores (paracellular transport) or through cells (transcellular 
transport) by diffusion (Figure 4, left panel). Simple diffusion is the adenosine 
triphosphate (ATP) -independent passage of molecules across lipid bilayers of the cell 
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membranes and the cytoplasm in-between. For small uncharged molecules, the rate of 
diffusion is governed by Fick’s Law of diffusion, being proportional to the surface area for 
exchange and inversely proportional to the thickness of the placental barrier. Small 
hydrophobic molecules cross cell membranes easily, so their transplacental flux depends 
principally on the concentration and electrochemical gradient. The main factor 
maintaining such a gradient is the rate of blood circulation on both sides of the 
membrane, refreshing and depleting the donating and receiving pools respectively 
(Burton, Fowden, and Thornburg 2016). Hence, exchange of molecules such as the 
respiratory gas O2 and lipophilic drugs are flow-limited, thus changes in maternal or fetal 
blood flow have a strong impact on their net flux (Wilkening and Meschia 1992).  
Since the STB represent a true syncytium, no intercellular spaces exist in the transporting 
epithelium of the human placenta. However, there are evidences for transtrophoblastic 
channels (Figure 4, second from left), pores filled with water traversing the 
syncytiotrophoblast revealed by electron microscopy and by physiological data obtained 
in several species with hemochorial placentae, demonstrating that the transplacental flux 
of small inert hydrophilic molecules is proportional to their water diffusion coefficients 
(Kertschanska, Kosanke, and Kaufmann 1997). Although STB are able to generate and 
maintain significant concentration differences for a large variety of molecules across the 
placental barrier, including Ca2+ and amino acids, the transfer of large molecules such as 
alpha-fetoprotein across perfused placental cotyledons ex vivo are confirming the 
existence of transtrophoblastic channels (Brownbill et al. 1995). Occasional membrane 
clefts and ruptures resembling intercellular spaces have been reported, but may 
represent areas of repair associated with fibrin deposits. However, the primary route of 
transport across the placental barrier for nutrients and important ions is in most cases 
conveyed by specific solute carrier-mediated transport mechanisms (Sadovsky and 
Jansson 2015). 
Active transport 
The transplacental transfer of most nutrients and ions is dependent on carrier proteins 
spanning the cell membranes to facilitate the passage of highly hydrophilic molecules 
(Figure 4, middle panel). They are characterized similar to enzymes by features such as 
substrate specificity, saturation kinetics, and the ability to be inhibited. When mediated 
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membrane transport does not require energy, the transport is termed facilitated 
transport, while active transport implies that energy is consumed usually by ATP 
hydrolysis. Transport mechanisms are generally classified as direct primary active 
transport, indirect secondary active or indirect tertiary active transport. The most 
common pathway for regulated nutrient transport in the placental barrier is via 
transporter proteins in the STB plasma membranes. Materno-fetal glucose transfer 
mediated by facilitative glucose transporters (GLUT1) expressed in the MVM and BM of 
the STB is an example of facilitated transport (such as depicted in green Figure 4). Calcium 
efflux across the BM, mediated by calcium (Ca2+)-ATPase, is an example of primary active 
transport. Sodium (Na+)-dependent transport systems for amino acids, such as System A, 
represent a secondary active transport mechanism and hence the tertiary active like 
System L transport of large neutral amino acids is maintained by System A dependent 
amino acids gradients (see 1.5.1 on p.12). Transplacental transport may also be facilitated 
by the expression of substrate binding proteins such as fatty acid-binding proteins in the 
STB cytosol (Sadovsky and Jansson 2015). Of note, there is evidence of great clinical 
relevance indicating that expression of transporter systems is responsive to nutritional 
and hormonal stimuli. This flexibility allows the placenta to adapt functionally by insertion 
of transporter proteins into the appropriate membrane (Winterhager and Gellhaus 2017; 
Thomas Jansson and Powell 2007). 
Transcytosis 
Receptor-mediated or passive intracellular vesicle formation occurs by invagination of the 
apical or basolateral side plasma membrane of STB. Subsequently, vesicles may be 
transported to the opposite side of the cell, where the vesicle content can be released 
into the extracellular space following fusion of the vesicles with the plasma membrane 
(Figure 4, right panel). In non-mediated endocytosis and transcytosis vesicles are formed 
at the plasma membrane incorporating fluid and any dissolved solute. Vesicles from non-
mediated endocytosis are transferred across the syncytium via Brownian movement 
(Sadovsky and Jansson 2015). Mediated endocytosis involves the binding of a specific 
ligand to a receptor in the plasma membrane, which initiates the clathrin-mediated 
invagination of the plasma membrane. Transfer of vesicles formed by mediated 
endocytosis across the cytoplasm is guided by intracellular trafficking and specific 
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cytoskeletal components, respectively (R. Fuchs and Ellinger 2004). Transcytosis plays an 
important role in the transfer of immunoglobulin G (IgG), iron (see 1.5.2 on p.19), and 
lipoproteins across the placental barrier. Large molecules such as IgG and cholesterol are 
transported by transcytosis as third class of mechanisms for transplacental transport 
(Figure 4). IgG binds to the MVM of the STB surface, concentrates in clathrin-coated pits 
or is internalized through non-mediated endocytosis, and delivered to early endosomes 
(Henning Schneider and Miller 2010). Uptake of maternal proteins by endocytosis has 
been described for megalin-mediated albumin endocytosis in the human STB (Lambot et 
al. 2006) and is particularly prominent during the histotrophic period in the first trimester 
when maternal glycoproteins are secreted by the endometrial glands (Burton et al. 2002).  
 
Figure 4: Schematic representation of the general nutrients transport mechanisms in the human 
placenta. The three main processes by which materials such as gases, ions, water, sugars, amino 
acids, lipids, vitamins and minerals, but also drugs and xenobiotics can cross the placental barrier: 
diffusion, transporter-mediated, and endo-/exocytosis. Transcellular non-mediated (dashed 
arrow) and transtrophoblastic channel-facilitated diffusion are depicted to the left. Solute carrier- 
or transporter-mediated transport often form interactive transport systems, that are composed 
of channels or facilitators (green), co-transporter (grey) and gradient-dependent exchanger 
(orange), which are ultimately driven by ATPase activity (yellow). Transcytosis is mediated by 
clathrin-dependent endocytosis, intracellular trafficking, and exocytosis (right panel). Modified 
from (Burton, Fowden, and Thornburg 2016). 
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1.5.1 Amino acid transport 
Beside representing the fundamental building components required for fetal protein 
synthesis, amino acids constitute critical precursors for the biosynthesis of porphyrins, 
nitric oxide, neurotransmitters and nucleotides. It is estimated that 32% of the energy 
requirement of well-nourished fetal sheep is derived from amino acid oxidation and used 
as fetal energy source (Faichney and White 1987). Comparable amino acid oxidation 
estimates were published in humans. In two studies healthy pregnant women received 
continuous stable isotope infusions of the essential amino acids 13C-leucine, 13C-valine, 
15N-phenylalanine and 13C-methionine 4 h before elective cesarean section. Then the 
enrichment and concentration of amino acids and carbon dioxide was measured in cord 
blood. Fetal whole-body accretion of leucine carbon was 69% of the umbilical uptake. 
Both studies estimated that 33-40% of total leucine carbon uptake is oxidized, although 
whole-body protein synthesis was much faster in the fetus than in adults (Van Den Akker 
et al. 2011; Chien et al. 1993). 
The role of amino acid concentrations in placental transport 
Appropriate fetal growth is largely dictated by the availability of amino acids in the 
maternal circulation, which is ensured during pregnancy by the capacity of the placenta 
to transfer amino acids from the maternal into the fetal circulation (Frederick C. Battaglia 
and Meschia 1988; Vaughan et al. 2017). For most amino acids, the concentrations in the 
umbilical vein are two- to threefold higher than in the uterine vein, demonstrating that 
the transfer of amino acids is an active energy-dependent process against counter-
directed feto-maternal gradients (Philipps et al. 1978; Irene Cetin et al. 1990; Thomas 
Jansson 2001; Jane K. Cleal and Lewis 2008). This is also supported by the observation that 
placental concentrations of amino acids are, in general, much higher than in the blood on 
either side of the placental barrier (Philipps et al. 1978). Already in 1973 Hill et al. 
demonstrated in placenta perfusion experiments in guinea pigs that System L-mediated 
materno-fetal leucine transfer was two-fold increased after application of feto-maternal 
gradients (Hill and Young 1973). However, extrapolation of results from animal 
experiments to humans must be done with caution, specifically as the structure and 
anatomy of the human placenta is quite unique among mammals (Schmidt et al. 2015). 
To our knowledge, no human trophoblast studies have assessed the functional effect of 
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counter-directed amino acid gradients on transplacental amino acid transfer in vitro. 
There are few studies that investigated materno-fetal amino acid transfer under different 
physiological and pathological conditions in vivo. This was performed by measuring amino 
acid concentration differences between fetal arterial and fetal venous sera obtained from 
umbilical cord blood and/or from the uteroplacental unit in the maternal circulation 
(Pohlandt 1978; Malinow et al. 1998; McIntosh, Rodeck, and Heath 1984; Irene Cetin et 
al. 1988; Karsdorp et al. 1994; Irene Cetin et al. 2005; Bajoria et al. 2001; Cockburn et al. 
1971). Such observational correlation studies revealed interesting associations by 
comparing paired amino acid concentrations in maternal radial artery and uterine vein 
with fetal umbilical vein and artery sides with each other (Holm et al. 2017). However, 
potential relationships between amino acid gradients and demographic data such as 
maternal constitution or fetal growth have not been reported yet.  
Transplacental amino acid transport 
Amino acid transporters expressed in human placenta are categorized into accumulative 
transporters, exchangers and facilitators (Table 1). Accumulative transporters mediate 
cellular uptake, resulting in increased intracellular amino acid concentrations. Amino acid 
exchangers exchange one amino acid for another, resulting in altered amino acid 
composition without changing total concentration (S. Bröer 2002). The primary driving 
force for amino acid uptake across the MVM mediated by accumulative cotransporters is 
the extra-intracellular directed Na+ gradient exploited by Na+-dependent System A and 
taurine transporter families (see Table 1). The difference of the membrane potential is 
the driving force mediating uptake of the cationic amino acids (arginine, histidine, and 
lysine) by System y+, y+L or b0,+ families (see first section in Table 1). The System L-amino 
acid transporters LAT1, LAT2, LAT3 and LAT4 are exchangers using the outwardly directed 
concentration gradients of nonessential amino acids as tertiary active mechanism to drive 
the uptake of essential amino acids (e.g. leucine), against its counter-directed 
concentration gradient (Figure 5). The energy for the uphill transport of amino acids is 
ultimately generated by the Na+K+-ATPase, which extrudes sodium in exchange for 
potassium, thereby maintaining a low intracellular Na+ concentration and creating a 
potential difference across the plasma membrane (Johansson, Jansson, and Powell 2000). 
Subsequently, amino acids are transferred across the BM by non-mediated or facilitated 
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diffusion driven by the intra-extracellular directed concentration gradient (see more 
details in the next paragraph). Although the amino acid uptake mechanisms and 
interactions across the MVM into the STB are well studied, the mechanisms by which 
amino acids are transported out of the STB towards the fetal circulation across the BM 
and the ratio to which amino acids are metabolized by the human placenta are not well 
elucidated yet (Jane K. Cleal and Lewis 2008; J. K. Cleal et al. 2011). The asymmetric 
distribution of amino acid transporters between the STB MVM and BM is critical to 
generate a net materno-fetal flux of amino acids. Of note, the human STB expresses at 
least 20 different amino acid transporters (Table 1), with each transporter mediating the 
uptake of several amino acids, and each amino acid can be transported by multiple 
transport systems (Sadovsky and Jansson 2015). Computational modelling of amino acid 
transfer demonstrated the importance and interrelation of amino acid gradients by 
considering separate maternal and fetal compartments and specific kinetic properties of 
accumulative and exchanging amino acid transporter systems (Sengers, Please, and Lewis 
2010). Although there is a well-known interdependence between Na+ and different amino 
acid transport systems depending on co-substrate gradients, no human trophoblast 
studies have assessed the functional effect of counter-directed materno-fetal amino acid 
gradients on transplacental transfer of essential amino acid so far. 
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Table 1: Amino acid transport systems in the human placenta, modified and updated from (Sadovsky and Jansson 2015) 
System  Activity  Protein Gene Transport type* Localization  Substrates  Ref. 
Na+-dependent transporters for neutral amino acids 
   
A  MVM ≫ BM  SNAT1 SLC38A1 CoT / Na+ MVM  (Gly), Ala, Ser, Cys, Gln, Asn, His, (Met), MeAIB [1-3]   
SNAT2 SLC38A2 CoT / Na+ MVM  Gly, Pro, Ala, Ser, Cys, Gln, Asn, His, Met, MeAIB  [4]   
SNAT4 SLC38A4 CoT / Na+ MVM, BM  Gly, (Pro), Ala, Ser, Cys, Asn, (Met), (MeAIB)  [4] 
ASC  BM MVM?  ASCT1 SLC1A4 CoT / Na+, ExT / AA 
 
Ala, Ser, Cys, Thr [1]   
ASCT2 SLC1A5 CoT / Na+, ExT / AA 
 
Ala, Asn, Ser, Cys, Thr, Gln  [3] 
B0  ? B0AT1 SLC6A19 
 
nd  neutral amino acids; Ala, Asn, Cys, Gln, Gly, Ile, Leu, Met, 





nd  large, neutral amino acids  
N  MVM?  SNAT3 SLC38A5 CoT / Na+, ExT / H+ nd  Ala, His, Gln, Asn  [7]   
SNAT5 SLC39A3 CoT / Na+, ExT / H+ nd  Asn, Gln, His, Ser [8] 
Gly  MVM  XT2 SLC6A18 
 
nd  Gly  [9] 
β  MVM ≫ BM  TauT SLC6A6 
 
MVM, BM  Tau, β-ala  [10,11] 
Na+-independent transporters for neutral amino acids 
   
L  MVM, BM  
LAT1 SLC7A5 




LAT2 SLC7A8 ExT MVM (50 kD) 
BM (30 kD)  
Ala, Ser, Cys, Thr, Asn, Gln, His, Met, Leu, Iso, Val, Phe, Tyr, 
Trp, T3, T4, BCH 
[3] 
 
BM?  LAT3 SLC43A1 FaT  BM  L-BCAAs, amino alcohols [12,13]  
BM?  LAT4 SLC43A2 FaT  BM  Phe, Leu, Iso, met, BCH  [14]  
BM? TAT1 SLC16A10 FaT  BM Phe, Leu, T3, T4 [13] 
Transporters for cationic amino acids 
  
  
y+  MVM>BM  CAT1 SLC7A1 FaT (non-obligatory ExT) BM  Arg, Lys, His  [15]   
CAT2B SLC7A2 FaT  nd  Arg, Lys, His  [16]   
CAT3 SLC7A3 FaT  nd  Arg, Lys     
CAT4 SLC7A4 OrT nd  Arg, Lys, ornithine  
y+L  BM>MVM  y+LAT1 SLC7A7 ExT / Na+, Arg, Lys, His nd  Arg, Lys, His (Na+ indep.); Gln, Met, Leu (Na+ dep.) [15]   
y+LAT2 SLC7A6 ExT / Na+, Arg, Lys, His nd  Lys, Arg, Gln, His, met, Leu,a Ala, Cys [16] 
b0,+ BM? b0,+ AT SLC7A9  nd Lys, Arg, Ala, Ser, Cys, Thr, Asn, Gln, His, Met, Iso, Leu, Val, 
Phe, Tyr, Trp 
 
Transporters for anionic amino acids 
  
  
X−AG  MVM, BM  EAAT1 SLC1A3 CoT / Na+, H+, K+ nd  Glu, Asp, Cys  [17]   
EAAT2 SLC1A2 CoT / Na+, H+, K+ nd  Glu, Asp  [18]   
EAAT3 SLC1A1 CoT / Na+, H+, K+ nd  Glu, Asp   
References: [1] (L. W. Johnson and Smith 1988), [2] (Michelle Desforges et al. 2009), [3] (Hoeltzli and Smith 1989), [4] (Schiöth et al. 2013), [5] (Pramod et al. 
2013), [6] (Lassance et al. 2015), [7] (Peter I. Karl, Tkaczevski, and Fisher 1989), [8] (Novak and Beveridge 1997), [9] (Dicke et al. 1993), [10] (Miyamoto et al. 
1988), [11] (Norberg, Powell, and Jansson 1998), [12] (Kudo and Boyd 2001), [13] (J. K. Cleal et al. 2011), [14] (Jane K. Cleal et al. 2007), [15] (Furesz, Moe, and 
Smith 1995), [16] (Ayuk et al. 2000), [17] (Hoeltzli et al. 1990), [18] (Moe and Smith 1989); *Abbreviations for transport type: CcT: Cotransporter; ExT: 
Exchanger; FaT: Facilitated transporter; OrT: Orphan transporter. 
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System L mediated leucine transport across the placenta 
The System L amino acid transporters are a Na+-independent exchanger family that 
mediates cellular uptake of essential amino acids, such as leucine, methionine and 
tryptophan. Since no accumulative transporters that transport essential amino acids are 
expressed in the MVM, System L exchange of nonessential amino acids in the STB cytosol 
with extracellular essential amino acids is critical for the uptake of essential amino acids 
across the MVM (Sadovsky and Jansson 2015). The Na+-independent System L-
transporters expressed in the human placenta are heterodimeric exchangers consisting of 
the light chain L-type amino acid transporter 1 (LAT1 / SLC7A5) or L-type amino acid 
transporter 2 (LAT2 / SLC7A8), responsible for amino acid transport, covalently attached 
to the heavy chain 4F2 (SLC3A2), important for trafficking of the light chain to the plasma 
membrane (Fotiadis, Kanai, and Palacín 2013). Moreover, the SLC43-family members LAT3 
(SLC43A1) and LAT4 (SLC43A2), known to be involved in facilitated amino acid diffusion 
(Bodoy et al. 2013; J. K. Cleal et al. 2011), are expressed at the BM (Table 1). As depicted 
in Figure 5, LAT1 and LAT2 are predominantly localized at the MVM of human term 
placenta, LAT2 is also present at the BM and in endothelial cells lining the fetal capillaries 
(Gaccioli et al. 2015). Kudo and Boyd have suggested that LAT1 expression at the MVM 
mediates System L activity across the placental barrier (Kudo and Boyd 2001), whereas 
Lewis et al. have shown LAT2 as the predominant transporter in the MVM (R. M. Lewis et 
al. 2007). The efflux transporters LAT3 and LAT4 are expressed in the placenta, and LAT4 
has been demonstrated to be functional in isolated perfused human placental cotyledons, 
suggesting that the System L facilitators LAT4 and probably also LAT3 may also play a role 
in the efflux of certain essential amino acids across the BM (Jane K. Cleal et al. 2007). 
In the last decade, increasing evidence suggests a tight link between the reduced activity 
of placental System L-transporters and intrauterine growth restriction (IUGR) (Paolini et 
al. 2001; Lager and Powell 2012), and their upregulation in placentae of large for 
gestational age (LGA) infants (Thomas Jansson et al. 2002). Such altered fetal 
development has a fundamental impact on lifelong health and wellbeing, and may 
contribute by fetal programming to an increased prevalence for cardiovascular disease 
and diabetes/adiposity later in life (Harder et al. 2007; Eriksson et al. 2003; Boney et al. 
2005; Leon et al. 1998). Notably, it has been reported that LAT1 or its associated 
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glycoprotein 4F2hc is involved in placenta decidualization and fusogenic trophoblast 
differentiation (Ohgaki et al. 2017). This could imply that the diminished leucine uptake 
found in knock-down cell models (Balthasar et al. 2017) results rather from failure in 
trophoblast differentiation than from reduced SLC7 transport activity. Hence, small 
molecules which induce only short-term inhibition of transporter activity are a valuable 
experimental tool to study placental transfer mechanisms as they will not affect 
trophoblast differentiation and associated processes like trophoblast fusion. Therefore, 
studying placental amino acid transfer by using specific small molecule inhibitors of amino 
acid transporters instead of silencing or knock-out could help to reveal the relevance of 
LAT1 or LAT2 in materno-fetal leucine transfer without affecting cell differentiation. Since 
LAT1 was found to be selectively expressed and upregulated in various rapidly 
proliferative cancer types (Häfliger and Charles 2019; B. C. Fuchs and Bode 2005; Kaira et 
al. 2008) and has a putative role in drug delivery across the blood-brain barrier (Peura et 
al. 2011), efforts have been made to pharmaceutically target this transporter using 
substrate-mimicking or virtual screening approaches (Singh et al. 2019; Augustyn et al. 
2016; Geier et al. 2013; Kongpracha et al. 2017; Scalise et al. 2018). The substrate-
mimicking tyrosine analog JPH203 (also known as KYT-0353) was tested in several in vitro 
and in vivo cancer cell proliferation experiments and described as potent LAT1-specific 
inhibitor (Enomoto et al. 2019; Cormerais et al. 2019; Muto et al. 2019; Häfliger et al. 
2018; Yothaisong et al. 2017). To delineate the contribution of LAT1 from LAT2 in 
materno-fetal leucine transport, the collaborating chemists within the NCCR TransCure 
network synthesized the LAT1-specific inhibitor JPH203, the structurally closely related 
inhibitor JG336 and two other small molecule inhibitors (JX009, JX020) with high leucine 
uptake inhibition efficiency but lower LAT1-specificity (structures see Figure 22 on p.85). 
To our knowledge, no human trophoblast studies have tried to dissect transporter 
interplay by application of transporter selective small molecule inhibitors or transporter 
targeted Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) /CRISPR-
associated endonuclease (Cas9) mutagenesis for the generation of SLC knockout cell lines. 
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Figure 5: Asymmetric expression of amino acid transporters allows leucine transfer across the 
human placenta against a counter-directed gradient. The uptake of the essential amino acid 
leucine (Leu) from the maternal circulation across the microvillous membrane (MVM) into the 
syncytiotrophoblast (STB) represents the active step of amino acid transport and is mediated by 
accumulative System A transporters (green) in the interplay with amino acid exchangers 
(LAT1/SLC7A5 in red, LAT2/SLC7A8 in yellow). System A transporters mediate cellular uptake 
across the MVM, resulting in increased intracellular concentrations of non-essential amino acid 
like glutamine (Gln). On the other hand, amino acid exchangers like LAT1 and LAT2, both expressed 
at the MVM, exchange one branched-chain amino acids (BCAA, like Leu) for another (in this case 
Gln), resulting in altered amino acid composition without changing the total intra-extracellular 
concentration. The driving forces for the amino acid uptake mediated by accumulative 
transporters are the inwardly directed Na+ gradient that is ultimately maintained by the Na+/K+-
ATPase (grey). System L exchangers use the extracellularly directed concentration gradient of 
nonessential amino acids (NEAA) to drive the uptake of Leu against its materno-fetal 
concentration gradient. Finally, Leu is transferred across the BM by facilitators like LAT3-, LAT4- 
or potentially TAT1-mediated diffusion driven by the extracellularly directed concentration 
gradient on the fetal side. The font size of the amino acid in the 3-letter code represents an 
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estimation of their relative concentration in the fetal (left in pink and red), intracellular (middle in 
blue) and maternal (right in orange) compartment. 
1.5.2 Iron transport 
In humans, the iron requirement during pregnancy is significantly higher in comparison to  
the nonpregnant state to fulfill fetal and placental iron needs (Figure 6). As pregnancy 
progresses, iron requirements for fetal growth rise steadily in proportion to the weight of 
the fetus. Although, the requirements of iron are even lower in the first trimester, if 
compared to the nongravid state, around 80% of the gestational iron requirements are 
accumulating during the third trimester upon term (Thomas H. Bothwell 2000). All iron 
homeostasis genes known to be expressed in human placenta are listed in Table 11 on 
p.91. 
 
Figure 6: Estimated daily iron requirements during pregnancy in a 55 kg woman from (Thomas 
H. Bothwell 2000). Although reduced during the first trimester, iron requirements rise to 4-6 mg 
in the second and third trimesters, respectively. Major changes in the red blood cell mass start in 
the middle of the second trimester, iron requirements may reach as much as 10 mg/d during the 
last 6-8 weeks of pregnancy (T H Bothwell et al. 1979). Irrespective of the exact value, it is apparent 
that daily iron requirements cannot be met from dietary absorption alone in the latter part of 
pregnancy, even from the most optimal diet. In diets containing large quantities of bioavailable 
iron, e.g. diets with generous quantities of meat, poultry, fish and foods containing high amounts 
of ascorbic acid, overall iron absorption is usually 3-4 mg/d and, at most, 5 mg/d (T H Bothwell et 
al. 1979). The amount of iron absorbed is much lower when the diet contains only small amounts 
of bioavailable iron, as is often the case in many developing countries where the staple food is 
cereal and the intake of meat and ascorbic acid is limited (Thomas H. Bothwell 2000). 
 
Introduction - Nutrient transport across the placenta 
20 
Iron uptake at the maternal side across the microvillous membrane 
Since there is no possibility in human placenta to secrete iron across the MVM into the 
maternal circulation, placenta mediated fetal iron homeostasis is controlled exclusively 
by regulating iron uptake. Figure 7 depicts the pathways of transplacental iron transport 
in humans. Transferrin (Tf) -iron is the major, if not the only maternal iron source for 
placental transfer. Tf receptor 1 (TfR1) is a homodimeric transmembrane protein with 
high affinity for diferric Tf (2Fe3+-Tf). Expressed in virtually all cells except mature 
erythrocytes, TfR1 is found at extraordinarily high levels in STB. This is probably the 
reason, why TfR1 was first isolated in placental tissue (Seligman, Schleicher, and Robert 
1979). Despite the likely importance of TfR1, the mechanism of iron transport in the 
placenta remains poorly characterized, partly because of the lack of in vitro models that 
mimic the polar iron physiology of the placental STB (C. Cao and Fleming 2016). 
Immunohistochemical studies have localized TfR1 and Tf to the apical membrane of 
syncytiotrophoblasts in clathrin-coated endosomes (Booth and Wilson 1981). The 
disruption of endosomal acidification after endocytosis by the weak base chloroquine 
inhibits placental accumulation (promoting H+-dependent DMT1) and fetal transfer of Tf-
iron, demonstrating the requirement of acidification in Tf-iron utilization in the classic Tf 
cycle (Contractor and Eaton 1986).  
In endosomes of erythrocytes, ferric iron (Fe3+) is reduced to ferrous iron (Fe2+) by the 
ferrireductase six-transmembrane epithelial antigen of the prostate 3 (STEAP3) and is 
subsequently transported across the endosomal membrane by divalent metal transporter 
1 (DMT1/SLC11A2). Although there is still a lack of experimental proof, STEAP3 and DMT1 
play probably essential roles in the placenta (C. Cao and Fleming 2016). Of note, the 
alternative ferrireductase candidate STEAP4, a homolog of STEAP3, is also highly 
expressed in the human placenta (Ohgami et al. 2006).  
Beside DMT1 there are also alternative ferrous iron transporter that mediate endosomal 
iron export from the endosome into the cytosol. DMT1 is critical for endosomal iron 
release in erythrocytes and in enterocytes (Veuthey and Wessling-Resnick 2014). There 
are in vivo studies suggesting DMT1 as not exclusive endosomal iron exporter, as 
demonstrated in the two DMT1 mutant animal models microcytic anemia (mk) -mouse 
and Belgrade-rat (Tabuchi et al. 2000; Veuthey and Wessling-Resnick 2014; Farcich and 
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Morgan 1992). Due to viable but severely anemic birth of Dmt1-null mice, the role of 
DMT1 in placental iron transport requires further experimental confirmation (Gunshin et 
al. 2005). Other potential endosomal iron transporters with high expression in the human 
placenta are Zrt- and Irt-like protein 8 (ZIP8/SLC39A8) and Zrt- and Irt-like protein 14 
(ZIP14/SLC39A14), both members of the SLC39 zinc (Zn2+/(HCO3-)2) transporter family that 
also transport ferrous iron (Fe2+) (Jenkitkasemwong et al. 2012). ZIP14 has been shown to 
mediate plasma membrane uptake of non-Tf-bound iron (Liuzzi et al. 2006) as well as Tf-
iron from endosomes (Zhao et al. 2010). Targeted Zip14 mutants have no abnormal birth 
phenotype except lower birth weight (Hojyo et al. 2011), while deletion of Zip8 in mice 
leads to complete mortality before birth (Wang et al. 2011). Despite different pH-
dependence, ZIP14 and ZIP8 together with DMT1 probably play redundant roles in 
placental endosomal iron export.  
Finally, there is discrepancy of ferritin expression in STB. There are reports showing a lack 
of expression (Bastin et al. 2006; Maymon et al. 2000), while others demonstrate some 
staining for a placental-specific ferritin heavy chain (FHC) homolog (Brown et al. 1979; 
Yasemin et al. 2011). This discrepancy may be due to the use of inadequate antibodies 
reacting differentially with each ferritin isoform. However, fetal villous stromal cells 
consistently show pronounced ferritin staining in all studies cited above (Bastin et al. 
2006; Maymon et al. 2000; Brown et al. 1979; Yasemin et al. 2011). This raises the 
possibility that the villous stroma may serve as a buffer between the STB and fetal 
circulation to ensure adequate, but not excessive, iron supply. Whether synthesis and 
degradation of ferritin in the stromal cells respond to fetal iron demand is unknown (C. 
Cao and Fleming 2016). The function of the villous macrophages, known as Hofbauer cells 
(see in histological picture Figure 3 on p.8), is not well defined but may include the support 
of trophoblast differentiation, stromal development, angiogenesis and erythroid cell 
maturation (Tang et al. 2011; Van Handel et al. 2010). Interestingly, Hofbauer cells express 
most of the major heme and nonheme iron transporters and storage proteins (Bastin et 
al. 2006; Georgieff et al. 2000), suggesting a role in iron transport and/or regulation (Van 
Handel et al. 2010). Therefore, Hofbauer cells may serve as the temporary iron storage 
buffer in the villous stroma, storing iron when maternal supply exceeds fetal demands and 
releasing iron when iron supply is low.  
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Although, it can be inferred that TFR1, DMT1, STEAP3, ZIP8 and ZIP14 are essential for 
iron uptake in the placenta, experiments designed to exactly localize and functionally test 
this hypothesis are still lacking.  
Iron efflux at the fetal side across the basal membrane 
Iron export from the STB to the fetal stroma is mediated by the iron exporter ferroportin 
1 (FPN1/SLC40A1). FPN1 is abundantly expressed along the BM of human STB (Bastin et 
al. 2006) Mouse embryos with a hypomorphic mutation leading to a reduced expression 
of Fpn1 are severely iron deficient at embryonic day 12.5 (E12.5) 12.5 and exhibit defects 
in neural tube closure and forebrain patterning (Mao et al. 2010), strongly suggesting a 
role of Fpn1 in materno-fetal iron transport. Additionally, an iron-responsive elements 
(IREs) deletion in the Fpn1 untranslated region (UTR) results in dysregulation of Fpn1 in 
organogenesis of multiple organs and markedly reduced FPN1 protein expression in the 
mouse placenta, causing severe anemia and iron deficiency in embryonic tissue at birth 
(Mok et al. 2004). These results strongly suggest that Fpn1 expression and function at the 
materno-fetal interface is essential for normal embryonic development. Although all 
mouse studies suggest an essential role of Fpn1 in placental iron transfer, to our 
knowledge, there are no articles investigating iron efflux across the BM of STB towards 
the fetal circulation.  
Iron must be re-oxidized to the ferric state (Fe3+) before being able to be bound by Tf. The 
three multicopper ferroxidases ceruloplasmin (CP), hephaestin (HEPH), and zyklopen 
(Zp/HEPHL1) have been detected in placental tissue (see Table 11 on p.91). CP is a soluble 
copper-dependent ferroxidase that facilitates iron efflux and was detected by 
immunohistochemical staining in STB and fetal capillaries (Guller et al. 2008). 
Unexpectedly, Cp-null animals exhibit a normal phenotype at birth, suggesting that Cp is 
not essential for placental iron transfer (Harris et al. 1999). HEPH has not been localized 
to human placenta, but expression of HEPH mRNA has been detected and quantified in 
BeWo cells (Y. Q. Li et al. 2012). In 2010, an international group with scientists from the 
US, UK, China and Lebanon identified a placenta-specific ferroxidase in connection with 
sex-linked anemia (SLA) -mice harboring a mutation in Heph. Interestingly, they proposed 
the name “zyklopen” (Zp) after the mythical one-eyed iron workers called cyclops in Greek 
mythology who helped Hephaestus, Hera's parthenogens child and blacksmith of the gods 
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in Olympia (Chen et al. 2010). Zp has approximately 50% protein identity with CP and 
HEPH, and contains a transmembrane domain and an extracellular ferroxidase domain 
with appropriate topology to interact with FPN1 (Chen et al. 2010). Absent in liver and 
intestine, Zp is abundantly expressed in the placenta and has been localized to the 
labyrinth, spongiotrophoblasts and yolk sac of mouse placenta (Chen et al. 2010). 
Furthermore, the intracellular iron chaperone protein poly(rC)-binding protein 2 (PCBP2) 
was suggested to act as a recipient of iron from DMT1 and as a donor of iron to FPN1 
based on localization using confocal microscopy and binding studies using pulldown 
techniques (Yanatori et al. 2016). Since iron is potentially toxic because it catalyzes the 
generation of ROS, the carrying-over of iron by chaperons like PCBP2 could be relevant 
for protection of fetal tissue from putative oxidative ferrous iron and for iron release at 
the placental barrier across the BM (C. Cao and Fleming 2016). Stunningly, there are 
evidences that all 3 ferroxidases and the chaperon PCBP2 are expressed in the human 
placenta, but little has been experimentally investigated regarding their functions in the 
iron transport mechanism across the placenta. 
Non-transferrin-bound iron transport 
As indicated before, there is no proof whether Tf-mediated iron uptake is the exclusive 
pathway for placental iron acquisition. Therefore, other circulating forms of iron such as 
free non-Tf-bound iron and heme iron could be taken up by the placenta as well. Although 
global deletion of Tfr1 in mice leads to embryonic lethality by day of embryonic 
development (E)12.5, some Tfr1-/- embryos were still able to develop hemoglobin-
containing erythrocytes upon E10.5 (Levy et al. 1999), suggesting that the Tf cycle may 
not be essential for erythropoiesis during early development. Furthermore, it is unclear 
whether anemia in Tfr1-/- embryos is due to insufficient placental iron transport or to 
defects in erythroid iron uptake or both. Tissue-specific knockout of Tfr1 in the placenta 
would be needed to answer this question.  
Electron microscopy of placental villi from radio-labeled ferritin-injected animals showed 
ferritin-containing endosomes (Lamparelli et al. 1989) and ferritin accumulation in the 
basement membranes (Thornburg and Faber 1976) suggesting ferritin endocytosis and 
transport in the placenta. Li et al. found that scavenger receptor class A member 5 
(SCARA5) conveys serum ferritin binding and then stimulates its endocytosis from the cell 
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surface with consequent iron delivery into ureteric bud tips of the kidney (J. Y. Li et al. 
2009). However, the molecular mechanism of ferritin endocytosis by STB the relevance of 
this process to maternal delivery of iron to the fetus is unknown yet.  
Finally, the placenta may be able to utilize heme iron sources, as suggested by its high 
expression of heme iron transporters and heme catabolic enzymes (see Table 11 on p.91). 
The recent finding that the placenta represents a major hematopoietic organ that 
supports hematopoietic stem cell development, was shedding light on placental heme 
pathways (Lee et al. 2010). Therefore, several heme iron homeostasis proteins, including 
lipoprotein receptor-related protein 1 (LRP1), heme carrier protein 1 (HCP1), heme 
oxygenase 1 and 2 (HO1 / HO2), have been localized to the STB and/or stroma. Very 
recently scientist found that HO1 overexpression in human placenta-derived 
mesenchymal stem cell (hPMSC) decreased apoptosis and enhanced migration properties 
by improving the balance of angiogenic factors in vitro (Wu et al. 2020). The improved 
placental vascularization by HO1-hPMSC motivates the authors to further studying this as 
an alternative treatment for preeclampsia. However, data are lacking on placental 
localization of the more recently identified heme transporters such as feline leukemia 
virus subgroup C receptor 1 (FLVCR1) and heme-responsive gene 1 (HRG1).  
As depicted with numerous ? in Figure 7, experimental prove of placental heme-iron 
transfer, the relevance of chaperones, ferritin uptake, endosomal or MVM localization of 
several iron transporter and the putative redundancy of ferroxidases is missing. 
Furthermore, mechanisms like ferritin capturing, heme transport and expression of 
alternative transporter like ZIP8 / ZIP14 might explain relatively mild effect of the TfR1 
and DMT1 knockout in mouse (Levy et al. 1999; Gunshin et al. 2005). Pioneer research is 
needed to characterize alternative iron transport pathways across the placenta. 
Regulation of placental iron transport 
The iron regulatory hormone hepcidin (HEPC) is highly expressed by the human liver and 
in placental tissue, but also in mouse embryos in the second trimester (Yoon et al. 2006). 
HEPC binding results in rapid ubiquitination of FPN1 causing its internalization and 
degradation (Qiao et al. 2012). Thus, HEPC negatively regulates cellular iron export via 
FPN1 across the BM towards the fetal circulation. Furthermore, HEPC may play a role in 
fetal sensing of the placental iron status and hence in signaling fetal demand to the 
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mother (C. Cao and Fleming 2016). The anemic, iron-deficient phenotype of transgenic 
mouse embryos overexpressing Hepc further supports this notion (Nicolas et al. 2002). 
More research is needed to reveal the role of HEPC in regulating placental iron 
homeostasis and to identify other fetal factors regulating placental iron transport, such as 
those related to growth and pathology. Another protein that is expressed in placenta and 
regulates iron metabolism is the hemochromatosis Factor HFE (Parkkila et al., 1997). HFE 
is an MHC class I-like glycoprotein that assembles with β2-microglobulin to form a 
heterodimeric complex. A mutation in the HFE gene results in the autosomal iron-
overload disease hereditary hemochromatosis (Feder et al., 1996). HFE associates with 
TfR (Feder et al., 1998; Gross et al., 1998; Salter-Cid et al., 1999) and DMT1 (Gruper et al. 
2005). 
Of note, the relative resistance of fetal hemoglobin levels to maternal anemia highlights 
the ability of the placenta to respond to altered maternal iron supply. Stable isotope data 
in human pregnancies has shown that more iron from maternal diet is transferred to the 
fetus when the maternal stores are low (O’Brien et al. 2003). This is probably a 
consequence of intestinal and placental iron transporters and TFR1 upregulation (Young 
et al. 2010; Gambling et al. 2001). The mechanisms underlying this regulation are not well 
characterized and may involve placental iron regulatory protein 1 and 2 (IRP1 / IRP2) and 
intracellular iron. In brief, during cellular iron deficiency, IRPs bind to the stem-loop 
structure of IREs within the UTR of iron-regulated genes including TfR1, ferritin, FPN1 and 
DMT1. The binding of IRPs to of 3’-IREs promotes stabilization of mRNAs mediating 
increased iron uptake mainly via TfR1, whereas binding to 5’-IREs prevents translation of 
mRNAs involved in iron storage and export via ferritin and FPN1 (Wilkinson and 
Pantopoulos 2014). Both IRP1 and IRP2 activity have been detected in human placentae 
(Bradley et al. 2004). IRP regulation of placental FPN1 is less clear (C. Cao and Fleming 
2016). 
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Figure 7: Schematic representation of the mechanisms and regulation of materno-fetal iron 
transfer across the placenta. Iron (Fe) is transferred from the mother to the fetus across the 
blood-placenta barrier (right to left). The placenta is in direct contact with the maternal blood 
circulation via a monolayer of syncytialized trophoblast cells (blue). After transferrin receptor 
(TfR1)-mediated uptake ferric iron (Fe3+, red) by clathrin-dependent endocytosis at the maternal 
side of the syncytiotrophoblasts (villous membrane, MVM) into endosomes, divalent metal 
transporter 1 (DMT1) is supposed to release divalent iron (Fe2+, yellow) from endosomes into the 
cytosol. Transferrin (Tf) and TfR1 return to the apical microvillous membrane (MVM) to be used 
for further cycles. Cytosolic iron is transferred to the fetal circulation presumably through the iron 
exporter ferroportin (FPN1) or stored intracellularly in oxidized form bound to ferritin heavy chain 
(FHC). The exact mechanisms as well as the role of other transporters such as the Zrt- and Irt-like 
proteins (ZIP) ZIP8 or ZIP14 in transplacental iron transfer are currently still unclear. Although the 
lipoprotein receptor-related protein 1 (LRP1), heme carrier protein 1 (HCP1) and feline leukemia 
virus subgroup C receptor 1 (FLVCR1) were found to be apically expressed, the relevance of heme 
iron transport across the placenta and the possibility of reverse transfer of iron into the maternal 
circulation need more investigation. Similar speculative is the function of scavenger receptor class 
A member 5 (SCARA5) maybe mediating the binding and endocytosis of serum ferritin. 
Furthermore, human poly (rC) binding protein 1 (PCBP1) is an iron chaperone that probably 
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protects fetal tissue by delivery of oxidative ferrous iron from DMT1 to FPN1 or ferritin (dotted 
gray lines). Regulatory wise, HEPC likely act as sensor of the placental iron status and initiates 
FPN1 degradation at placental BM and in enterocytes of the mother (dashed gray lines). The 
binding of IRP1 to of 3’-IRE promotes mRNAs expression of TfR1 and DMT1, whereas binding to 
5’-IREs prevents mRNA translation of iron storage and export via FHC and FPN1. 
 
Adverse effects of imbalanced iron homeostasis for gestation 
Maternal iron stores are generally improved by iron supplementation, but often no 
changes are observed in cord ferritin and maternal ferritin levels. Preziosi et al. found in a 
small observational studies only a weak relationship with neonatal ferritin levels (Preziosi 
et al. 1997). In contrast, a study from the Institute of Food Science, Swiss Federal Institute 
of Technology in Zurich, Switzerland including pregnant women (n=381) in the second and 
third trimester showed a clear benefit of iron supplementation (Hess et al. 2001). 65% of 
women were taking iron supplements and had significantly higher serum ferritin 
concentrations compared to those not taking an iron-containing supplement. Of note, the 
success of folate supplementation was clearly higher compared to iron supplementation. 
Furthermore, a more recent study in China including 3702 mother-newborn pairs, 
detected a strong correlation between maternal and neonatal ferritin levels in women 
whose plasma ferritin levels fell below a threshold of depletion (13.6 μg/L serum ferritin). 
Below this threshold very unit of decrease in maternal serum ferritin was corresponding 
to a 2.4-unit drop in cord ferritin (Shao et al. 2012), suggesting a “broken stick” 
relationship between maternal and fetal iron parameters. However, most studies are 
based on healthy pregnancy, neglecting that conditions with underlying placental 
abnormalities, such as intrauterine growth restriction (IUGR) and GDM, may disrupt the 
normal regulatory mechanism of the placenta and negatively affect fetal iron transfer (C. 
Cao and Fleming 2016). GDM is another common pregnancy complication associated with 
decreased infant iron stores at birth (further information in 1.2 on p.2). Unlike expression 
of placental TFR1 in IUGR, expression of placental TFR1 in GDM shows a significant 
relationship between fetal iron stores and placental IRP1 (Georgieff et al. 1999).  
These findings were an incentive for us to mechanistically investigate changes in placental 
iron homeostasis as consequence of hyperglycemic stress and to identify involved iron 
transport pathways and cellular response mechanisms (see specific aims in 1.6.2 on p.30). 
Introduction - Nutrient transport across the placenta 
28 
1.5.3 Glucose transport  
Glucose is the main energy source for the growing fetus, but due to the limited 
gluconeogenesis ability of the unborn most glucose is provided by the mother (Desoye, 
Gauster, and Wadsack 2011). Due to very low permeability of glucose across the placental 
barrier formed by the STB, a carrier mediated transport system through transporters is 
needed. Glucose is taken up by transporters embedded in the MVM. Glucose transporter 
proteins from the GLUT family play a crucial role in the transport mechanism. Previous 
studies revealed that 6 isoforms of the GLUT family are expressed on mRNA level during 
pregnancy, but the composition, distribution and localization changes throughout 
pregnancy (N.P. Illsley 2000). The glucose transporter 1 (GLUT1) is responsible for glucose 
transport during pregnancy. It acts sodium independent and is the major isoform 
expressed in the placental STB and CTB (Baumann, Deborde, and Illsley 2002; Carter 
2012). The glucose concentration in the blood of the mother is a key factor in the 
maternal-fetal transport mechanism as it determines the net transport across the 
placental barrier. GLUT1 has a higher expression level in MVM than in the BM (T. Jansson 
et al. 2002). The asymmetric expression leads to higher transport capacity in the MVM 
whereas the BM indicates the rate-limiting step in the glucose homeostasis during 
pregnancy (Gallo, Barrett, and Dekker Nitert 2017). Therefore, transplacental glucose 
transfer represents a typically non-mediated and transporter facilitated mechanism as 
depicted green in Figure 4 on p.11. The GLUT1 expression level increases with progressing 
pregnancy as the demand for glucose in the fetus increases as well. Previous studies have 
shown that the expression of GLUT1 on the basal side is increased in GDM patients 
compared to healthy pregnancies (Baumann, Deborde, and Illsley 2002). To our 
knowledge, there are no studies yet that investigated the effect of changing iron levels on 
GLUT1-mediated glucose transport across the placenta. 
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1.6 Hypotheses and specific aims of the thesis 
The placenta is a temporary fetal organ serving as the only connection of the developing 
fetus to the ex utero world. It maintains the balance between nutrition and growth control 
of the fetus through selective and regulated supply of macronutrients such as 
carbohydrates, protein, lipids and critical micronutrients like minerals and vitamins for 
fetal development. This work focused mainly on the SLC-mediated materno-fetal 
transport of essential amino acids like leucine and iron as most abundant trace element 
in human body. Therefore, the hypotheses and specific aims of this PhD project are 
divided into two parts, namely amino acid transport (A) and iron transport (B).  
1.6.1 Amino acid transport 
The placental amino acid transport is maintained by a complex interplay between 
accumulative transporter, facilitating channels and exchanger systems. The exchanger-
mediated transfer of leucine is mainly maintained by the heteromeric System L 
transporters LAT1 and LAT2. However, whether amino acid gradients affect transplacental 
amino acid transport and how important the highly expressed leucine transporter LAT1 is 
for uptake and transfer across the placental barrier, still needs to be answered.  
Hypotheses: 
1. Materno-fetal amino acid gradients are crucial for transplacental amino acid transport 
and correlate with selected maternal and fetal parameters. 
2. Counter-directed amino acid gradients in vivo affect leucine uptake into trophoblasts 
and transfer across the placental barrier. 
3. Specific inhibition of SLC7 transporters or knockout of single transporter genes can 
reveal the relevance of single solute carriers in placental nutrient acquisition. 
The specific aims in the amino acid transport part were: 
A1) To determine maternal and fetal amino acid concentrations in healthy term 
pregnancies.  
A2) To perform correlation analysis between materno-fetal amino acid gradients and 
parameters characterizing the maternal nutritional condition and fetal growth. 
A3) To study the effect of substrate concentrations on System L-mediated leucine uptake 
into trophoblasts and leucine transport across the placental barrier in vitro. 
A4) To characterize the effect of trophoblast differentiation on expression and function of 
placental leucine transporters. 
A5) To investigate small molecule inhibitors as tool compounds for modulating placental 
leucine uptake by acting on SLC7 transporters. 
A6) To generate and characterize trophoblast knockout cell lines for nutrient transporters 
by CRISPR/Cas9 mutagenesis. 
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1.6.2 Iron transport 
In contrast to the materno-fetal amino acid transfer, the transport of non-heme iron 
across the placenta is largely underinvestigated. GDM has been associated with elevated 
iron concentrations in sera (Bo et al. 2009; Zein et al. 2015; Afkhami-Ardekani and Rashidi 
2009; Fu et al. 2016), but a potential impact of GDM on placental iron transport has never 
been investigated.  
Hypotheses: 
1. The expression of placental iron-transporters and iron-regulatory proteins is altered in 
GDM. 
2. Simulation of hyperglycemic and hyperlipidemic conditions in trophoblasts induces 
cellular stress and affects iron uptake.  
3. The reduction of cellular stress levels recues placental iron homeostasis. 
The specific aims in the iron transport part were: 
B1) To characterize expressional changes of iron homeostasis genes in GDM-affected 
placental tissues. 
B2) To establish and characterize trophoblast models mimicking human GDM and 
investigate the effect of hyperglycemic and hyperlipidemic conditions on 
transplacental iron transfer. 
B3) To identify cellular stress pathways responsible for altered placental iron homeostasis 
under hyperglycemic and hyperlipidemic conditions. 
B4) To test whether increasing antioxidative potential rescues the hyperglycemic effect on 
placental iron homeostasis. 
B5) To analyze expression patterns of placental iron homeostasis genes in an obesogenic 
mouse model that develops GDM-like symptoms. 
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2 Materials and Methods 
2.1 Human placental collection and processing 
2.1.1 Tissue and paired materno-fetal sera sampling for free amino acids profiling 
Placentae from normal healthy pregnancies were collected after elective Caesarean 
section at the Division of Gynecology and Obstetrics, Lindenhofgruppe, Bern, Switzerland. 
The study was conducted in accordance with the Declaration of Helsinki, and the protocol 
was approved by the Ethics Committee of the Canton of Bern (Basec Nr. 2016-00250). 
Anthropometric characteristics of healthy donors of placentae for this study are shown in 
Table 7 on p.62. A graphical summary of the sera sampling is depicted in Figure 8. 
Maternal venous whole blood samples were prospectively sampled before administration 
of the spinal anesthesia from 22 inconspicuous pregnancies approx. 5 min prior to 
parturition by caesarean section. The corresponding fetal blood (n=22) was sampled from 
placental arteries and veins within 20 min after delivery. Contamination with maternal 
blood was impossible. After collection of the whole blood sample in a S-Monovette with 
clotting activator (Sarstedt Group, Nümbrecht, DE), the blood was allowed to clot for 15-
30 min at room temperature (RT). The clot was removed by centrifugation with 1000 rcf 
for 10 min at 4°C. The supernatants (=sera) were aliquoted and stored at -20°C upon 
analysis.  
The acquisition of the full amino acid spectra was carried out in serum by ion exchange 
chromatography. The concentrations of 20 amino acids were determined in the Centre of 
laboratory medicine (ISO 17025 accredited) at the University Hospital of Bern by ion 
exchange chromatography with post column derivatization with Ninhydrin on an 
automated Biochrom 30+ Series amino acid analyzer (Biochrom, Cambridge, UK). 
Norleucin (5.24 mg/100 mL sulfosalicylic acid) was used as internal standard and 
calibration was obtained using amino acid standards from Laborservice Onken (Art. Nr. 
5.403.151) and Sigma (Art. Nr. A-9906). The inter-assay coefficient of variation of the 
analysis was 7%.  
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Figure 8: Schematic summary of the standardized collection of mother-fetal paired blood sera 
from Caesarean sections in collaboration with the Lindenhof Hospital, Bern, Switzerland. After 
unsuspicious pregnancy women, who want to deliver by caesarian section, were informed about 
our studies and recruited by our collaborating clinicians at the Lindenhof hospital in Bern. 
Maternal venous blood samples were prospectively collected from healthy patients approx. 5 min 
prior to parturition by caesarian section. The corresponding fetal blood was sampled from 
placental arteries and veins within 20 min after delivery of the placenta. The acquisition of the full 
amino acid spectra was carried out in maternal and fetal serum samples by ion exchange 
chromatography. There are passing about 45 min from blood collection until the processed serum 
samples are stored in -20°C upon analysis. 
 
2.1.2 Patient selection and tissue collection to compare healthy and GDM diseased 
placental tissue 
For the characterization of GDM-specific alternation in placental iron homeostasis 22 
women with elective Caesarean section at the Department of Obstetrics and 
Gynaecology, University Hospital Bern, Switzerland were enrolled. Anthropometric 
characteristics of healthy and GDM-affected placentae for this study are shown in Table 
10 on p. 90. To minimize blood contamination, each piece of tissue was intensively washed 
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in Dulbecco's phosphate buffered saline (DPBS). Tissue samples were immediately snap-
frozen in liquid nitrogen and stored at -80°C upon further analysis. GDM was diagnosed in 
11 pregnancies according to the criteria of the American Diabetes Association based on 
pathologic glucose plasma values following a 75 g oral glucose tolerance test (OGTT) 
performed between the 24th-28th gestational week and normal OGTT values at the 6th 
postpartum week (Basevi et al. 2011). The control group (n=11) consisted of pregnancies 
without pathologies and terminated at term by elective primary caesarean section upon 
patient’s request or due to breech presentation. All GDM-affected women did not show 
glucose intolerance before pregnancy. None of the subjects included in the study showed 
iron excess or deficiency or any type of hematological abnormalities. This study was 
approved by the cantonal ethical committee, Bern, Switzerland, and written informed 
consent was obtained from all participants. 
2.1.3 Primary trophoblast isolation 
Placentae from normal healthy pregnancies were collected after elective Caesarean 
section at the Division of Gynecology and Obstetrics, Lindenhofgruppe, Bern, Switzerland. 
The study was conducted in accordance with the Declaration of Helsinki, and the protocol 
was approved by the Ethics Committee of the Canton of Bern (Basec Nr. 2016-00250). The 
collected tissue was used to isolate primary CTB cells by three consecutive digestions with 
trypsin followed by a Percoll® density gradient centrifugation as previous described 
(Nikitina et al. 2011; Xiao Huang et al. 2016; Kallol, Moser-Haessig, et al. 2018). Freshly 
isolated cells were cultured on Cell-BIND plates in Dulbecco’s modified Eagle’s medium 
containing 4.5 g/L glucose (DMEM-highGlucose, Gibco, Paisley, UK) and characterized by 
analyzing the expression of cytokeratin-7 and vimentin as previously described (Kallol, 
Huang, et al. 2018). Primary trophoblasts were evaluated for leucine uptake at the CTB 
(after 12 h of culture) and STB stage (after 48 h of culture) when spontaneous 
differentiation and fusion has occurred (Kallol, Moser-Haessig, et al. 2018; Shi et al. 1993).  
2.1.4 Placental membrane protein isolation 
Placental tissues from healthy pregnancies were used to simultaneously isolate 
microvillous membranes (MVM) and basal membranes (BM) by Mg2+ precipitation based 
on a previously published method (Nicholas P. Illsley et al. 1990). In brief, approximately 
100 g villous tissue from central and lateral areas of the placenta was washed 3-times with 
Materials and Methods - Human placental collection and processing 
34 
NaCl 0.9% to remove blood. All following steps were performed at 4°C or on ice. After the 
final wash, the tissue was homogenized in Buffer H (250 mM sucrose, 10 mM Hepes, 
adjusted pH to 6.95, supplemented with protease inhibitor cocktail) for 2 min with a 
Polytron homogenizer (Kinematica AG). The crude homogenate was centrifuged with 
1000 rcf to remove cellular debris. Two differential centrifugation steps at 10’000 rcf for 
15 min at 4°C (Optima L-90K ultracentrifuge with TFT70.38 rotor) were performed. The 
supernatants of both centrifugations were combined and filtered through 4 layers of 
gauze on ice and then centrifuged at 125’000 rcf for 30 min at 4°C (TFT 70.38 rotor). The 
pellets containing all cellular membranes were homogenized with a Teflon homogenizer 
and diluted with Buffer H, followed by Mg2+ precipitation applying a final Mg2+ 
concentration of 12 mM by adding 240 mM MgCl2 and slowly stirring for 20 min. The 
centrifugation with 2500 rcf for 10 min separates MVM in the supernatant and all other 
membranes in the pellet. To isolate the BM-fraction from the pellet by ultracentrifugation 
on a 2 step gradient, it was first washed, then resuspended with Buffer E (0.1% bovine 
serum albumin in 1 mM Titriplex® III, Merck, Darmstadt, Germany) and homogenized 
using a Teflon homogenizer. A two-step sucrose gradient was prepared in a thin-walled 
ultra-centrifuge Beckman SW28 tube (Beckman Coulter, Brea, CA, USA) by applying a 
bottom layer with 1.192 g/cm3 density, a middle layer with 1.162 g/cm3 density and on 
top the homogenized membrane-fraction. This gradient was centrifuged at 100’000 rcf 
for 60 min using a Beckman SW28 swing-out rotor (Beckman Coulter, Brea, CA, USA). The 
BM deposit between the bottom and the middle layer was removed. Finally, the BM-
fraction and the MVM pellets were resuspended in buffer E and homogenized with a 
Teflon homogenizer. MVM and BM were centrifuged at 125’000 rcf for 30 min for a final 
clean-up. The pellets were resuspended in buffer H, snap frozen in liquid nitrogen and 
stored at -80°C. Anthropometric characteristics of healthy donors of placentae for this 
study are shown in Table 2. The total membrane isolation (TMI) fraction was collected 
prior to MVM/BM separation.  
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Table 2: Anthropometric characteristics of healthy patients donating placental tissue and their 
offspring. 




r Number of individuals 11  
Maternal age (years) 33.9  ± 3.48 
Parity 1.8  ± 0.60 






Weight of placenta (g) 569.3  ± 86.1 
Weight of baby (g) 3367.3  ± 284.0 
Sex of baby 3♂ /   6♀ 
 
2.2 Analysis of placental transmembrane proteins 
2.2.1 Immunoblotting  
Cells were lysed by adding hypotonic lysis buffer (10 mM Tris-HCl, Sigma T5941; 10 mM 
NaCl, Sigma 71376; 1.5 mM MgCl2, Millipore 1.05833; 1% Triton X-100, Sigma T8787; 1 
bottle/100 mL protease inhibitor cocktail, Sigma P2714; adjusted pH to 7.4). The samples 
were vortexed in hypotonic lysis buffer every 5 min during 30 min on ice for thorough lysis 
of the cells. Subsequently, the cell lysates were centrifuged with 1000 rcf for 10 min at 
4°C to remove cellular debris and stored upon analysis at -80°C. Protein content was 
measured using the Pierce™ BCA Protein Assay Kit. 50 µg cell lysates were loaded on 10% 
acrylamide gels and separated by sodium dodecyl sulfate polyacrylamide gel 
electrophoresis (SDS-PAGE) using the Biorad minigel system. The immobilized bands were 
then semi-dry transferred to nitrocellulose membranes (GE Healthcare). Blots were 
blocked with 5% non-fat milk in Tris Buffered Saline with 0.1% Tween-20 (TBST). The 
primary polyclonal rabbit anti-LAT1 antibody (KE026/TG170215 Transgenic Inc.), Anti-
LAT2/SLC7A8 antibody produced in rabbit (Sigma AV43930), anti-DMT1/SLC11A2 
antibody clone 4C6 (Sigma WH0004891M1), anti-FPN1 antibody (Thermo Fisher Scientific 
PA5-22993), Anti ZIP8/SLC39A8 (Sigma HPA038833), purified Mouse Anti-BiP/GRP78 (BD 
Transduction Lab. 610978), SQSTM1/p62 Antibody (Cell Signaling Technology 5114S), 
Anti-LC3-I/II Antibody (Millipore ABC929), Anti-GLUT-1 (Millipore 07-1401) and in a 
second staining round for the reference signal (loading control) the mouse anti-beta-actin 
antibody (Sigma A2228) were incubated overnight at 4°C, followed by 4 times washing 
with TBST, and incubation with DyLight 680 or 800 fluorescence conjugated secondary 
antibodies (Thermo Scientific™). The immunoreactive bands were quantified with the 
Materials and Methods - Analysis of placental transmembrane proteins 
36 
OdysseyW Sa Infrared Imaging System (LI-COR) to obtain relative densitometry values 
without signal saturation.  
The effect of LAT2 glycosylation on SDS-PAGE segregation was tested by Peptide N-
glycosidase F (PNGase F) treatment according to the protocol from Promega V4831. In 
brief, 40 μg lysate of knockout candidate clones was incubated with 1% Nonidet P-40 and 
50 mM sodium phosphate (pH 7.5, 25°C) and PNGase F at 37°C for 2 h. Samples were then 
denatured with SDS-PAGE loading buffer without boiling and further quantified by 
immunoblotting and densitometry as explained above.  
2.2.2 Membrane protein isolation for MS/MS-based protein quantification 
Due to insufficient antibody specificity in the iron transporter project, we started a service 
collaboration with the FGCZ at the University of Zurich to develop a liquid chromatography 
tandem mass spectrometry (LC-MS/MS) -based quantification method for 12 genes of 
interest (Figure 27 on p.94). The workflow, graphically visualized in Figure 9, started with 
the tissue collection from placenta donors at the Lindenhof hospital, continued with 
sample preparation, tryptic digestion and mass determination by tandem mass 
spectrometry. Finally, peptides suitable for MS-analysis were identified selected by 
MASCOT-search.  
Table 3: Genes of interest chosen for selected reaction monitoring (SRM) method used to 
quantitatively asses protein levels by tandem mass spectrometry in collaboration with 
Functional Genomics Center in Zurich (FGCZ). 
Gene ID Gene name Protein name project assignment 
Q01650 SCL7A5 LAT1 
Amino acid transport project Q9UHI5 SLC7A8 LAT2 
P08195 SLC3A2 4F2hc 
P02786 TFRC TFR1 
iron transport project 
P49281 SLC11A2 DMT1 
Q9NP59 SLC40A1 FPN1 
Q9C0K1 SLC39A8 ZIP8 
Q15043 SLC39AE ZIP14 
P04406 GAPDH G3P 
reference genes P63104 YWHAZ 1433Z Q15365 PCBP1 PCBP1 
O95477 ABCA1 ABCA1 
Prior to proteomic analysis TMI from placental tissues was performed to deplete highly 
abundant proteins (e.g. albumin). Approx. 50 mg of snap-frozen tissue was homogenized 
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in lysis buffer (250 mM Sucrose; 10 mM Hepes; protease inhibitor cocktail, all reagents 
from Sigma; pH adjusted to 6.95) with a Polytron® homogenizer (Kinematica AG, 
Switzerland) on wet ice. Large cellular debris was removed by a first centrifugation step 
at 4°C and with 1000 rcf for 5 min. The supernatants were collected and subjected to two 
consecutive centrifugation steps at 10’000 rcf for 15 min at 4°C. The pellets were 
discarded, and the two combined supernatants were subjected to a final ultra-
centrifugation step at 125’000 rcf for 30 min at 4°C. The pellets were consecutively 
washed with 1 mL ice cold 1M KCl and 1 mL 100 mM Na2CO3. The final TMI pellets were 
resuspended in 200 µL 50 mM Tris-HCl (pH 8) ice cold buffer using a glass-teflon 
homogenizer. The TMI homogenates were aliquoted for protein measurement using 
Pierce™ BCA Protein Assay Kit (Thermo Scientific™) and stored at -80°C until proteomic 
analysis. 
 
Figure 9: Schematic representation of the mass spectrometry-based approach to quantify 
placental membrane proteins. 
2.2.3 Development of a Parallel Reaction Monitoring (PRM) assay 
For the development of the quantification assay, preliminary experiments were 
performed to optimize the sample preparation and to select the proteotypic peptides of 
each target protein. 30 µg protein of TMI samples were subjected to filter-assisted sample 
preparation (FASP) and tryptic digested (Wiśniewski et al. 2009) with a subsequent 
desalting step by C18 solid phase extraction columns (Sep-Pak Fenisterre; Waters Corp., 
Milford, MA, USA). The dried samples were re-solubilized in 15 µL 3% acetonitrile, 0.1% 
formic acid and spiked with iRT peptides (Biognosys, Switzerland) for mass spectrometry 
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(MS) analysis which was performed on a QExactive mass spectrometer coupled to a nano 
EasyLC 1000 (Thermo Fisher Scientific). Solvent composition at the two channels was 0.1% 
formic acid for channel A and 0.1% formic acid, 99.9% acetonitrile for channel B. For each 
sample 1μL of peptides were loaded on a commercial Acclaim PepMapTM Trap Column 
(75 μm x 20 mm, Thermo Scientific™) followed by a PepMapTM RSLC C18 Snail Column 
(75 μm×500 mm, Thermo Scientific™). The peptides were eluted at a flow rate of 
300 nL/min by a gradient from 2 to 30% B in 115 min, 47% B in 4 min and 95% B in 4 min. 
The mass spectrometer was operated in data-dependent mode (DDA), acquiring a full-
scan MS spectrum (300−1700 m/z) at a resolution of 70’000 at 200 m/z after 
accumulation to a target value of 3’000’000, followed by HCD (higher-energy collision 
dissociation) fragmentation on the twelve most intense signals per cycle. HCD spectra 
were acquired at a resolution of 35’000 using a normalized collision energy of 25 and a 
maximum injection time of 120 ms. The automatic gain control (AGC) was set to 50’000 
ions. Charge state screening was enabled and singly and unassigned charge states were 
rejected. Precursor masses previously selected for MS/MS measurement were excluded 
from further selection for 30 s, and the exclusion window was set at 10 ppm. The samples 
were acquired using internal lock mass calibration on m/z 371.1010 and 445.1200.  
The acquired raw MS data were processed by MaxQuant (version 1.4.2.1) (Cox and Mann 
2008), followed by protein identification using the integrated Andromeda search engine. 
Spectra were searched against a uniprot Homo Sapiens (taxonomy 9606) reference 
proteome (canonical version from 2016-12-09), concatenated to its reversed decoyed 
fasta database and common protein contaminants. Carbamidomethylation of cysteine 
was set as fixed, while methionine oxidation and N-terminal protein acetylation were set 
as variable modifications. MaxQuant Orbitrap default search settings were used. Enzyme 
specificity was set to trypsin/P.  
The mass spectrometry proteomics data were handled using the local laboratory 
information management system (LIMS) (Türker et al. 2010) and all relevant data have 
been deposited to the ProteomeXchange Consortium via the PRIDE 
(http://www.ebi.ac.uk/pride) partner repository with the data set identifier o3022: 
MaxQuant 1.4.2.1 (WU146123) and o3176 : MaxQuant 1.4.2.1 (WU148929). 
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Based on these experiments, a set of proteotypic peptides was selected for 8 protein 
targets and 4 housekeeping proteins excluding, whenever possible, peptides containing 
cysteine, methionine, asparagine and glutamine (Table 3). For proteins with no or less 
than three proteotypic peptides, additional peptides were selected from the SRM Atlas 
(http://www.srmatlas.org) (Table 4). Stable isotope-labeled standard peptides 
corresponding to the proteotypic peptides and containing either a C-terminal (13C(6) 
15N(4)) arginine or a (13C(6) 15N(2)) lysine residue were chemically synthesized via SPOT 
synthesis (JPT Peptide Technologies, Germany) and used in unpurified form for PRM 
analysis. In total, the scheduled PRM assay targets 85 peptides (12 proteins, 37 peptides 
in Light/Heavy (L/H) form and 11 iRT peptides). The MS/MS spectra of these peptides were 
used for the generation of spectral libraries using Mascot (Matrixscience) according to the 
parameters previously described for MaxQuant (with, in addition, 13C(6) 15N(4) arginine 
and 13C(6) 15N(2) lysine as variable modifications) Finally, both the MaxQuant and the 
Mascot search results (dat. files) were imported into the Skyline software (v2.6.0) 
(MacLean et al. 2010) and spectral libraries were built using the BiblioSpec algorithm 
(Frewen and MacCoss 2007). 
Materials and Methods - Analysis of placental transmembrane proteins 
40 
Table 4: List of peptide sequences used to quantify proteins of iron homeostasis and reference 









NCE Comment Protein 
385.72402 2 14.71 16.71 27 M[-131.0404]VLGPEQK (light) DMT1 
389.73112 2 14.71 16.71 27 M[-131.0404]VLGPEQK (heavy)  
882.40090 2 39.15 41.15 27 ISIPEEEYSC[+57.021464]FSFR (light)  
887.40503 2 39.15 41.15 27 ISIPEEEYSC[+57.021464]FSFR (heavy)  
415.97925 4 30.72 32.72 27 LGVVTGLHLAEVC[+57.021464]HR (light)  
418.48132 4 30.72 32.72 27 LGVVTGLHLAEVC[+57.021464]HR (heavy)  
754.90823 4 50.08 52.08 27 TPQIEQAVGIVGAVIMPHNMYLHSALVK (light)  
756.91178 4 50.08 52.08 27 TPQIEQAVGIVGAVIMPHNMYLHSALVK (heavy)  
629.82495 2 38.48 40.48 27 DWIVVVAGEDR (light) FPN1 
634.82909 2 38.48 40.48 27 DWIVVVAGEDR (heavy)  
350.22361 2 19.49 21.49 27 TPALAVK (light)  
354.23071 2 19.49 21.49 27 TPALAVK (heavy)  
496.76162 2 16.59 18.59 27 FAQNTLGNK (light)  
500.76872 2 16.59 18.59 27 FAQNTLGNK (heavy)  
664.58471 4 42.46 44.46 27 FSVIC[+57.021464]PAVLQQLNFHPC[+57.021464]EDRPK (light) ZIP8 
666.58826 4 42.46 44.46 27 FSVIC[+57.021464]PAVLQQLNFHPC[+57.021464]EDRPK (heavy)  
420.21090 2 14.67 16.67 27 VDSYVEK (light)  
424.21800 2 14.67 16.67 27 VDSYVEK (heavy)  
749.99826 3 19.40 21.40 27 TYGQNGHTHFGNDNFGPQEK (light)  
752.66966 3 19.40 21.40 27 TYGQNGHTHFGNDNFGPQEK (heavy)  
726.37246 2 30.69 32.69 27 YGEGDSLTLQQLK (light) ZIP14 
730.37956 2 30.69 32.69 27 YGEGDSLTLQQLK (heavy)  
421.91045 3 30.42 32.42 27 ALLNHLDVGVGR (light)  
425.24654 3 30.42 32.42 27 ALLNHLDVGVGR (heavy)  
835.70816 3 36.71 38.71 27 NLSTC[+57.021464]FSSGDLFTAHNFSEQSR (light)  
839.04425 3 36.71 38.71 27 NLSTC[+57.021464]FSSGDLFTAHNFSEQSR (heavy)  
873.42830 2 43.36 45.36 27 SAFSNLFGGEPLSYTR (light) TfR1 
878.43244 2 43.36 45.36 27 SAFSNLFGGEPLSYTR (heavy)  
781.35246 2 16.96 18.96 27 LAVDEEENADNNTK (light)  
785.35956 2 16.96 18.96 27 LAVDEEENADNNTK (heavy)  
717.41614 2 44.83 46.83 27 VSASPLLYTLIEK (light)  
721.42324 2 44.83 46.83 27 VSASPLLYTLIEK (heavy)  
706.39882 2 31.59 33.59 27 GALQNIIPASTGAAK (light) GAPDH 
710.40592 2 31.59 33.59 27 GALQNIIPASTGAAK (heavy)  
435.25819 2 23.47 25.47 27 VIPELNGK (light)  
439.26528 2 23.47 25.47 27 VIPELNGK (heavy)  
882.40483 2 38.68 40.68 27 LISWYDNEFGYSNR (light)  
887.40896 2 38.68 40.68 27 LISWYDNEFGYSNR (heavy)  
774.86045 2 18.38 20.38 27 SVTEQGAELSNEER (light) YWHAZ 
779.86458 2 18.38 20.38 27 SVTEQGAELSNEER (heavy)  
1020.99728 2 36.61 38.61 27 GIVDQSQQAYQEAFEISK (light)  
1025.00438 2 36.61 38.61 27 GIVDQSQQAYQEAFEISK (heavy)  
711.33544 3 51.13 53.13 27 TAFDEAIAELDTLSEESYK (light)  
714.00683 3 51.13 53.13 27 TAFDEAIAELDTLSEESYK (heavy)  
694.91103 2 40.37 42.37 27 IITLTGPTNAIFK (light) PCBP1 
698.91813 2 40.37 42.37 27 IITLTGPTNAIFK (heavy)  
507.76998 2 18.95 20.95 27 QGANINEIR (light)  
512.77411 2 18.95 20.95 27 QGANINEIR (heavy)  
543.78054 2 17.82 19.82 27 IANPVEGSSGR (light)  
548.78468 2 17.82 19.82 27 IANPVEGSSGR (heavy)  
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2.2.4 Protein quantification of placental membrane proteins by mass spectrometry 
Prior to proteomic analysis TMI from placental tissues was performed as described in 2.2.2 
and a PRM assay was developed as described in 2.2.3. After assay development, protein 
digestion for the 22 TMI samples was further improved by using a commercial iST Kit 
(PreOmics, Germany) with an adapted version of the protocol. Briefly, 30 µg of protein 
were solubilized in lysis buffer, boiled at 95°C for 10 min and processed with High Intensity 
Focused Ultrasound (HIFU) for 30 s setting the ultrasonic amplitude to 85%. Then the 
samples were transferred to the cartridge and digested by adding 50 µL of the digestion 
solution. After 60 min of incubation at 37°C the digestion was stopped with 100 µL of stop 
solution. The solutions in the cartridge were removed by centrifugation at 3800 rcf, while 
the peptides were retained by the iST-filter. Finally, the peptides were washed, eluted, 
dried and re-solubilized in LC-Load buffer for MS-Analysis. For PRM quantification, 
samples were analyzed on a Q Exactive HF mass spectrometer (Thermp Scientific) 
equipped with a Digital PicoView source (New Objective) and coupled to a M-Class UPLC 
(Waters). Solvent composition at the two channels was 0.1% formic acid for channel A and 
0.1% formic acid, 99.9% acetonitrile for channel B. For each sample 1 μL of peptides were 
loaded on a commercial MZ Symmetry C18 Trap Column (100 Å, 5 µm, 180 µm x 20 mm, 
Waters) followed by nanoEase MZ C18 HSS T3 Column (100 Å, 1.8 µm, 75 µm x 250 mm, 
Waters). The peptides were eluted at a flow rate of 300 nL/min by a gradient from 5 to 
35% B in 50 min and 98% B in 5 min. The Q Exactive HF performed MS1 scans (350–
1250 m/z) followed by 16 MS/MS acquisitions in PRM mode. The full scan event was 
collected at a resolution of 15000 (at m/z 200) and an AGC value of 3e6 and a maximum 
injection time of 15 ms. The PRM scan events used an Orbitrap resolution of 120000, 
maximum fill time of 200 ms with an isolation width of 1.4 m/z, an isolation offset of 
0.5 m/z and an AGC value of 2e5. HCD fragmentation was performed at a normalized 
collision energy (NCE) of 27. The whole method included 74 L/H peptide precursors and 
11 Biognosys iRT standard peptides. Based on the spiked iRTs, the retention time of the 
target peptides was normalized and transformed into iRT values (Escher et al. 2012) 
allowing to set the scan windows to 4 min for each peptide in the final PRM method  
(Table 4). This ensured the measurement of 6–10 points per LC peak per transition. The 
results were calculated as fold changes relative to spiked peptides. GDM (n=11) and 
controls (n=11) were normalized to the reference gene glyceraldehyde-3-phosphate 
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dehydrogenase (GAPDH) (sp|P04406|G3P_HUMAN). The normalization was executed by 
subtracting. the protein value of GAPDH from the value of the target protein.  
2.3 Placenta histology 
2.3.1 Immunohistochemistry 
Tissues from 11 GDM- and 11 control-placentae were embedded in Tissue-Tek® optimum 
cutting temperature (O.C.T.) medium, cut at 5 µm thickness and mounted on Superfrost 
plus slides (Menzel, Germany). The frozen tissue blocks were stored at -80°C upon 
sectioning. The tissue sections were fixed in pre-cooled acetone (-20°C) for 10 min and 
washed 2 times for 5 min in 10 mM phosphate buffered saline (PBS, pH 7.4). Fixed sections 
were incubated in H2O2-Block (Dako S2023) at room temperature for 10 min to block 
endogenous peroxidase activity and again washed 2-times in PBS. The primary antibodies 
were diluted in PBS with 0.5% bovine serum albumin (DMT1 1:1000; FPN1 1:1000). Diluted 
primary antibodies (100 µL per slide) were added to cover the tissue on the slides and 
incubated in a humidified chamber (DMT1 for 2 h; FPN1 for 1.5 h) at 4°C. For the 
visualization of the antigens on the next day UltraVision LP Detection System (Thermo 
Scientific™ TL-015-HAS) was used according to the manufacturer’s instructions. Slides 
were washed with PBS and incubated with Antibody Enhancer solution for 20 min. After 
an additional washing step with PBS, the horseradish peroxidase (HRP) polymer was 
added for 30 min, the slides were washed again, and AEC chromogen was applied for 
5 min in the dark. Sections were washed in distilled water, counterstained with Gill's 
hematoxylin (Merck, 105174) and mounted with Aquatex® (EMD Millipore 1.08562). 
Negative controls were stained without prior incubation with the primary antibody. 
Immunohistochemical images were prepared with a DM6000 B microscope (Leica 
Microsystems, Germany). The staining intensity of DMT1 and FPN1 expression in all 
specimens was semi-quantitatively scored by a blinded expert (PD Dr. med. Meike Körner, 
Pathology Laenggasse, Bern, Switzerland). Staining intensity was rated on a scale of 0–3, 
with 0=negative, 1=weak, 2=moderate, and 3=strong and statistically assessed by 
Pearson's χ2 test.  
2.3.2 Special staining for lipid storage visualization in trophoblasts 
Oil red O staining and counter-stained with hematoxylin was performed as described on 
http://www.ihcworld.com/_protocols/special_stains/oil_red_o.htm. In brief, after 32 
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days of adaptation of previously in low-glucose cultured BeWo cells to the 3 
hyperglycemic conditions (see 2.4), cells were seeded on double chamber slides by 
avoiding 100% confluency. Then the slides were air dried for 30 min at room temperature 
and then fix in ice cold 10% formalin (22.0 mL 7% Formaline in 58.0 mL PBS, pH 7.4) for 
5 min, followed by rinsing in 3 changes of distilled water and repeated air drying for 
another 30 min. Before the actual staining the cells were equilibrated in absolute 
propylene glycol (1,2-Propanediol, Sigma, 398039) for 5 min to avoid carrying water into 
Oil Red O. Lipid stores in the cells were stained in pre-warmed 0.5% Oil Red O (Sigma, 
102419) in 100% propylene glycol solution for 10 min in 60°C oven differentiated in 85% 
propylene glycol in distilled water solution for 5 min, followed by rinsing in 2 changes of 
distilled water. In a second step the cells were counter-stained in Gill's hematoxylin for 
30 s and washed thoroughly in running tap water for 3 min and finally covered by cover-
glass and Aquatex®. Cells were visualized via inverted light microscopy and photographed.  
2.4 BeWo cell culture 
As primary cultures of trophoblasts do not proliferate in vitro, the choriocarcinoma-
derived BeWo cell line (clone b30; donated by Dr. Alan L. Schwartz, Washington University 
School of Medicine, USA) was used as trophoblast cell model. BeWo cells are 
conventionally cultured in Dulbecco’s modified Eagle’s medium containing 25 mM glucose 
(DMEM-HG, Gibco, Switzerland) with 10% fetal bovine serum (LabForce, Basel, 
Switzerland) and antibiotic-antimycotic (Gibco 15240062) in a humidified incubator under 
a 5% pCO2 atmosphere at 37°C. To adapt BeWo cells to physiological glucose 
concentrations, they were grown in medium containing 5.5 mM glucose (DMEM-low 
glucose, Gibco, Switzerland) for 28 passages. These low glucose BeWo cells were used for 
all Leucine uptake (see 2.7.1) and Transwell (see 2.7.4) assays, but also to establish cell 
models mimicking different grades of diabetic severity in the iron project. Beside the 
normoglycemic condition (N; DMEM 5.5 mM glucose) the cells were exposed to a 
hyperglycemic (H; DMEM 25 mM glucose) and a hyperglycemic/hyperlipidemic condition 
(HL; H + 100 µM palmitic acid). The stock solution of palmitic acid was prepared by 
conjugation with bovine serum albumin (BSA). In brief, palmitic acid was dissolved in pre-
heated 0.1 M NaOH and diluted 1:10 in pre-warmed 12% BSA solution to obtain a final 
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concentration of 10 mM. N and H media contained same amounts of 0.1 M NaOH and BSA 
without lipid (Sinha et al. 2004). 
2.4.1 Induction of oxidative stress and rescue by antioxidant treatment 
For oxidative stress induction following antioxidant treatment, BeWo cells were seeded 
in DMEM 5.5 mM glucose medium with 10% fetal bovine serum (FBS, Seraglob, 
Schaffhausen, Switzerland) till they reach approx. 80% confluency, followed by incubation 
in serum-free DMEM 5.5 mM glucose medium and different oxidative stress conditions 
using 0.8 µM Rotenone (Sigma, R8875) or 1 mM tert-Butyl hydroperoxide (tert-BOOH; 
Sigma, 458139). We tested 0.1 µM sodium selenite (NaSe) inducing GSH-dependent 
antioxidative pathways in trophoblasts (A. Khera, Vanderlelie, and Perkins 2013) and 
50 µM quercetin as well-known dietary antioxidant (Bach et al. 2010). Finally, we aimed 
to use the best method for the rescue experiment by antioxidants treatment. See the 
results in Figure 36D on p.107. 
2.5 CRISPR/Cas9-mutagenesis of single placental nutrient transporter  
Sequence specific gene knockout by CRISPR/Cas9-mutagenesis, allows to assess the role 
of a single transporter in complex nutrient transport pathway such as materno-fetal 
amino acid or iron transport. Trophoblast cells lacking the expression and function of a 
single nutrient transporter by specifically and CRISPR/Cas9-mediated knockout, would 
reveal its role at the materno-fetal barrier in the placenta. The strategy adapted for 
CRISPR/Cas9-mutagenesis of placental nutrient transporter is depicted in Figure 39 on 
p.114.  
2.5.1 Design of target sites and synthesis of sgRNA 
Four nutrient transporter and the trophoblast hormone human choriogonadotropin (hCG) 
as reference target (J. Li et al. 2018) were selected to be targeted by CRISPR/Cas9-
mutagenesis: LAT1 (SLC7A5), LAT2 (SLC7A8), DMT1 (SLC11A2), ZIP8 (SLC39A8) and beta 
subunit 3 of the human chorionic gonadotropin (hCGB3). The genomic sequence for each 
target was downloaded from National Center for Biotechnology Information (NCBI) GENE 
database. Potential target sites were independently generated using the online target site 
searching and analysis webpages CRISPOR (http://crispor.tefor.net) and CHOPCHOP 
(http://chopchop.cbu.uib.no). The integrated bioinformatics tool software (UGENE 
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software from NCBI, US, freeware) was used to annotate sequences essential for gene 
expression, such as the initial ATG or splice sites of the target gene and the final target 
sites inclusive protospacer adjacent motif (PAM) -sequence. This information was used to 
plan the double-strand-break location with an effect on gene expression and function as 
devastating as possible. Three different target sites per target gene were designed. The 
target site is defined by 20 nucleotides each with <5’-20bp-NGG-3’>-structure. Both target 
site searching tools CRISPOR and CHOPCHOP generated additionally to the target sites 
sequence, primer pairs flanking the proximity of the respective target sites. We further 
used the NCBI- Basic Local Alignment Search Tool (BLAST) online tool to analyze the target 
sites for off-targets. The PAM sequence (=NGG) on the 3’-end of the target site, which 
does not count to the 20 bp of the target site nucleotides, but is essential for Cas9-
mediated cleavage (Jinek et al. 2012). The G or GG at the 5’-end of the target site is 
required since these are the last nucleotides of the T7-transcriptase recognition site, but 
also the first nucleotides transcribed to ribonucleic acid (RNA) and hence already part of 
the guide RNA. We added another G, if there was only one G at the 5’-end of the target 
site to get a more efficient transcription (Bassett et al. 2013). The final versions of 
designed target sites are listed in Table 5. 
Table 5: List of target sequences designed for CRISPR/Cas9-mutagenesis with respective primer 
pairs to amplify the flanking target sequence for sequencing. 
Name 
target site 
Sequence target site (5’-3’) Forward primer (5’-3’) Reverse primer (5’-3’) fragment 
length 
LAT1 MK1 GATGCTGTCGTCCGAGGCCG TGACCAACCTGGCCTACTTC GTAGGGGAGGCTTAGAGATGTG 170 bp 
LAT1 MK2 GCAGGCTTACCGTGAACACG GTCTGTCCACAGGCTCTTCTTC ACATTTGAGCTGTCACCCAGT 229 bp 
LAT1 MK3 GCTGCCCGTCTACTTCTTCG CTGCCTGTGTTCTTCATCCTG GAGATACTCACAGATGCCCTGG 177 bp 
LAT2 142 GGATGTGGGGAACATTGTGC TGTAAGGCTACACGCATGCA AAAGTGAGTGGGGCTACAGC 305 bp 
LAT2 184 GGAGCTTCTCTCCAAAAGTC GTTCTGCTTGTGTGCCTTGG GGGGAAATCTCAGGGTGTGG 306 bp 
LAT2 1539 GGCATCCAACGCCGTCGCTG ACATCCAGATGCCCACACAG CCAGAGTGAAGTGGGAGCTG 293 bp 
DMT1_92 GGCCTGCTGCACTCTACATT AGGCAGAGAAACGAAGGAGC CATGGTGGAGCTCTGTCCTG 304 bp 
DMT1_1312 GGCCCTCACATTTGGATATG TAAGGAGAGCGGGAATGGGA TTTAAACCTGGGAGCCCCTG 387 bp 
ZIP8_567 GTGGAGTCAAAATCAATCCG ACATCATTTGGTTCCTTGCTCT TAGCCAACATCCTTACCTCTGG 244 bp 
ZIP8_694 GCTTGGGCCGATCCTCACAT CTCTGTCATCTGTCCAGCAGTC GCAATAAAGCAGAAAAAGAGGC 182 bp 
hCGB3 GATCCCGACTCCCGGGGCCCT CCTCAGGTGGTGTGCAACT AGAAGCCTTTATTGTGGGAGGA 290 bp 
hCGB3_1 GCCACGGCGTAGGAGACCAC CCTCAGGTGGTGTGCAACT AGAAGCCTTTATTGTGGGAGGA 290 bp 
Before continuing with “single guide“-RNA (sgRNA) synthesis the target sites were 
validated by amplification of the target site from the BeWo genome by GoTag G2 hot start 
polymerase (Promega, M7401), oligo cleaning using “ReliaPrep DNA clean-up and 
concentration system” kit (Promega, A2892) and subsequent sequencing using 
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Microsynth oligo sequencing service (Microsynth AG, Switzerland: 
https://srvweb.microsynth.ch/SingleTubeSequencing). All kits mentioned above were 
used according to the protocols provided by manufacturers. 
The synthesis of target site-specific sgRNA was done as described before in (Burger et al. 
2016). In brief, before we were able to perform the in vitro transcription (IVT) for sgRNA 
generation, the double strand deoxyribonucleic acid (DNA) template for each target had 
to be prepared. To reduce oligo synthesis costs, we profit from the hybridization ability of 
DNA oligos and ordered one 63 bp long target-specific oligo per target site called 
CRISPRfwd (green sequence in Figure 10) and only one 80 bp long oligo called sgRNArev 
with a 20 bp overlap with all CRISPRfwd ordered shown as red sequence in Figure 10. 
Therefore, only a single CRISPRfwd oligo was needed to be ordered per target site, while 
the sgRNArev oligo was used for all sgRNA IVT templates. 
 
Figure 10: Schematic annealing of the target-specific CRISPRfwd and sgRNArev oligonucleotide 
as template for sgRNA synthesis. After thermal annealing, the CRISPRfwd and sgRNArev oligos 
expose two 3’-ends allowing sequence elongation. Subsequent elongation was performed by 
running a standard PCR using the GoTaq® G2 Hot Start polymerase (Promega) to get a linear in 
vitro transcription (IVT) template; 4 µL of 10 µM sgRNArev oligo, 4 µL 10 µM CRISPRfwd oligo and 
42 µL nuclease free water were mixed with the 2 x master mix followed by standard PCR. The 
CRISPRfwd sequence (green) was bearing the T7 promotor sequence (underlined) ending with a 
GG. This GG represented the start of the target site designed for target gene binding (blue 
background) and the start of the final sgRNA, respectively. The sgRNArev oligonucleotide (red) 
includes the whole sgRNA sequence downstream of the target site responsible for Cas9 
recognition.  
After polymerase chain reaction (PCR) -elongation (Figure 10), the double stranded 
template DNA was precipitated in 10% sodium acetate (3 M) and 40% isopropanol with 
subsequent ethanol (95%) wash on ice, to remove reagents from elongation reaction. The 
target site-specific DNA template was transcribed using the 
MAXIscript™ T7 Transcription Kit (Invitrogen AM1312) optimized for sgRNA synthesis. In 
brief, the reaction was composed as follows: 8 µL of 10 mM NTPs (Thermo Fischer 
18109017), approx. 300 ng of purified template DNA, 2 µL T7 Polymerase, 2 µL 10 x 
transcription buffer and nuclease free water to adjust total volume to 20 µL. Transcription 
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components were mixed well by pipetting and incubating at 37°C overnight (not in water 
bath to avoid condensation on the cap). The synthesized sgRNA were purified first by 
protein precipitation with chloroform by adding 80 µL of RNase free water per 20 µL 
reaction and chloroform with a 1:2 (v/v) ratio and followed by centrifugation for 5 min at 
10’000 rcf at 4°C. The upper organic phase (sgRNA) was transferred into a fresh 1.5 mL 
tube, while the lower aqueous phase was discarded. The sgRNA was further washed 3-
times by replacing the supernatant volume with ice-cold 95% ethanol and again 
precipitated overnight at -20°C. The sgRNA samples were then centrifuged with 10’000 rcf 
for 60 min at 4°C, to carefully discard the supernatant, followed by drying the RNA pellet 
for 10 min below a laminar flow bench. The pellet was resuspended in 30 µL RNase free 
water and stored at -80°C until transfection. Concentration of the sgRNA was measured 
with Nanodrop (Thermo Fischer). For several samples, the quality of the RNA was 
measured on a Bioanalyzer (Agilent) chip according to protocol provided by the company. 
2.5.2 Transfection methods for sgRNA and Cas9 into trophoblasts 
Two different transfection strategies were tested for bringing finally active sgRNA and 
Cas9 protein into trophoblasts (Figure 11). The first strategy A includes simultaneous 
transfection of previously transcribed sgRNA and Cas9 plasmid, bearing promotor 
sequences for instant expression in each transfected trophoblast cell. The second strategy 
B was to directly deliver active preassembled sgRNA-Cas9 ribonucleoprotein complexes 
(RNPs) into trophoblasts. Both strategies should lead to sequence-specific binding of the 
nuclease Cas9 and mutation of the targeted placental nutrient transporter gene. Multiple 
methods were tested for sgRNA-Cas9-plasmid and sgRNA-Cas9- ribonucleoprotein (RNP) 
transfection, followed by fluorescence-activated cell sorting (FACS) sorting and 
characterization of potential emerged new knockout cell candidates.  
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Figure 11: Two strategies to generate nutrient transporter knockout trophoblast lines by 
CRISPR/Cas9 mutagenesis. Either simultaneous transfection of sgRNA and pCas9_green 
fluorescent protein (GFP) plasmid (A) or direct transfection of active sgRNA-Cas9 
ribonucleoprotein complexes (RNPs) into trophoblasts (B) were performed to generate target 
sites-specific destructive mutations in placental nutrient transporter genes. Strategy A requires 
expression of the Cas9-GFP gene on the transfected plasmid and sgRNA-Cas9 protein assembly 
through the target cell itself, while in strategy B already reactive and in vitro preassembled RNPs 
should convey efficient CRISPR/Cas9 mutagenesis immediately after RNP transfection. A, The 
pCas9_GFP plasmid (Addgene ID 41824) includes a chimeric intron (blue), which significantly 
increase transgene expression, a Cas9 gene (orange), followed by a SV40 nuclear localization signal 
(NLS, bright blue) for cellular transport of Cas9 into the nucleus. Furthermore, the Cas9 gene is 
fused to an enhanced green fluorescent protein (Cas9-2A-eGFP) reporter gene sequence for post-
transfectional selection by flow cytometry. The SV40 poly(A) signal after the gene sequences on 
the plasmid convey mRNA stability in the targeted cell. The sequences in the red dashed box were 
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used for bacterial cloning of the pCas9_GFP plasmid. B, highly pure GFP labeled Cas9-NLS protein 
(MJ922, orange) was kindly provided by the group of Prof. Dr. Martin Jinek (Department of 
Biochemistry, University of Zurich).  
For all transfection experiments, BeWo and HEK-293 (human embryonic kidney 293) cells 
were seeded one day before starting the transfection experiment into conventional 96-
well plates using DMEM low glucose (Gibco, 21885) for BeWo or EMEM (Gibco, 15240-
062) for HEK-293 respectively, but both with 10% FBS and 1 x antibiotics. They were 
incubated overnight at 37°C and 5% pCO2. The transfection of both cell lines was 
performed according to the same protocol. The seeding density for BeWo was 
42’000 cells/well and 60’000 cells/well for HEK-293. 
2.5.2.1 Transfection strategy A: sgRNA-Cas9-plasmid 
Three different transfection reagents were tested to simultaneously transfer sgRNA and 
pCas9_GFP plasmid (Addgene ID 41824, see Figure 11) into trophoblasts to generate 
knockout cell lines by sgRNA delivery and Cas9 expression in the targeted cells. Finally, 
the Xfect™ Transfection Reagent from TAKARA was selected for further experiment (see 
description of the method below), due to better performance compared to DharamFECT™ 
Duo from Horizon or XtremeGENE9 DNA transfection reagent from Roche. 
Xfect™ Transfection Reagent (TAKARA PT5003-2) was used to transfect BeWo and HEK-
293 cells with Cas9 plasmid and sgRNA in a molar ratio of 1:2. The manufacturer’s protocol 
was adapted as follows: Cas9 plasmid and sgRNA were mixed with the transfection 
reagent and incubated 15 min at room temperature before adding to the cells. The cells 
were incubated together with transfection complex reagent for 18 h, followed by medium 
change to complete medium with 10% FBS. Further analysis was done 48 h post 
transfection.  
2.5.2.2 Transfection strategy B: sgRNA-Cas9-RNP transfection 
Transfection Reagents from two companies were used to transfect the BeWo cells with 
the Cas9-GFP protein together with the sgRNA as a preassembled RNP complex. The aim 
was to attain fast and efficient knockout after transfection of already active sgRNS-
Cas9protein-RNPs as done before in the framework of a Master of Science Project at the 
University of Zurich “Maximizing mutagenesis with solubilized CRISPR-Cas9 
Materials and Methods - CRISPR/Cas9-mutagenesis of single placental nutrient transporter 
50 
ribonucleoprotein complexes” in Danio rerio embryos by microinjection (Burger et al. 
2016). 
Xfect™ Protein Transfection Reagent (Takara PT5166-2) is a modified peptide with cell-
penetrating activity, whose amino acid composition enables an interaction with a protein 
cargo and transport across a cell membrane barrier. The manufacturer’s protocol was 
adapted as follows: 350’000 BeWo and 550’000 HEK-293 cells were seeded 18 h before 
transfection in a 12-well plate. In step 2b 0.8 - 2 µg of Cas9 protein (2 µg Cas9=10.4 pmol) 
were mixed with 10.4 pmol of sgRNA, then Xfect protein buffer was added to bring the 
volume to 40 µL. The rest was done according to protocol (www.takarabio.com/assets/-
documents/User%20Manual/PT5166-2_032712.pdf).  
jetCRISPR (Polyplus 502-01) was used, similar to Xfect™ Protein before, to transfect BeWo 
and HEK-293 cells with the Cas9 protein together with the sgRNA in an RNP complex. 
jetCRISPR® is especially designed after a confidential principle to deliver RNP in a 
CRISPR/Cas9 experiments. 350’000 BeWo and 550’000 HEK-293 cells/well were seeded 
18 h before transfection in a 12 well plate. The manufacturer’s protocol was linearly 
scaled to a 12 well plate leading to the following amounts: 1 mL of total volume, 31,3 μL 
serum free medium, 30,4 pmol of Cas9 and 30,4 pmol of sgRNA. Add 92 µL of final RNP 
solution to 828 µL of cell medium (www.polyplus-transfection.com/wp-content/-
uploads/2017/09/Short-Protocol-jetCRISPR-RNP.pdf).  
2.5.3 Sorting of transfected cells with flow cytometry 
After transfection, the cells were washed once with DPBS then trypsinized using 0.05% 
Trypsin-ethylenediaminetetraacetic acid (EDTA) (Gibco 25300). The cells were 
resuspended in DPBS with 1% FBS. Then GFP-positive cells were sorted into a 96-well plate 
containing 100 µL DMEM low glucose, 10% FBS and 1 x antibiotics using a flow cytometer 
(BD FACSAria™ III sorter) operated by Dr. Stefan Müller at the FACSLab of the University 
of Bern. The transfected cells were sorted according to further analysis as single cells, 100 
cells or 200 cells per 96-well. The sorted cells were cultured at 37°C and 5% pCO2. The 
medium was carefully exchanged one week after the sorting to avoid the loss of mutant 
cells. Apart from that, the medium was exchanged 1-2 times per week. After formation of 
tight colonies, the cells were redistributed by trypsinization within the well and 
subsequently transferred into a bigger well format up to a T75 flask. Cell mutant 
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candidates were frozen in FBS containing 10% dimethyl sulfoxide (DMSO, Merck, 
Darmstadt, Germany) and stored in liquid nitrogen. Every mutant candidate line was 
tested for loss of target gene expression by immunoblotting and functionally according to 
the target gene function by leucine (2.7.1 on p.57) respectively iron uptake assay (2.7.2 
on p.57). For direct analysis of the mutation rate after transfection the treated cells (GFP-
positive and GFP-negative) were sorted directly into PCR tubes prefilled with PCR-
mastermix and corresponding primer pair to amplify the target site DNA for sequencing. 
The Single-Tube Sequencing service of Microsynth AG in Switzerland was used for 
sequencing, while the resulting sequence trace chromatogram was analyzed using the 
UGENE software from NCBI, US.  
2.5.4 Determination of mutation rate by T7 Endonuclease 1 assay 
Purified genomic DNA from CRISPR/Cas9-targeted cells was analyzed with EnGen 
Mutation Detection Kit (NEB E3321) also known as T7 endonuclease 1 assay to estimate 
the mutation rate by genome editing. This assay is based on the property of the T7 
Endonuclease 1 which cleaves non-perfectly matched respectively hybridized DNA. 
Leading to a shedding of mutated DNA. The resulting DNA pieces with different sizes of a 
PCR product after digestion which are analyzed on an 1% agarose gel. Purification of 
genomic DNA was done with the ReliaPrep DNA Clean-Up and Concentration System 
(Promega A2892) and directly after stopping the digestion with 0.25 M EDTA (Sigma) the 
samples were loaded with BenchTop 100 bp DNA ladder (Promega G8291) on an 1% 
agarose gel containing RedSafe (Intron Biotechnology) as substitute for EtBr (ethidium 
bromide). The gels were running with 60 mV for 40 min.  
2.6 Biochemical investigation of placental tissue and cell lysates 
TRI Reagent (Sigma, T9424) was used for the isolation of RNA from various cell lines and 
placental tissue, as for example BeWo or primary trophoblasts, but also from fresh or 
frozen tissue samples. Therefore, approximately 50-100 mg of placental tissue or up to 
1 x 107 cells (T75-flask with confluent BeWo) were subjected to RNA isolation as 
previously described (X. Huang et al. 2013). This procedure is an improvement of the 
single-step method for total RNA isolation reported by (Chomczynski and Sacchi 2006). 
TRI Reagent is a mixture of guanidine thiocyanate and phenol in a monophase solution, 
effectively dissolves DNA, RNA, and protein on homogenization or lysis of tissue sample. 
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After adding chloroform or 1-bromo-3-chloropropane and centrifuging, the mixture 
separates into 3 phases: an aqueous phase containing the RNA, the interphase containing 
DNA, and an organic phase containing proteins. Briefly, approx. 50 mg of frozen or fresh 
placental tissue were subjected to homogenization in 1 mL TRI Reagent 2-times for 30 s 
on ice with a Polytron® homogenizer (Kinematica AG, Switzerland) followed by 
centrifugation at 12000 rcf for 10 min at 4°C (optional step 2 in the Invitrogen protocol). 
Phase separation was performed with 200 µL 1-bromo-3-chloropropane followed by 
centrifugation at 12000 rcf for 15 min at 4°C. The RNA was precipitated from the water 
phase by adding 500 µL isopropanol (100%), incubated for 10 min at room temperature 
and centrifuged with 12000 rcf for 10 min at 4°C. After washing the pellet with 1 mL EtOH 
(75%) and centrifugation at 7500 rcf for 5 min at 4°C, the RNA pellet was partially air dried 
below the laminar flow hood and redissolved in RNase free water, followed by incubation 
at 55°C for 10 min. Total RNA concentration was measured by NanoDrop 1000 (Thermo 
Scientific). All RNA samples included in the study had an OD260/280 ratio >1.8. Structural 
RNA integrity was measured for all samples in the iron project using a microchip 
electrophoresis system on an AGILENT 2100 Bioanalyzer© (Agilent Technologies). Chips 
were prepared and loaded according to the manufacturer’s instructions using the Agilent 
RNA 6000 Nano Kit (Agilent Technologies). Total RNA degradation was expressed as RNA 
Integration Numbers (RIN) (Schroeder et al. 2006).  
Cell lysis with hypotonic buffer with protease inhibitor is another quick method to isolate 
proteins and protecting them from degradation. In brief, in vitro cultured cells were lysed 
by adding hypotonic lysis buffer (10 mM Tris-HCl; 10 mM NaCl; 1.5 mM MgCl2, 1% Triton 
X-100; protease inhibitor cocktail, Sigma P2714; pH 7.4). The samples were vortexed in 
hypotonic lysis buffer every 5 min during 30 min on ice for thorough lysis of the cells. 
Alternatively, hypotonic lysis buffer was directly added to adherent cell and scraped using 
Techno Plastic Products AG (TPP) cell scrapers followed by thorough vortexing as 
explained before. Subsequently, the cell lysates were centrifuged at 1000 rcf for 10 min 
at 4°C to remove cellular debris and stored upon analysis at -20°C. Protein content in any 
case was measured using a commercial Pierce™ BCA Protein Assay Kit. 
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2.6.1 Quantitative RT-PCR 
First-strand cDNA was synthesized from 2 μg of total RNA with Oligo(dT)15 primers and 
GoScript™ Reverse Transcriptase (Promega, Switzerland) according to the manufacturer's 
instructions. The reverse transcription-quantitative polymerase chain reaction (RT-qPCR) 
reaction in SYBR® Green reagent was performed in a volume of 10 μL which contained 
0.5 μM primers, 2 x GoTaq®qPCR Master Mix (Promega, Switzerland) and 1 μL cDNA. 
Primer nucleotide sequences are described in Table 6. Amplification reactions were 
performed as duplicates in 384-well plates (Applied Biosystem, USA) with the ViiA7 system 
(Applied Biosystem, USA). Melting curves were analyzed to exclude the presence of 
additional unspecific PCR products. 
Table 6: Primer sequences used to quantify amino acid transporter, iron homeostasis and 
reference genes by RT-qPCR. 
Protein  Gene  Forward sequence, 5'-3' Reverse sequence, 5'-3' 
Length 
[bp] 
β-actin ACTG1 AACTCCATCATGAAGTGTGACG GATCCACATCTGCTGGAAGG 234 
GAPDH  GAPDH ACCACAGTCCATGCCATCAC TCCACCACCCTGTTGCTGTA 452 
UBI UbC TCGCAGCCGGGATTTG GCATTGTCAAGTGACGATCACA 64 
1433Z YWHAZ CCGTTACTTGGCTGAGGTTG AGTTAAGGGCCAGACCCAGT 143 
LAT1 SLC7A5 CAGGGCATCTTCTCCACGAC TGGGTTCGAGGAGGTGATCTA 137 
LAT2 SLC7A8 AGGCCCTCCTCTGTGGCTGG GTGCAGCAGGAGTGGCTGGG 106 
4F2hc  SLC3A2 AGCTGGAGTTTGTCTCAGGC GGCCAATCTCATCCCCGTAG 127 
DMT1# SLC11A2 TGCTATCAATCTTCTGTCT ACTGTAACATACTCATATCCA 177 
ZIP8# SLC39A8 GACAGTTATGTTGAGAAGG TGACCATTCTGACCATAT 107 
CP# CP CACTTACACCGTTCTACA GTATGCTTCCAGTCTTCT 170 
HEPH# HEPH GCTGAGATGGTGCCCTGGGAAC AGGAGGGGCCATGGAGCAAGAC 117 
Zp# HEPHL1 AAGATTCAGAAGGAGCCCTATACCCAG CGTCGATGTGCGAATGGTACACCC 171 
TfR1# TFRC GTAGATGGCGATAACAGT CCAATCATAAATCCAATCAAGA 167 
FPN1# SLC40A1 AGATCACAACCGCCAGAGAG CACATCCGATCTCCCCAAGT 111 
Zip14# SLC39A14 CTGCTGCTCTACTTCATA CAGACTTGGAGACATAATAATC 118 
MFRN1# SLC25A37 AACACTCAGGAGAACGTGGC AAGCAATTTCTCGCTCCCCT 467 
FTH# FTH1 TTGAGACACATTACCTGAA AAGAGATATTCCGCCAAG 112 
HEPC# HAMP TCCCACAACAGACGGGACAACTTG GCAGATGGGGAAGTGGGTGTCTC 119 
IRP1# IREB1 ACAAGCAGGCACCACAGACTATCC GCACCGTACTCTTTGCCAGCCAG 124 
IRP2# IREB2 GGTGGATTTTGCTGCTATGAGGGAG CACCTCCAGGATTTGGTGCATTCTG 155 
HIF-1α# HIF1A  TCCATGTGACCATGAGGAAA CCAAGCAGGTCATAGGTGGT 251 
GLUT1# SLC2A1 GAACTCTTCAGCCAGGGTCC ACCACACAGTTGCTCCACAT 114 
TRFE# TF AGCCTGCACTTTCCGTAGAC AACCACTTGGGCCAGTGAAA 112 
HFE# HFE ATTGGAGAGCAGCAGAACCC TGGTAGGTCCCATCCCCATT 334 
TfR2# TFR2 CAATCACAGGACCTCCACCC GTTGTCCAGGCTCACGTACA 322 
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Table 6 (continued) 
STEAP3# STEAP3 GAAAACCACACTGGCTCCAAC CACAGGGGAAGTAAGCTAGAGTC 207 
HCP1# SLC46A1 CGCTCACCACGCAGTATCTG GTGGGAGGTAAGGGTCTCCAC 131 
HRG1# SLC48A1 TTCTCAGAGTGCCCTTGCTG GCTGATACAAATGGCCGCTG 327 
FLVC1# FLVCR1 CTCGCGAAAGGATACCTCCC CTGGATCCACTGAAAGGCGT 330 
FLVC2# FLVCR2 CCCAACATTGAAGACCGGGA AGCATTCACTTCTTCCCCCG 327 
LRP1# LRP1 CAGCAAACGAGGCCTAAGTC CATGGGTTGGTCACTTCGGG 201 
SCARA5# SCARA5 TCTGAGGGGACAAGGCTCTA CTTGCCCGCCGTTTGTGAC 195 
HO1# HMOX1 ATGACACCAAGGACCAGAGC GTCGCCACCAGAAAGCTGAG 172 
HO2# HMOX2 GGAAACCTCAGAGGGGGTAG TGTGAAGTAAAGTGCCGTGG 317 
ATFX ATF5 ACCTTCTTTCTTCAGCCGAGG  GAGTTTCCCATAGTCTACGAGC 262 
BiP (GRP78) HSPA5 TGTGCAGCAGGACATCAAGT  TCCCAAATAAGCCTCAGCGG 166 
GRP94 
(Endoplasmin) 
HSP90B1 GCCAGTTTGGTGTCGGTTTC  GGGTAATTGTCGTTCCCCGT 168 
iNOS NOS2 GGAGCCAGCTCTGCATTATC  GTGCACTCAGCAGCAAGTTC 251 
Nrf2 NR2F1 ATCGTGCTGTTCACGTCAGAC  TGGCTCCTCACGTACTCCTC 104 
Legend: #, iron homeostasis proteins know to be expressed in human placental tissue. 
2.6.2 Colorimetric ferrozine-based assay for iron quantitation 
50 mg placental tissue from the same localization as the samples for mRNA and protein 
quantification was lysed in 50 mM NaOH (200 µL for 24 well-plate cultures). 100 mM 
NaOH with a ratio of 1:2 was used to reach 50 mM NaOH in samples lysed in hypotonic 
buffer with protease inhibitor. Tissue lysates were homogenized for 2 min with a 
Polytron® homogenizer in iced water or alternatively for adherent cells were lysed for 2 h 
on a shaker in a humidified atmosphere. FeCl3 standard dilutions with concentrations 
from 1.562 – 300 µM were prepared in 10 mM HCl (Sigma 258148) diluent. 50 mM NaOH 
(S8045 Sigma) solution was added with equal volume to standard dilutions to reach 
50 mM NaOH/ 5 mM HCl. Accordingly, 100 mM NaOH solution and 10 mM HCl was added 
with 1:2 volume/volume (v/v) ratio to 50 µL tissue or cell lysates to reach the same NaOH 
and HCl concentration as in standard dilutions. Aliquots of these lysates were used for 
iron quantitation and protein measurement (Pierce™ BCA Protein Assay, Thermo 
Scientific™). To the lysates and standard dilutions, respectively, freshly prepared iron 
releasing reagent (solution of equal volumes of 1.4M HCl and 4.5% weight/volume (w/v) 
KMnO4, Sigma 31404 in distilled water) was added 1:1 v/v. Samples were incubated for 
2 h at 60°C. After cooling the samples to RT, 30 µL of the iron-detection reagent (6.5 mM 
ferrozine; 6.5 mM neocuproine; 2.5 M ammonium acetate; and 1 M ascorbic acid (VWR, 
Switzerland); all dissolved in distilled water) was added to 300 µL sample volume. Samples 
were further incubated at RT for 30 min. The absorbance was measured in duplicates at 
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550 nm using the microplate reader (VMax® Kinetic ELISA Microplate Reader with 
Softmax® Pro Software, Molecular Devices LLC, USA). Absorbance of samples was 
compared to the absorbance of equally treated FeCl3 standard multiplied by dilution 
factor 2. The iron content was normalized to the protein concentration of the sample. 
2.6.3 Determination of oxidative damage and antioxidative potential of trophoblasts 
To measure oxidative stress levels in the BeWo cell models (N, H and HL), we determined 
products of the lipid peroxidation cycle and protein carbonylation. Furthermore we 
assessed the antioxidant potential of BeWo cells by quantifying GSH levels according to 
(Rahman, Kode, and Biswas 2007).  
2.6.3.1 Lipid peroxidation assay 
The products of lipid peroxidation, such as malondialdehyde (MDA), were measured using 
a thiobarbituric acid reactive substances (TBARS) assay in cell culture supernatant. MDA 
combines with thiobarbituric acid (TBA) in a 1:2 stoichiometry to form a fluorescent 
adduct. TBARS are expressed as MDA equivalents and normalized to total cellular protein 
concentration (Potter, Neun, and Stern 2011). Cell media were collected after 30 days of 
treatment and stored upon analysis at -20°C. For the other oxidative stress assays the cells 
were trypsinized, washed in cold PBS and stored at -20°C. 15% w/v trichloroacetic acid 
(TCA, Merck, Germany), sample or MDA standard (1,1,3,3 Tetraethoxypropane) and 
0.67% w/v TBA (VWR, Switzerland) in 2.5 M HCl were mixed in a 4:5:8 ratio, vortexed and 
boiled for 20 min at 95°C. The MDA standard curve was prepared as a 1:2 dilution series 
from 2 – 0.007 nmol/mL. After cooling the samples to RT, 2 mL 1-butanol was added and 
gently mixed. Spinning the samples for 1 min at 1000 rcf speeded up the phase separation. 
For the measurement, the butanol phase (top) was transferred to a black-wall 96-well 
plate and measured using Flex Station II fluorescence microplate reader (Thermo Fisher 
Scientific, Switzerland) at an excitation/emission wavelength of 530/550 nm, respectively. 
MDA equivalents were calculated by interpolation to the MDA standard curve. 
2.6.3.2 Protein carbonylation assay 
Carbonyl groups (aldehydes and ketones) are produced on protein side chains when they 
are oxidized. The detection of protein carbonyl groups involves their reaction with 2,4-
dinitrophenylhydrazine (DNP), which leads to the formation of a stable 2,4-dinitrophenyl-
hydrazone product, followed by its spectrophotometric quantification (Levine et al. 2009). 
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The cell pellets were resuspended with 2.5% w/v TCA and centrifuged at 11’000 rcf for 
3 min. 500 µL of 10 mM DNP in 2 M HCl was added to the precipitates and allowed to 
stand for 1 h at room temperature, with vortexing every 10-15 min. Thereafter, 20% w/v 
TCA was added for precipitation, followed by three washing steps with ethanol-
ethylacetate (1:1) to remove free reagent. The precipitated proteins were dissolved in 
600 µL of 6 M guanidine solution. The carbonyl content was calculated from the OD405 nm 
measured by Vmax Kinetic Enzyme-linked Immunosorbent Assay (ELISA) Microplate Reader 
(VWR) using a molar absorption coefficient of 22’000 M-1 cm-1. Carbonyl contents were 
normalized to the protein concentration. 
2.6.3.3 Measurement of total glutathione levels 
The assay to estimate the antioxidant potential of cultured trophoblasts is based on the 
reaction of GSH with 5,5'-dithio-bis-2-nitrobenzoic acid (DTNB) forming the chromophore 
5-thio-2-nitrobenzoic acid (TNB). The rate of TNB formation was measured at 405 nm 
using Vmax Kinetic ELISA Microplate Reader and is proportional to the concentration of 
GSH in the sample. The determination of total-GSH concentration detects both forms of 
glutathione, the reduced sulfhydryl form (GSH) and the oxidized glutathione disulfide 
(GSSG). The assay was performed according to the protocol from Rahman et al. 2007 
(Rahman, Kode, and Biswas 2007). The total-GSH concentration was calculated from the 
linear standard curve based on a 1:2 dilution series ranging from 125 - 1.96 nmol/mL. 
2.7 Placental nutrient uptake and transfer 
Trophoblasts are in direct contact with the maternal circulation, act as main transport unit 
and are responsible for tightly controlled nutrient acquisition for the vulnerable intra 
uterine growth. Therefore, nutrient uptake assays are used to investigate the first and 
crucial step in materno-fetal transport of leucine and iron respectively transfer assays to 
study transplacental leucine transport in vitro. As first, BeWo cells were seeded at a 
density of 100’000 cells/cm2. The isolated primary trophoblasts were seeded at a density 
of 1’000’000 cells/cm2 on 96-well plates which were coated with 430 µL per Transwell 
with 4.3 cm2 (or 55 µL per 96-well resp. 92 µL per 12-well) of 1:30 diluted Matrigel™ 
basement membrane matrix (VWR 734-1100) per 96-well. Trophoblasts were cultured 
until they reached their assigned differentiation stage and then washed 3-times with 
buffer depending on further procedure to leucine or iron uptake. Unstimulated BeWo 
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cells (BeWo-CTB) were investigated after overnight culturing. To obtain the 
syncytiotrophoblast (BeWo-STB) stage, BeWo cells were cultured overnight followed by 
stimulation with 100μM forskolin (Sigma F3917) for 48 h as described in (Azar et al. 2018). 
2.7.1 Leucine uptake 
The recently published leucine uptake method (Häfliger et al. 2018) was adapted to test 
the effect of different substrate concentrations on leucine uptake kinetics. In brief, 
cultured BeWo cells were cultured in complete growth medium (DMEM-lowGlucose, 
Gibco, Paisley, UK) containing 10% FBS and 1 x antibiotic-antimycotic and washed 3-times 
after culturing according to their assigned differentiation stage with pre-warmed Na+-free 
Hank’s buffer (125 mM choline chloride, 25 mM HEPES, 4.8 mM KCl, 1.2 mM MgSO4, 
1.2 mM KH2PO4, 1.3 mM CaCl2, 5.6 mM glucose, adjusted pH to 7.4). After equilibration 
by incubation in Hank’s buffer at 37°C for 7 min in a humidified incubator under 5% pCO2 
atmosphere, the cells were incubated for 3 min with pre-warmed Hank’s buffer containing 
L-Leu substrate including 1 µCi/mL respective 20 nM radioactive L-[3,4,5-3H(N)]-leucine 
(PerkinElmer, Waltham, MA, USA). leucine uptake was stopped by three washing steps 
with ice-cold Na+-free Hank’s buffer to remove the substrate. Cells were lysed by intense 
shaking for 1.5 h in MicroScint™-20 (PerkinElmer, Waltham, MA, USA). Finally, leucine 
uptake was quantified by a TopCount® NXT™ Scintillation and Luminescence Counter 
(PerkinElmer, Waltham, MA, USA). 
2.7.2 Iron uptake 
The different BeWo cell lines N, H and HL (see 2.4) were seeded 2 h before starting the 
experiment into 96-well plates (Corning® 96 Wellplate Flat Clear Bottom White 
Polystyrene TC-Treated, #3610) at a density of 60’000 cells/well and incubated with the 
respective medium. The preparation of Tf, the experimental procedure and calculation of 
iron-uptake was adapted from (Gambling et al. 2001). In brief, to prepare 55FeCl3 
(PerkinElmer, Germany)-labelled the uptake solution, human apo-Tf was dissolved in 
balanced salt solution (BSS; 136 mM NaCl, 5 mM KCl, 1 mM CaCl2, 1 mM MgCl2 and 18 mM 
4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES), pH 7.4) and added to 7.5% 
w/v NaHCO3. The previously mixed hot and cold iron was added for Tf binding at 37°C for 
2 h. The concentrated iron-transferrin (Fe-Tf) solution with the concentration of 
45 nmol/mL Tf, 90 nmol/mL 55FeCl3 and 243 µmol/mL NaHCO3 was diluted in BSS buffer 
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to final iron concentration of 179.8 pmol/mL. Binding of Fe3+ to Tf was confirmed by 
measuring E470 nm /E280 nm absorption ratio (data not shown). The cells were washed 3 x 
with BSS and incubated 30 min at 37°C for equilibration before 100 µL of the diluted 
uptake solution was added. Iron uptake was stopped at defined time points (1.5 min – 
2 h) by washing 3 x with BSS. 10% of uptake solution volume was measured separately to 
obtain dosage control (DC) values. For cell lysis and 55Fe detection 100 µL scintillation 
solution MicroScint-20 was added and the wells were shaken for 1.5 h at RT. The uptake 
data was acquired by TopCount Microplate Scintillation and Luminescence Counter 
(PerkinElmer, Germany). Counts per minute (cpm) were determined for each timepoint 
and then transformed into iron-uptake in % of total dose using the following equation:  
   %  
⁄ ( )  ⁄ ( )  
    ( ) × 
 ×   
To monitor the time-dependent adaptation processes on a functional level, iron-uptake 
time courses in BeWo cells were performed for 30 d under N, H and HL conditions. 
2.7.3 Glucose uptake 
Glucose uptake was measured using 2-Deoxy-D-glucose (2-DG; Sigma D8375) to study the 
effect of iron depletion on placental glucose uptake. 2-DG is a glucose analog that inhibits 
glycolysis via its actions on hexokinase, the rate limiting step of glycolysis. It is 
phosphorylated by hexokinase to 2-DG-P which cannot be further metabolized by 
phosphoglucose isomerases. This leads to the accumulation of 2-DG-P in the cell and is 
therefore the substrate of choice to study glucose uptake into trophoblasts as previously 
shown in competitive uptake assays using different glucose analogs (Larry W. Johnson and 
Smith 1985). In brief, 60’000 cells per well were seeded on a white-walled 96-well plates. 
BeWo cells were treated 18 h after seeding with FBS free medium with deferoxamine 
(DFO) (0, 15 and 30 µM) for 48 h in 7 replicates. BeWo cells were washed once with 100 μL 
KRH buffer (Krebs-Ringer-HEPES buffer; 50 mM HEPES, 137 mM NaCl, 4.7 mM KCl, 
1.85 mM CaCl2, 1.3 mM MgSO4; adjusted to a pH 7.4 with 0.5 M NaOH). Radiolabeled 2-
[1,2-3H (N)]-DG (3H-2-DG; 1 mCi, Perkin Elmer NET328001MC) was used for uptake 
quantification. 50 μL KRH buffer containing 2-DG and 3H-2-DG was added to each well 
(6.5 mM 2-DG and 0.5 µCi/well 3H-2-DG). Uptake was measured at different time points 
with a range from 0-120 min. Uptake was stopped by washing three times with ice cold 
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KRH buffer. For glucose uptake quantification 100 μL/well scintillation MicroScint™-20 
cocktail was added. In one row of the assay plate 55 μL lysis buffer for each time point 
was added to measure protein concentration using Pierce™ BCA Protein Assay Kit. Plate 
was mixed for 1.5 h on shaker (Edmund Bühler, type KS10) at 250 rpm and measured on 
TopCount NXT scintillation and luminescence counter. Uptake was normalized to protein 
concentration.  
2.7.4 Leucine transfer across placental barrier using Transwell technique 
Trophoblast monolayers with verified tightness were selected after 7 days of culturing on 
Transwell® membranes and randomly assigned to leucine transfer time courses and 
inhibition experiments. The inserts with cultured BeWo cells and an insert without cells 
(non-cell control) were placed in 12-well plates and washed 3-times with pre-warmed Na+-
free Hank’s buffer. Prior to starting the time course, the cells were equilibrated in Hank’s 
buffer for 30 min at 37°C. Leucine transfer from the upper (maternal) towards the lower 
(fetal) compartment was started by simultaneously replacing the buffer in both 
compartments. The buffer in the lower chamber was replaced with Na+-free Hank’s 
containing 300 μM glutamine and 167 μM unlabeled L-leucine to obtain a physiological 
counter-directed leucine gradient. Consecutively the buffer in the upper compartment 
was replaced with Hank’s containing 30 μM leucine (labeled with 3.7 nM L-[3,4,5-3H(N)]-
leucine), 300 μM glutamine and either vehicle DMSO or a constant 10 µM-dose of JPH203, 
JG336, JX020 or JX009, respectively. Inhibitors were applied in the upper compartment 
which is comparable to previous in vivo experiments (Wempe et al. 2012). At defined time 
points between 5 min and 6 h, 50 µL samples were taken from the maternal and fetal 
compartment. At the end of the experiment, all membranes were washed twice with 
DPBS and sampled to determine intracellular leucine levels. The medium and membrane 
samples including non-cell controls were collected in 3 mL of scintillation cocktail (Zinsser 
Analytic, Frankfurt, Germany). Radioactivity was quantified using Tri-carb 2100TR Liquid 
Scintillation Counter (PerkinElmer, Waltham, US).  
2.8 Leucine transport inhibition by small molecules 
JPH203, JG336, JX020 and JX009 were synthesized by our collaborators within the NCCR 
TransCure project (group of Prof. Karl-Heinz Altmann, ETH Zurich) following the routes 
described in the European Patent Application EP 2-959-918-A1, 2014. Compounds were 
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obtained as hydrochlorides, dissolved in DMSO and applied in the concentration range 
from 0.001-31.6 μM. JPH203 has been characterized as highly LAT1-specific; JX009 is 
described as LAT1 and LAT2-specific inhibitor (Endo et al. 2008). JG336 is a derivate of 
JPH203 with an additional methoxy group at the peripheral phenyl moiety residue, but 
unknown efficiency and specificity. JX009 is a meta-tyrosine in which the hydroxyl group 
at the phenol residue has been extended with a bulky side chain, while the amino acid of 
the other meta-tyrosine derivate called JX020 was fixed with a second ring. Meta-tyrosine 
would probably be a substrate itself, but the side chains in JX009 and JX020 prevents 
System L transport. Compound structures are depicted in Figure 22 on p.85.  
2.9 Statistics 
Data are expressed as mean ± standard deviation (SD) for or median with interquartile 
range. Transcript and protein levels were usually presented as fold-change or relative 
abundance and plotted as boxplots with Tukey whiskers (1.5-times interquartile range 
(IQR)) depicting mean (+), median (-). Of note, the chosen statistical test is mentioned in 
each Figure legend. In general, data sets were first tested, whether they came from 
Gaussian distribution by Shapiro-Wilk normality test. Hence, parametric statistical 
analysis was applied only if the values were following a normal distribution. Statistics 
comparing maternal-vein, fetal-artery and fetal-vein amino acid profiles were performed 
using paired two-way Analysis of variance (ANOVA) with Tukey’s correction. Spearman 
correlation was performed to test associations between physiological amino acid levels 
and anthropometric values. Differences between various uptake and transfer conditions 
and the difference in MS/MS-determined protein quantities between GDM and control 
were tested by Sidak's multiple comparisons test. For the detection of intracellular leucine 
retention in leucine transfer experiments by System L inhibition were statistically tested 
using a parametric one-way ANOVA analysis. Paired student T-tests were performed to 
detect differences in mRNA levels between CTBs and STBs or unstimulated BeWo-CTB or 
stimulated BeWo-STB. Expression changes of iron homeostasis genes in placental tissue, 
the analysis of sex dimorphism of iron homeostasis genes and in asymmetric System L 
transporter expression in MVM / BM membrane protein fractions were compared by 
using nonparametric Mann-Whitney test. Anthropometric and clinical data were 
compared between GDM and controls by unpaired two-tailed Student's t-test. For 
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immunohistochemistry the non-parametric chi-square (χ2)-test was used to compare 
semi-quantitative protein expression between control and GDM placentae. A p-value 
<0.05 was considered as statistically significant and shown as asterisk in figures next to 
the data points, *p<0.05, **p<0.01, ** p<0.001, ****p<0.0001. For collection and 
arrangement of numeric data we used Excel from Microsoft Office, while statistical 
comparisons were performed using GraphPad Prism (GraphPad).  
 
3 Results 
The following results part is divided into two sections investigating first the specific aims 
A1-A5 (1.6.1 on p.29) regarding the effect of counter-directed amino acid gradients on 
transplacental leucine transport, the expression of the System L transporter LAT1 and 
LAT2 in differentiating trophoblasts, the role of these singe transporter in placental 
leucine transport using small molecule inhibitors. In the second part of the results, the 
specific aims B1-B6 (1.6.2 on p.30) are elucidated concerning the relation between GDM-
mediated hyperglycemia and disturbed placental iron homeostasis. Herein expressional 
comparisons of iron homeostasis genes in placental tissues from GDM patients and 
healthy control were analyzed to identify affected iron transport pathways under GDM-
mediated hyperglycemia. Moreover, newly developed hyperglycemic in vitro models were 
applied to reveal functional disturbances and underlying cellular mechanisms and an 
obesogenic diet during mouse pregnancy was tested as alternative in vivo model system. 
3.1 Amino acid transport 
3.1.1 Relevance of physiological amino acid concentrations on gestation and fetal growth 
3.1.1.1 Determination of maternal and fetal amino acid spectra  
Maternal vein (MV) serum and the corresponding fetal vein (FV)/ fetal artery (FA) serum 
samples were prospectively collected from 22 clinically unsuspicious patients by Caesarian 
section at term (Table 7).  
The concentrations of the 20 standard proteinogenic amino acids are shown in Figure 12 
and Table 8. Brackets represent expected physiological ranges of amino acid 
concentrations in adults (>15 years) and newborns (0-1 month), respectively, based on 
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internally measured standard values at the University Hospital Bern. Particularly essential 
amino acids like Thr, Val, Trp and Lys and some conditionally essential amino acids such 
as Gly and Tyr were significantly higher concentrated in both fetal FA and FV 
compartments compared to MV. There was no difference between maternal and fetal 
concentrations for Cys and Asn. Ser and Gln showed significant greater concentrations in 
FA compared to MV. For Cys all quantitative measurements (4 µM in FV and 5 µM in MV) 
were clearly below the expected range of 25-80 µM for FV and 20-85 µM for MV. Due to 
the discrepancy to published data (Irene Cetin et al. 1988; Hayashi et al. 1978; Velazquez 
et al. 1976), Cys concentrations and gradients were excluded in the follow-up correlation 
analysis .There was no significant difference between female and male babies. 
 
Table 7: Anthropometric characteristics of healthy patients and their offspring. 









Delivery mode  cesarean sections 
Maternal age (years) 34.36 ± 3.74 
Preconceptional weight (kg) 67.52 ± 11.47 
Weight at partum (kg) 82.05 ± 14.30 
Height (cm) 163.95 ± 7.50 
Preconceptional BMI (kg/m
2
) 25.04 ± 4.76 
BMI at partum (kg/m
2
) 30.53 ± 5.06 
Weight gain (kg) 15.86 ± 5.83 
Gravidity 2.55  ± 1.34 
Parity 1.82  ± 0.85 
Gestational age at partum 38 3/4  ± 1     
Systolic blood pressure 117.36  ± 9.33 
Diastolic blood pressure 69.91  ± 10.05     
     Placental weight (g) 644.18  ± 112.80 





    
Gender 9 ♂  / 13 ♀ 







 ± 28.56 
 
Data are presented as mean ± standard deviation (SD). Abbreviations: BMI, body mass index. # 
Percentile were calculated by using child growth standards published by WHO 
(www.who.int/childgrowth/standards/weight_for_age); March 2020).  
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Figure 12: Full proteinogenic amino acid profile of maternal-fetal matched blood samples. The 
concentrations of the 20 standard proteinogenic amino acids (AA) were measured in prospectively 
collected blood sera from clinically unsuspicious woman and the placenta of their newborns 
(n=22) within 20 min after elective Caesarian section. The AA concentrations were measured by 
ion exchange chromatography in three different compartments, namely in blood sera from 
maternal vein (grey), in fetal artery (red) and fetal vein (blue). Data are depicted as Boxplots with 
Tukey whiskers. The various AA are classified according to their chemical structure and properties 
(see colored backgrounds). Brackets represent expected physiological ranges of AA 
concentrations of adults (>15 years) and newborns (0-1 month), respectively. The maternal-fetal 
matched blood samples were compared using paired two-way ANOVA with Tukey’s correction; * 
p<0.05, ** p<0.01, *** p<0.001. AA concentrations in sera from healthy mother-baby pairs at birth 
were significantly different by comparing maternal vein versus fetal artery for Gly, Ser, Thr, Val, 
Tyr, Trp, Gln, Asp, Glu and Lys. An overview on all results is presented in Table 8. 
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Table 8: Paired materno-fetal amino acid concentrations and materno-fetal gradients. 
Amino acid / 
classification 
Fetal arterial  
(FA) [µM] 










  mean  ± SD mean  ± SD mean  ± SD mean  ± SD mean  ± SD mean  ± SD 
Small Gly
(!)
 324  ± 67 290  ± 68 195  ± 38 129  ± 73  *** 95  ± 64  *** -34  ± 56 *** 
 Ala 429  ± 88 425  ± 77 421  ± 65 8  ± 87 5  ± 86 -4  ± 52 
Nucleophilic Ser 141  ± 26 124  ± 35 118  ± 18 23  ± 26  * 6  ± 32 -17  ± 32 
 Thr
!
 260  ± 41 252  ± 39 194  ± 35 66  ± 27  *** 58  ± 30  *** -8  ± 23 
 Cys
(!)
 5  ± 5 4  ± 4 5  ± 6 0  ± 3 -1  ± 3 -1  ± 2 
Hydrophobic Val
!
 216  ± 38 212  ± 33 170  ± 39 46  ± 30  *** 42  ± 34  *** -4  ± 22 
 Leu
!
 116  ± 21 113  ± 19 94  ± 13 22  ± 21 18  ± 20 -4  ± 17 
 Ile
!
 60  ± 13 59  ± 10 46  ± 8 14  ± 11 13  ± 10 -1  ± 8 
 Met
!
 28  ± 5 27  ± 4 21  ± 4 7  ± 5 6  ± 5 -1  ± 3 
 Pro
(!)
 189  ± 45 184  ± 42 173  ± 52 16  ± 25 11  ± 33 -5  ± 19 
Aromatic Phe
!
 79  ± 12 76  ± 10 64  ± 11 15  ± 13 12  ± 12 -3  ± 9 
 Tyr
(!)
 77  ± 15 75  ± 13 50  ± 21 27  ± 25  * 25  ± 24   * -2  ± 7 
 Trp
!
 70  ± 10 71  ± 8 39  ± 7 31  ± 11  ** 32  ± 10   ** 1  ± 8 
Amide Asn 55  ± 13 54  ± 11 55  ± 10 0  ± 13 -2  ± 11 -1  ± 11 
 Gln
(!)
 391  ± 145 376  ± 144 362  ± 62 29  ± 171 ** 14  ± 167 -16  ± 55 
Acidic Asp 98  ± 81 74  ± 51 41  ± 13 57  ± 82  *** 33  ± 56   ** -24  ± 75 * 
 Glu 279  ± 116 218  ± 99 111  ± 34 168  ± 115 *** 107  ± 104 *** -61  ± 100 *** 
Basic His
!
 122  ± 45 120  ± 46 104  ± 39 18  ± 16 15  ± 16 -2  ± 11 
 Lys
!
 320  ± 48 311  ± 48 152  ± 23 168  ± 35  *** 159  ± 38  *** -9  ± 29 
  Arg
(!)
 79  ± 23 72  ± 14 74  ± 17 5  ± 24 -2  ± 19 -7  ± 14 
Legend: Statistical comparison between different blood compartments, e.g. FA versus MV, FV versus MV and FV versus FA were performed in 22 healthy 
controls using 2 way ANOVA and multiple comparison with Tukey testing; α=0.05, * p<0.05, ** p<0.01, *** p<0.001. Amino acids are abbreviated according 
to 3-letter amino acid code. Fetal arterial (FA); Fetal venous (FV); Maternal venous (MV); !, essential amino acids; (!), Conditionally essential amino acids.  
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3.1.1.2 Individual and amino acid-specific differences in materno-fetal gradients 
The difference between FA and MV was selected as AA-gradient relevant for materno-
fetal transfer. We found significant FA-MV differences for the small AA Gly, the 
nucleophilic AA Ser and Thr, the hydrophobic AA Val, and the aromatic AA Tyr and Trp. 
Similar differences were also found when comparing the FA-MV against FV-MV gradients. 
Of note, large differences were found for essential AA. The non-essential AA Ser, Asp and 
Gln additionally showed highly negative veno-arterial (FV-FA) differences (Table 8), i.e. 
they disappear in placental capillaries and are secreted into the placenta towards 
maternal circulation, respectively (Holm et al. 2017). Although there were negative means 
of FV-FA differences for all AA except Trp (Table 8), 7 out of 22 individuals showed 
predominantly positive FV-FA differences (Figure 13). Thus, the placentae included in our 
studies can be classified into either accumulative (positive FV-FA difference; 45.5%) or 
secretive (negative FV-FA difference; 54.5%) tissues. Of note, only four placentae (18%) 
exposed a mixture of accumulation and secretion mode, which could be a transient state. 
 
Figure 13: Individual differences in fetal net amino acid accumulation and secretion. The means 
of veno-arterial (FV-FA) differences of 20 amino acids (AA) are represented in a stacked bar 
diagram. The analyzed individuals are depicted on the x axis in ascending order. 12 out of 22 
individuals showed a negative, while 7 out of 22 individuals showed a clear positive sum of veno-
arterial differences. Of note, only four placentae (18%) exposed a mixture of accumulation and 
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secretion (≈). In general, the 22 individuals can be classified based on their veno-arterial 
differences in either accumulative placentae, performing fetal AA uptake or in secretory 
placentae, performing fetal AA efflux. Since there were more secretory placentae present in this 
study, the total FV-FA difference as listed in Table 8 is negative. 
3.1.1.3 Amino acid concentrations and materno-fetal gradients correlate with selected 
anthropometric data 
Next, the concentrations of all 20 amino acids, their materno-fetal gradients and fetal 
veno-arterial differences were correlated to the corresponding anthropometric data 
listed in Table 7. The summary of all significant Spearman’s correlations is shown in Table 
9, negative correlations are marked with (↓). In general, 79% of all Spearman’s 
correlations between the different sera compartments and clinical parameters concerning 
maternal constitution, fetal growth or maternal blood pressure were positively 
associated. Interestingly, 36 out of 85 (42%) significant positive Spearman’s correlations 
were associated with amino acid concentrations in the MV, which is affected by the diet 
and fasting time of the mother. In contrast, all negative correlations were associated to 
fetal amino acid concentrations. 69% of all and 56% of MV correlations, respectively, were 
associations between LAT1 substrates and anthropometric parameters. Based on the 
latter results, we focused in this study specially on LAT1 substrates as highlighted in Table 
9.  
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Table 9: Spearman correlations between amino acid concentrations, materno-fetal gradients and corresponding anthropometric data 





Age FV                     ↓FA                 
preconception 
Weight 
  MV       FA MV FV   FA MV-FV MV-FV       MV MV       
          MV   MV   MV                     
                  MV-FV                     
Weight at 
partum 
  MV       MV MV MV MV FA MV MV     MV   MV MV     
                  MV   MV-FV                 
Weight gain FA FV                     ↓FV                
FV                       MV-FA                
↓MV-FV                       MV-FV               
Height         ↓FV     MV-FA                   MV-FA     
          MV-FA                         MV-FV     
          MV-FV                               
BMI mother at 
partum 
  MV       MV MV FA MV FA             MV MV     
              FV   MV             MV-FV       
              MV                         
preconception 
BMI           FA FV FA   FA             MV MV     
            MV MV FV   MV                     
                MV                         
Gravidity                                 MV       
BP Syst mother ↓FA ↓FA ↓FA MV-FA   ↓FA ↓FA   ↓FV   ↓FA     ↓FA   ↓FV     ↓FA   
  ↓FV     MV-FV   MV-FA ↓FV       ↓FV     ↓FV   MV-FV         
  MV-FV                   MV-FA     MV-FA             
BP Diast 
mother 
  MV-FA   MV-FA   MV-FA         MV-FA   FV-FA       ↓FV     MV-FA 





        ↓FV-FA                   ↓MV-FV ↓MV-FA         
Weight placenta MV-FV MV-FV MV   FV-FA                     MV-FV MV        
                                MV-FV       
Weight 
offspring FV                     ↓FA                 
Gender 
offspring                            MV             
Legend: Statistical significant correlations between different blood compartments, e.g. FA versus MV, FV versus MV and FV versus FA were 
performed in 22 healthy controls by Spearman correlations; α=0.05; !, essential amino acids; (!), conditionally essential amino acids; Green, LAT1 
substrates; orange, Glutamine (Gln) as LAT1 co-substrate; ↓, nega ve correla ons. 
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3.1.1.4 Associations between amino acid concentrations in maternal and fetal compartments 
with clinical data 
The correlations between clinical data with amino acid concentrations in maternal and 
fetal sera, but also with materno-fetal gradients are listed in Table 9. There were positive 
correlations between preconceptional weights and the MV concentrations for Ala, Val, 
Leu, Ile, Pro, Asp and Glu (Table 9), but also FA concentrations for Val and Pro respectively 
FV concentration of Ile. All MV concentrations correlating with preconceptional weights 
were also correlating with maternal weight at partum but also to Met, Phe, Tyr, Gln and 
His (Table 9). Figure 14 shows Spearman correlation with maternal weights and body mass 
index (BMI) as scatter plot for Leu, that seems to persist throughout pregnancy. The group 
of hydrophobic amino acids and LAT substrates Val, Leu and Ile were showing similar 
correlation patterns. For maternal weight gain as parameter combining the weight before 
pregnancy and at term only fetal amino acid concentrations such as for Gly Ala and Trp 
were correlating significantly (Table 9). Analogous to the relation between 
preconceptional weights and the weights at partum, there were comparable correlations 
between amino acid concentrations and preconceptional BMI and BMI at term (Figure 14).  
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Figure 14: Linear relation between leucine concentrations and maternal anthropometric data. 
The relation between measured leucine (Leu) concentrations in maternal venous sera (MV) and 
(A) maternal preconceptional weights, (B) maternal weights at partum (C) preconceptional body 
mass index (BMI) and (D) BMI at partum was analyzed by Spearman correlation for 22 healthy 
controls (n=22). Data are presented as scatter plots with the anthropometric parameters on the 
x-axis and AA concentrations in the maternal vein (MV) on the y-axis. Preconceptional weights, 
maternal weights at partum and BMI were mainly correlating with MV concentrations of AA which 
are LAT1 substrates. The results of all significant correlations are listed in  Table 9. Statistical values 
describing the linear relationship between two parameters are denoted to the right of the scatter 
plots: rs , Spearman correlation coefficient; CI, confidence interval; p, two-tailed p value. 
 
3.1.1.5 Correlations of the amino acid gradients and veno-arterial differences with clinical data 
Amino acid gradients across the materno-fetal barrier were calculated as difference 
between MV and FV or FA. Positive correlations were detected between materno-fetal 
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amino acid gradients and maternal weights of Pro, Phe and Tyr before conception and Tyr 
at partum as well (Table 9). Furthermore, amino acid gradients of Ile, His were correlating 
with maternal heights, while putting weights and height into relation Glu MV-FV was 
correlating with BMI at partum. Negative correlations were found between amino acid 
gradients and clinical data of Gly MV-FV with maternal weight gain, but also of Gln and 
Asp with gestational age (Table 9). The MV-FV gradients of the three aromatic amino acids 
Phe, Tyr and Trp were correlating with the different maternal weight parameters like 
preconceptional weight, weight at partum and weight gain (see Figure 4 for Tyr and Trp). 
For the veno-arterial (FV-FA) difference only few positive correlations with 
anthropometric data were detected, namely between maternal diastolic blood pressure 
and Trp (see, 3.1.1.7) respectively between placental weight and Cys, whereas FV-FA 
difference for Cys were negatively related to gestational age (Table 9).  
3.1.1.6 Placental weight correlates with MV-FV gradients of non-essential amino acids 
MV-FV gradients of the non-essential small amino acids Gly and Ala, but also the two 
acidic amino acids Asp and Glu, as well as MV levels of Ser and Glu were positively 
associated with placental weight (Table 9). However, Fetal gender and birth weight were 
largely independent of the amino acid concentrations. As exceptions there were 
correlations for weights of offspring with Gly concentration in FV and the negative relation 
with Tyr in FA, whereas only Asn in MV was correlating with fetal sex (Table 9).  
3.1.1.7 Association between maternal blood pressure and fetal amino acid concentrations  
The concentrations of Gly, Ala, Ser, Val, Leu, Met, Phe, Asn, Asp and Lys in fetal vein and 
artery were significantly decreasing with increasing systolic blood pressures values (Table 
9). The decreasing fetal amino acid levels relative to the elevation in systolic blood 
pressure resulted in a positive correlation with materno-fetal gradients and systolic blood 
pressure. MV-FV gradients for Gly, Thr, Asp, Glu and Arg and MV-FA gradients for Ala, Thr, 
Val, Phe, Asn, and Arg were positively correlating with diastolic and systolic blood pressure 
(Table 9).  
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Figure 15: Representative correlations between tyrosine and tryptophan gradients across 
materno-fetal barrier and anthropometric data. Amino acid (AA) gradients across the materno-
fetal barrier were calculated as difference between concentrations in maternal vein (MV) and fetal 
artery (FA) or fetal vein (FV) for 22 mother-fetus paired serum samples (n=22). Since AA levels are 
generally higher in the fetal as compared to the maternal circulation, AA gradients are negative 
values and therefore represent counter-directed materno-fetal gradients. Significant Spearman 
correlations were found between (A) tyrosine (Tyr) gradients and maternal preconceptional 
weights, (B) Tyr gradients and maternal weights at partum, (C) Trp gradients and maternal weight 
gain (defined as maternal weight at partum minus preconceptional weight) and (D) Alanine (Ala) 
gradients and placental weight. Results are presented as scatter plots with anthropometric data 
on the x-axis and AA gradients on the y-axis. Additional significant correlations for other significant 
correlations (Table 9).  Statistical parameters describing the linear relationship are denoted below 
the scatter plots: rs, Spearman correlation coefficient; CI, confidence interval; p, two-tailed p 
value. 
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3.1.2 Effects of counter-directed gradients on placental leucine transfer 
3.1.2.1 Increased extracellular leucine levels facilitate leucine uptake into trophoblast cells 
Two different extracellular leucine concentrations were applied to test the effect of amino 
acid gradients on leucine uptake efficiency into the choriocarcinoma cell line BeWo and 
the colon carcinoma cell line HT-29. A leucine concentration in the upper clinical range 
(167 µM) was selected and compared to a lower concentration of 30 µM leucine. 30 µM 
leucine corresponds to approx. 1/3 of the mean leucine -MV concentration. As shown in 
Figure 7A, increased extracellular leucine levels facilitated uptake of leucine into 
undifferentiated BeWo-CTB from 15.9 to 47.3 nmol/mg protein (mean difference and 
standard error = 31.4 ± 3.5 nmol/mg protein), and into differentiated BeWo-STB from 30.7 
to 103.4 nmol/mg protein (mean difference and standard error = 72.8 ± 8.5 nmol/mg 
protein). In comparison, the uptake into HT-29 cells increased from 32.7 to 66.2 nmol/mg 
protein (mean difference and standard error = 33.5 ± 5.0 nmol/mg protein). Therefore, 
for trophoblasts a 2-times higher basic leucine uptake rate was found in BeWo-STB 
compared to BeWo-CTB. A comparable leucine uptake capacity was observed in BeWo-
STB and HT-29 cells under low substrate conditions, but a clearly enhanced uptake 
capacity of trophoblasts was detected under high extracellular leucine concentrations 
(Figure 16A). The LAT1-specific inhibitor JPH203 was applied to assure that leucine uptake 
in Na+-free conditions was mediated by LAT1. LAT1-specific inhibition in a dose-response 
experiment resulted in a dramatic reduction of leucine uptake into both BeWo-CTB with 
85% and into BeWo-STB 76% reduction with half maximal effective concentration (EC50) 
values in the nanomolar range (Figure 16B), suggesting an only minor involvement of 
other System L transporters like LAT2 at exceeding leucine concentrations. These results 
indicate a primarily LAT1-mediated leucine uptake process in trophoblasts with high 
dependency on extracellular substrate availability.  
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Figure 16: Amino acid concentration influences LAT1-mediated leucine uptake in the BeWo cell 
model. (A) The effect of extracellular leucine (Leu) concentrations on the Leu uptake capacity into 
BeWo trophoblasts was assessed and compared to the frequently used colon cancer cell model 
HT-29 cell. Leu uptake assays were performed with Leu concentrations of 167 µM, reflecting an 
upper clinical range, and a lower concentration of 30 µM. Moreover, the uptake capacity between 
syncytiotrophoblasts (STB) and cytotrophoblasts (CTB) was compared by stimulating 
undifferentiated BeWo cells (BeWo-CTB) with 100 µM forskolin for 48 h (BeWo-STB). For all cell 
types Leu uptake was measured within 3 min and normalized to the total protein concentration. 
BeWo-CTB are depicted in blue, BeWo STB in red and HT-29 in grey (A-B). Differences were tested 
by Sidak's multiple comparisons test; * p<0.05, ** p<0.01, *** p<0.001. Of note, the stimulation 
of Leu uptake through increased extracellular Leu concentration was more then 2-times higher in 
BeWo-STB, as compared to the other undifferentiated cell types. The results of 3 individual 
experiments with 4 replicates each are presented as mean (+), median (-) and Tukey whiskers (1.5-
times IQR). (B) To verify the presence of LAT1/SLC7A5-mediated Leu uptake and its susceptibility 
to different substrate concentrations, a dose-response experiment with the LAT1-specific inhibitor 
Results - Amino acid transport 
74 
JPH203 was performed. Leu uptake under high Leu concentration (167 µM Leu) are depicted as 
solid lines and lower (30 µM Leu) as dashed lines (B). BeWo-STB with high Leu levels showed 
significantly higher Leu uptake rates, but also a much higher susceptibility to inhibition by JPH203 
compared to BeWo-CTB. Interestingly, even high doses of JPH203 did not inhibit Leu uptake in 
BeWo-STB at 167 µM Leu as markedly as in BeWo-CTB. Differences were tested by Sidak's multiple 
comparisons test; * p<0.05, ** p<0.01, *** p<0.001. Error bars represent standard deviation (SD) 
of a representative experiment with 4 replicates each. 
3.1.2.2 Counter-directed leucine gradient promotes leucine transfer across the materno-fetal 
barrier 
The materno-fetal leucine transfer was measured by applying either equimolar leucine 
concentrations (30 µM each) in the upper (maternal) and lower (fetal) compartment (Leu 
materno-fetal gradient = 0 µM) or by applying a counter-directed gradient with 30 µM 
leucine in the maternal and 167 µM leucine in the fetal compartment (counter-directed 
leucine materno-fetal gradient = 137 µM). Figure 17B shows the experimental setup and 
the concentration changes of radio-labeled leucine measured in the upper (Maternal 
venous (Mv)) compartment and in the receiving lower (Fetal arterial (Fa)) compartment 
from a representative Transwell® experiment over 6 h. The application of a counter-
directed leucine gradient of 137 µM significantly stimulated the materno-fetal transfer of 
leucine by 47.2% in average within the last three time points (4 – 6 h). Moreover, leucine 
transfer was significantly reduced by applying 10 µM of LAT-specific inhibitor JPH203 
(Figure 17A, dashed line), indicating that mainly LAT1-mediated leucine transfer across 
the materno-fetal barrier occurs. Within three successively and independently performed 
Transwell® experiments (n=3), there were significant differences detected from 120 min 
transfer time onwards (Figure 17C). The intracellular leucine content measured at the end 
of the experiment (Figure 17D) was not significantly different between equimolar leucine 
concentrations and counter-directed leucine gradient. Intracellular leucine retainment 
would be a sign for leucine efflux limitations forwards the lower fetal compartment. 
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Figure 17: Counter-directed leucine gradient increases amino acid transfer across the placental 
barrier. (A) Materno-fetal leucine (Leu) transfer across a tight trophoblast monolayer was studied 
using the Transwell® system. BeWo cells were cultured on a semi-permeable membrane and 
differentiated by stimulation with 100 µM forskolin 24 h after seeding. Leu transfer was measured 
by simultaneous sampling and measurement of diminishing radiolabeled Leu (L-[3,4,5-3H(N)]-
leucine) in the upper maternal vein (Mv) compartment and appearing radiolabeled Leu in the 
lower compartment representing the fetal artery (Fa) over 360 min (A). Two different conditions 
were compared: materno-fetal Leu transfer in the condition with 30 µM Leu both in the Mv and 
the Fa compartment (no gradient, blue) or against a counter-directed Leu gradient with 30 µM 
Leu in Mv and 167 µM Leu in the Fa compartment (orange). In all conditions there was 300 µM 
Gln as exchange partner in both compartments. The schematic representation of the experimental 
setup is shown in panel B. Leu transfer across the placental barrier was increased against a 
counter-directed 137 µM Leu-gradient. A, shows results of a representative dataset from 3 
independent experiments. The combination of the 3 independent Transwell® experiments (n=3) 
are shown in panel C. Measured accumulation of intracellular Leu at the end of the experiment is 
presented in panel D. Differences were tested by 2 way ANOVA with Tukey's multiple comparisons 
test; * p<0.05, ** p<0.01, *** p<0.001. 
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3.1.3 Trophoblast differentiation affects placental amino acid uptake  
3.1.3.1 LAT1, LAT2 and 4F2hc are asymmetrically expressed in the human placenta 
Before MVM- and BM-fractions were used for protein localization studies, the enrichment 
of MVM and BM samples was approved by determining alkaline phosphatase activity and 
FPN1 expression for each isolation as shown in Figure 18. 
 
Figure 18: Characterization of MVM/BM enrichment by determining alkaline phosphatase 
activity as MVM-marker and FPN1 as BM-marker expression. Alkaline phosphatase is a marker 
enzyme for the syncytiotrophoblast (STB) apical membrane/microvillous membrane (MVM) 
(Nicholas P. Illsley et al. 1990), while Ferroportin 1 (FPN1) as iron exporter is expressed in the basal 
membrane (BM) (Bastin et al. 2006). Alkaline phosphatase activity in MVM and BM samples from 
membrane isolations were compared to their corresponding homogenate fraction before 
MVM/BM enrichment using a parametric paired t-test. Alkaline phosphatase activity relative to 
homogenate as depicted in A was 7.0-times higher in MVM (9.6-times enrichment) compared to 
BM (1.6-times enrichment). B left panel shows p-nitrophenyl phosphate (pNPP) hydrolysis 
(colorless) to p-nitro-phenol (yellow, λabs.=405 nm) by alkaline phosphatase activity of a 
representative experiment during 2 min. FPN1 expression was analyzed by immunoblotting (C). 
BM-marker FPN1 was increased in BM compared to MVM fractions. A-C, Characterization of 
MVM/BM enrichment was performed for 6 out of 11 isolations (n=6). 
 
Histological investigation of healthy placental tissue demonstrated strong expression of 
LAT1 at the apical membrane of STB (arrows in Figure 19A), if compared to almost no 
signal at the basal membrane of STB (arrowheads in Figure 19A). Very similar asymmetric 
LAT1 expression was found by comparing the strong signal in the MVM versus BM fraction, 
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both compared to total membrane homogenate from 11 MVM/BM isolation experiments 
(Figure 19B). The investigation of the asymmetric expression was expanded from LAT1 to 
LAT2 and 4F2hc by immunoblot analysis in paired MVM/BM isolated fractions from term 
control placentae. LAT1 was predominantly expressed at the MVM as reflected in a mean 
MVM to BM ratio of 6.9 (range 3.5 – 14.9; Figure 19B). Western blot analysis of MVM and 
BM pairs revealed a significantly higher expression of LAT1 in MVM compared to BM 
(p=0.0015; Figure 19C). The results of these two independent experimental approaches 
suggest almost exclusive LAT1 expression at the apical membrane which is in direct 
contact with maternal blood. In contrast, LAT2 was found to be expressed in both MVM 
and BM (Figure 19C), with an apparent predominance of the two LAT2 variants (30 and 
50 kDa) in BM as reported before(Rosario et al. 2013). Expression of 4F2hc, the heavy 
chain partner protein of LAT1 and LAT2, was higher in MVM as compared to BM (Figure 
19C).  
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Figure 19: Asymmetric expression of the Na+-independent leucine transporters LAT1 and LAT2 
at the placental barrier. A, Representative picture showing apical LAT1 localization in 
immunohistochemistry performed on human term placenta. Arrows indicate the apical MVM, i.e. 
maternal blood orientated side; arrowheads depict the BM of the STB. There was no signal in 
negative control. B, Left panel, representative immunoblot from a total of 11 human term 
placentae. B, Right panel, LAT1 was highly expressed in MVM, but negligible in BM protein 
fractions. The data are shown as boxplots with Tukey whiskers (Mann-Whitney test, α=0.05; 
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p<0.0001). Densitometric analysis was corrected for actin signal. C, The expression of LAT1 
(SLC7A5), LAT2 (SLC7A8) and 4F2hc (SLC3A2) was analyzed in total membrane isolation (TMI), 
microvillous membrane (MVM) and basal membrane (BM) fractions in two independent 
experiments (n=2) by immunoblotting. In the left panels, images of a representative immunoblot 
are shown with corresponding densitometric quantification on the right. In the right panels the 
densitometric analyses and consecutive statistics for both experiments are shown. LAT1 was 
almost exclusively expressed in MVM, while LAT2 was found in both MVM and BM. 4F2hc, the 
heavy chain partner protein of LAT1 and LAT2, was higher expressed in MVM as compared to BM. 
Beta-actin was used as reference gene. 
 
3.1.3.2 Trophoblast differentiation induces upregulation of LAT1 and 4F2hc expression  
To study the role of LAT1 at the placental barrier on the cellular level, LAT1 expression 
during trophoblast differentiation was analyzed in both primary human trophoblast cells 
and in the BeWo cell line model on mRNA and protein level. Forskolin-stimulated 
differentiation in BeWo cells resulted in a significant upregulation of LAT1 and 4F2hc, but 
no significant changes for LAT2 were observed (Figure 20A). Spontaneously occurring 
trophoblast differentiation in primary trophoblasts tended to increase LAT1 and 4F2hc 
mRNA levels, but due to the high variation between the individual placental cell isolations 
this effect did not reach statistical significance (Figure 20B). Interestingly, protein analysis 
by immunoblotting revealed a clear difference in the protein expression pattern between 
LAT1 and LAT2 depending on the differentiation state: while LAT2 was predominantly 
found in undifferentiated primary CTB and BeWo-CTB, LAT1 protein levels were clearly 
increased in differentiated primary STB and BeWo-STB (Figure 20C). Furthermore, 
increased 4F2hc expression was detected after differentiation in both primary and BeWo 
cells. 4F2hc protein expression was identified in the form of multiple bands ranging from 
70-120 kDa under reducing conditions. The shattered expression pattern of 4F2hc was 
found previously and is presumably due to dimerization with itself, with LAT1 or LAT2 
(Okamoto et al. 2002; Ohgaki et al. 2017; Costa et al. 2013). BeWo cells exhibited higher 
expression levels, but comparable expression changes during differentiation as primary 
trophoblasts. 
Results - Amino acid transport 
80 
 
Figure 20: Expression patterns of the placental System L-transporters in primary trophoblasts 
and BeWo cells depend on their differentiation stage. Comparison of the choriocarcinoma 
derived BeWo cell line (A) and primary trophoblasts (B) was performed with respect to LAT1 
(SLC7A5), LAT2 (SLV7A8) and 4F2hc (SLC3A2, CD98) mRNA levels at the undifferentiated 
cytotrophoblast (CTB) and differentiated syncytiotrophoblast (STB) stage. A, LAT1 and LAT2 
transcript levels of primary trophoblasts were not significantly increased in STB as compared to 
the CTB counterpart (paired T-test), while 4F2hc was upregulated after cell differentiation. 
Primary trophoblasts were harvested from 5 individual trophoblast isolations (n=5). They were 
lysed for mRNA isolation and quantitative RT-qPCR after 12 h at the CTB stage and after 72 h of 
culturing at the STB stage. B, LAT1 was upregulated, while LAT2 and 4F2hc expression in BeWo-
Results - Amino acid transport 
  81 
STB cells were not significantly increased relative to their BeWo-CTB control (paired T-test of 3 
independent experiments). BeWo-CTB were sampled after 24 h of culturing and BeWo-STB were 
analyzed after stimulation with 100μM forskolin for 48 h. A/B, Expression results were normalized 
to the mean of the reference genes YWHAZ, GAPDH and β-actin. Transcript data are presented as 
fold-change (2-ΔΔCt) and plotted as Tukey whiskers (1.5-times IQR) with mean (+), median (-), 
α=0.05, * p<0.05. C, Representative immunoblot (left panel) and densitometric analysis of both 
cell types revealed increased LAT1 protein expression after cell differentiation (CTB<STB). 
Generally higher LAT1 protein expression levels were found in the BeWo cell line compared to 
primary cells (BeWo-CTB/STB>pCTB/STB). The expression of the two LAT2 variants (50 kD; 30 kD) 
were decreased after trophoblast differentiation in both cell types (primary trophoblasts and 
BeWo cells). 4F2hc was increased in both primary trophoblasts and BeWo-STB as compared to the 
corresponding CTB-stage. Densitometric analysis in the right panel was corrected for actin signal. 
3.1.3.3 Leucine uptake increases with trophoblast differentiation 
We further investigated whether the expression changes caused by trophoblast 
differentiation resulted also in an increased leucine uptake efficiency in both primary 
(n=3; Figure 21A) and BeWo cells (n=3; Figure 21B). Indeed, both spontaneously 
differentiated primary trophoblasts (pCTB-Vmax=1.05 nmol/mg protein versus pSTB-
Vmax=2.34 nmol/mg protein=2.2-fold) and forskolin-stimulated BeWo cells (BeWo-CTB-
Vmax=4.96 nmol/mg protein versus BeWo-STB-Vmax=13.41 nmol/mg protein=2.7-fold) 
reached more than 2-times higher maximal uptake levels after 6 min compared to the 
undifferentiated stage. By comparing maximal leucine uptake levels between BeWo and 
primary cells, a 4.7-fold greater uptake capacity for the BeWo-CTB and 5.7-fold difference 
for the BeWo-STB stage was observed. However, the half-maximal leucine uptake time, 
calculated as Kd from the time course curve fit, for primary cells (pCTB-Kd=1.45 nmol/min; 
pSTB-hillslope=1.36 nmol/min) and BeWo cells (BeWo-CTB-Kd=1.19 nmol/min; BeWo-
STB-Kd=1.42 nmol/min) was similar between the differentiation stages. Thus, in 
accordance to expressional changes, also on functional level leucine uptake capacity was 
higher in BeWo cells compared to primary trophoblasts, but the kinetic changes due to 
cell differentiation were similar in both cell models (Figure 21). 
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Figure 21: Similar leucine uptake kinetics were detected for primary trophoblast and BeWo cells. 
A, In the BeWo cell model significantly increased Na+-independent leucine maximal uptake 
capacity (Vmax) was found in 3 independent experiments (n=3). Leucine uptake increased from 
4.96 nmol/mg protein in BeWo-CTBs to 13.41 nmol/mg protein in BeWo-STBs (2 way-ANOVA, 
α=0.05; p=0.018). Leucine uptake for BeWo-CTB was performed after 24 h of culturing and for 
BeWo-STB after stimulation with 100 μM forskolin for 48 h. B, Primary trophoblasts isolated from 
3 individual control placentae (n=3) significantly increased their Vmax over 6 min from 
1.046 nmol/mg protein in pCTB to 2.345 nmol/mg protein in pSTB stage (2 way-ANOVA, α=0.05; 
p<0.0001). The maximal leucine uptake capacity (Vmax) and half-maximal uptake time (Kd) was 
calculated using a saturation model curve fitting (y = Vmax*X/(Kd + x). The final concentration of 
leucine in all experiments was 167 nmol/mL including 1 µCi/mL 3[H]-L-leucine for detection. Error 
bars represent standard deviation (SD) of 3 individual experiments with 6 replicates each. 
 
3.1.4 Small molecule inhibitors reveal relevance of LAT1- and LAT2-mediated amino acid 
transport 
3.1.4.1 Leucine uptake is modulated by System L-specific small molecule inhibitors 
Based on the high leucine uptake capacity and the high expression levels of functional 
LAT1, the BeWo cell model was selected to test different LAT1 or LAT1/LAT2-specific small 
molecular inhibitors in dose-response experiments. Two new alternative compounds, 
JG336 and JX009 (Figure 22B,C), were investigated and compared in two separate 
experiments to the already established potent LAT1-specific inhibitor JPH203 (Figure 
22A). In BeWo-CTB all three inhibitors reached a maximal inhibition of less than 
0.8 nmol/mg protein at a concentration of 10 µM (corresponding to the bottom value of 
a four-parameter nonlinear fit with variable slope; kinetic parameters are listed in the 
panels on the right). The leucine analog 2-amino-2-norbornane-carboxylic acid (BCH) 
completely inhibited leucine uptake at a concentration of approx. 1 mM regardless of the 
differentiation stage (Figure 22E). This observation further verifies the relevance of SLC7-
mediated leucine uptake in trophoblasts. Although there was profound leucine uptake 
inhibition in BeWo-CTB, 10 µM of JPH203 and JG336 showed a residual uptake of 3.8 
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(56.3% inhibition) and 3.2 nmol/mg protein (62.4% inhibition), respectively. JX009 and 
JX020 (10 µM) blocked leucine uptake regardless of the trophoblast differentiation stage. 
In BeWo-STB leucine uptake was inhibited by 87% suggesting inhibition of most Na+-
independent SLC7-transporters by JX009 and JX020. While the dose-response 
experiments with the less specific inhibitors JX009 and JX020 revealed an EC50 of 
3.9 µM/0.62 µM for BeWo-CTB and 2.3 µM/2.5 µM for BeWo-STB, which is comparable 
with JPH203 (EC50=3.1 µM for BeWo-CTB and 2.6 µM for BeWo-STB), JG336 was identified 
as the most efficient inhibitor (EC50=0.8 µM for BeWo-CTB and 2.0 µM for BeWo-STB) in 
both differentiation stages of BeWo cells. Compared to the dose response curve of BCH, 
JX009 and JX020 showed both comparable efficiency but >180-times higher potency 
(Figure 22C/D). The new inhibitors JG336 and JX009 as well as JPH203 reached maximal 
inhibition (first concentration without significant difference to the bottom value) at a 
concentration of 10 µM, JG336 required 1 µM for maximal inhibition in BeWo-CTB. Of 
note, comparable inhibition patterns were also found in the colorectal adenocarcinoma 
cell line HT-29 (Figure 23). Lower substrate concentrations (30 µM instead of 167 µM 
leucine) lead to lower EC50 values (Figure 23 to the right of each curve). The LAT1 
overexpressing HT-29 cell line with an uptake dose of 30 µM leucine was previously used 
as model in structure–activity relationship studies in the NCCR TransCure network. In 
summary, the dose-response analysis of the three inhibitors suggested that JG336 inhibits 
LAT1-specific placental leucine transport with similar LAT1-specificity as JPH203, but 
exhibits an almost 4-times higher efficiency. JX009 represents a potent inhibitor of all 
active System L-transporters in trophoblasts; JX020 mediated 6-times higher efficiency in 
BeWo-CTB. 
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Figure 22: Inhibition of leucine uptake in BeWo cells using small molecule inhibitors with 
different specificities. Dose-response experiments in BeWo-cytotrophoblasts (BeWo-CTB) and 
forskolin-stimulated BeWo- syncytiotrophoblasts (BeWo-STB) for the established LAT1-specific 
inhibitor JPH203 (A) and for the alternative compound JG336 which carries an additional methoxy-
group as marked in the dashed red box (B). The results showed that both compounds conveyed a 
significant inhibition (JPH203=56%, JG336=62%), but suggest also that approximately 40 % of Na+-
independent leucine uptake is LAT1 independent. C, Application of JX009 and JX020, inhibitors of 
both LAT1 and LAT2, resulted in almost complete leucine uptake inhibition in BeWo-STB; JX020 
exhibited a higher efficiency in BeWo-CTB. Compared to the dose response performance of the 
leucine analog 2-amino-2-norbornane-carboxylic acid (BCH, E), JX009 shows comparable 
efficiency but >180-times higher potency. BCH is a widely accepted inhibitor blocking all System L 
transport. BCH completely blocked leucine uptake in BeWo-CTB with an EC50 of 709 µM and 
BeWo-STB with an EC50 of 442 µM (D). A-D, The new inhibitors JG336, JX020 and JX009 as well as 
JPH203 reached maximal inhibition (first concentration without significant difference to the 
bottom value) at a concentration of 10 µM, JG336 required 1 µM for maximal inhibition in BeWo-
CTB. BCH reached maximal inhibition with 1 mM in both differentiation stages. A-E All uptake 
assays were performed in two individual experimental setups (n=2) for 3 min, under the same 
conditions in Na+-free Hanks buffer with 167.2 µM leucine (1 µCi/mL 3H-L-leucine). The chemical 
structures of the small molecule compounds are depicted to the left of each dose-respond curve. 
Dose-response kinetics were calculated using the nonlinear four-parameter model 
[Y=Bottom+(Top-Bottom)/ (1+10^((LogEC50-X)*HillSlope))] and ordinary fit with GraphPad Prism 
software. Best-fit values of the including EC50 values are shown to the right of the dose-response 
curve. Error bars represent standard deviation (SD) of 2 experiments with 6 replicates each.  
3.1.4.2 Transfer of leucine across the placental barrier is reduced by inhibitors of System L-
transporters 
The small molecule inhibitors JPH203, JG336, JX009 and JX020 were also used to assess 
the relevance of LAT1 and LAT2 in leucine transport across the placental barrier using the 
Transwell® system (Figure 24). Leucine transfer experiments were performed in the 
presence or absence of the individual inhibitors with a fixed concentration of 10 µM 
applied at the upper compartment. This concentration was chosen as it showed in dose-
response experiments maximal inhibition for all three compounds (see Figure 22). Figure 
24B shows the experimental setup and the applied leucine concentrations in the upper 
compartment (corresponding to the maternal side of the placental barrier) and the lower 
chamber (corresponding to the fetal side) of the Transwell® system. Gradually diminishing 
radioactive signal 3[H]-leucine on the maternal side and increasing radioactivity on the 
fetal side was considered to represent leucine transfer across the trophoblast monolayer. 
Treatment with JPH203, JG336, JX009 and JX020 at the apical (maternal) side caused 
significant reduction of leucine transfer by 58%, 60%, 55% and48, respectively. All 
inhibitors significantly decreased leucine transfer from the apical towards the basal 
compartment from 60 min onwards. Measurement of intracellular 3[H]-leucine content in  
Results - Amino acid transport 
86 
 
Results - Amino acid transport 
  87 
Figure 23: Leucine uptake inhibition and substrate-dependence of EC50 values in HT-29 cells 
using SLC7- inhibitors. Dose-response experiments for leucine uptake inhibition in the colorectal 
adenocarcinoma cell line HT-29 were performed in Na+-free Hanks buffer with 167 µM leucine and 
1 µCi/mL 3H-L-leucine (left panels A, B and C) and in Na+-free Hanks buffer with 30 µM leucine and 
1 µCi/mL 3H-L-leucine (right panels A, B and C). HT-29 cells and a substrate concentration of 30µM 
L-leucine were used to compare EC50 values in structure–activity relationship studies as performed 
in the NCCR TransCure network. Dose-response experiments demonstrated complete leucine 
uptake inhibition with JPH203 (A left panel, EC50 2.17 µM) and the three novel SLC7-targeting 
inhibitors JG336 (B left panel, EC50 0.73 µM), JX009 (C left panel, EC50 3.76 µM) and JX020 (D left 
panel, EC50 1.55 µM) under physiological 167 µM leucine concentrations. JG336 was the most 
efficient inhibitor being 2.6-times more efficient than the LAT1-specific inhibitor JPH203. All tested 
inhibitors show markedly lower EC50 values at the lower substrate concentration of 30 µM, i.e. for 
JPH203 (A right panel) EC50=0.15 µM, JG336 (B right panel), EC50=0.21 µM and JX009 (C right 
panel), EC50=0.60 µM. The leucine uptake experiments were performed during 3 min in Na+-free 
Hanks buffer with 167 µM leucine (1 µCi/mL 3H-L-leucine) and are shown as representative 
experiments of two independent experiments (n=2). Dose-response kinetics were calculated using 
same statistical tools as explained in Figure 22. EC50 values are shown to the right of the dose-
response curve. Error bars represent standard deviation (SD) of 2 experiments with 6 replicates 
each. 
 
the trophoblast cell layer at the end of the transfer experiment (6 h) indicated significantly 
decreased intracellular leucine concentrations of 24% for JPH203, 41% for JG336 and 35% 
for JX020, respectively (Figure 24C). In contrast, JX009 had no effect on the intracellular 
3[H]-leucine concentration within the tested time course. The higher retention of leucine 
in JX009 treated cells suggests inhibition of leucine secretion likely towards the lower fetal 
compartment. 
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Figure 24: Relevance of LAT1- and System L-inhibition in leucine transfer across the placental 
barrier in vitro. A, Leucine (Leu) transfer across a tight BeWo monolayer was measured from the 
apical (i.e. upper compartment) towards the basal side (i.e. lower compartment) during 6 h using 
the Transwell® system. Leu transfer was significantly reduced by the System L inhibitor JX009 
(orange) and JX020 (blue), and the LAT1-specific inhibitors JPH203 (red) and JG336 (green) 
compared to the DMSO-control (black) already after 1 h. Equal concentrations (10 µM) of each 
inhibitor and DMSO as vehicle control were applied in three experiments (n=3) with two replicates 
per condition. B, The experimental setup represented as schematic illustration. All Leu transfer 
assays were performed against a counter-directed gradient of 137 µM (30→167 µM) Leu, in the 
presence of 300 µM glutamine (Gln) in both compartments. The Leu in the upper compartment 
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was spiked with 1 µCi/mL 3H-L-leucine for transfer quantification. C, The intracellular leucine 
content was measured after washing the cell layers with DPBS at the end of the experiment (after 
6 h). A significant reduction of intracellular Leu contents was detected for JPH203 (p=0.017), 
JG336 (p=0.0001) and JX020 (p=0.0003), but not for the System L-inhibitor JX009 (p=0.215). The 
detected intracellular leucine retention caused through LAT1 and LAT2 inhibition by JX009 
suggests a System L-dependent Leu efflux across the BM as rate limiting step. Statistical analyses 
were performed in three individual experiments (n=3) using a parametric one-way ANOVA analysis 
(α=0.05). 
3.2 Iron transport 
3.2.1 Influence of GDM on transplacental iron transport 
3.2.1.1 GDM affects clinical parameters of newborns and iron homeostasis genes 
To investigate the impact of GDM on placental iron homeostasis, we collected placental 
tissue from 11 diagnosed GDM and 11 healthy pregnancies according to the criteria of the 
ADA (American Diabetes Association 2007). As shown in Table 10 the mothers with GDM 
exhibited under comparable demographic characteristics significantly increased BMI 
before pregnancy and increased hemoglobin values at the day of delivery. Increased 
hemoglobin levels were detected in maternal sera, but no changes in the fetal iron status 
was documented. Upon exclusion of unequal gender distribution, the corresponding 
offspring of GDM pregnancies are born LGA as demonstrated by increased weight and 
body length of the newborns (Table 10).  
The RT-qPCR screening of 24 placental iron homeostasis genes (# marked primer pairs in 
Table 6) in the two cohorts revealed significant downregulation of the iron-transporters 
DMT1 and FPN1, upregulation of the ferroxidases HEPH and Zp, and of the iron-entry 
regulator HEPC in GDM (Table 11; Figure 25).  
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Table 10: Anthropometric and clinical characteristics of gestational diabetes mellitus (GDM) and 
control patients including their offspring 





Number of individuals  11  11   
Delivery mode Cesarean section Cesarean section   
Age (years) 30.91  ± 5.43 31.91   ± 7.66 0.7276  
BMI (pre-conceptional) 23.14  ± 3.92 29.53  ± 5.16 0.0038 **  
Parity 2.36  ± 0.67 2.09  ± 0.83 0.4080  
Gestational age at partum 39.00  ± 0.60 39.06  ± 1.29 0.8814  
Glucose (mmol/l) 4.92  ± 0.74 5.25  ± 1.51 0.5190  
Treatment  - 8 insulin/3 diabetes diet   
Creatinine (µmol/l)  46.82  ± 7.90 51.09  ± 10.67 0.2985  
RBC (T/l) 3.86  ± 0.35 4.10  ± 0.34 0.1201  
Hemoglobin (g/l) 115.27  ± 6.96 124.82  ± 10.90 0.0237 *  
MCV (fl) 88.64  ± 5.61 88.36  ± 3.96 0.8965  
MCH (pg) 30.00  ± 2.14 30.55  ± 2.07 0.5505  
MCHC (g/l) 337.82  ± 3.76 344.18  ± 9.45 0.0512  
Hematocrit (%) 0.34  ± 0.02 0.36  ± 0.03 0.0640  
Ba
by
 Weight (g) 3182  ± 242 3787  ± 419 0.0005 ***  
Length (cm) 48.4  ± 1.8 50.6  ± 2.0 0.0095 **  
Sex of baby         5♂, 6♀         5♂, 6♀   
Data are represented as mean ± standard deviation (SD). Differences between GDM and the 
control group were analyzed by two-way Student’s T-test; α=0.05, * p<0.05, ** p<0.01, *** 
p<0.001. Abbreviations: BMI, body mass index; MCH, mean corpuscular hemoglobin; MCHC, mean 
corpuscular hemoglobin concentration; MCV, mean corpuscular volume; PCV, packed cell volume; 
RBC, Red Blood Cells. 
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Table 11: Expression analysis of iron homeostasis genes in placentae from GDM patients and 
controls 
Accession No. Protein Name p value  
Iron endocytosis    
P02787 Tf Serotransferrin 0.6047  
P02786 TfR1 Transferrin receptor protein 1 0.9725  
Q07954 LRP1 Lipoprotein receptor-related protein 1 0.3494  
Q6ZMJ2 SCARA5 Scavenger receptor class A member 5 0.6539  
Iron transmembrane transporters   
P49281 DMT1 Divalent metal transporter 1 0.0139 * ↓ 
Q9C0K1 Zip8 Zrt- and Irt-like protein 8 0.7564  
Q15043 Zip14 Zrt- and Irt-like protein 14 0.1545  
Q9NP59 FPN1 Ferroportin-1 0.0032 ** ↓ 
Q9NYZ2 MFRN1 Mitoferrin-1 0.8633  
Q9Y5Y0 FLVCR1 Feline leuk. virus subg. C receptor 1 0.5516  
Q9UPI3 FLVCR2 Feline leuk. virus subg. C receptor 2 0.8238  
Q96NT5 HCP1 Heme carrier protein 1 0.2230  
Q6P1K1 HRG1 Heme transporter HRG1 0.1971  
Fe-storage   
P02794 FHC Ferritin heavy chain 0.2816  
Oxidoreductases   
P00450 CP Ceruloplasmin 0.3144  
Q9BQS7 HEPH Hephaestin 0.0242 * ↑ 
Q6MZM0 Zp Zyklopen 0.0201 * ↑ 
P09601 HO1 Heme oxygenase 1 0.6539  
P30519 HO2 Heme oxygenase 2 0.1517  
Q658P3 STEAP3 Metalloreductase STEAP3 0.4679  
Regulators   
P81172 HEPC Hepcidin 0.0242 * ↑ 
Q30201 HFE Hereditary hemochromatosis protein 0.2512  
Iron sensing, mRNA binding   
P21399 IRP1 Iron regulatory protein 1 0.0251 * ↓ 
P48200 IRP2 Iron regulatory protein 2 0.5116  
Quantitative RT-PCR analysis of placental tissues from GDM (n=11) and control (n=11) patients 
was performed in two independent experiments and normalized to the mean of the reference 
genes 14-3-3 protein zeta/delta (YWHAZ), GAPDH and ubiquitin (UBC). The results of the 
comparison between GDM and controls are represented by target-specific p-values and arrows 
displaying up- (↑) or downregula on (↓) in GDM. Sta s cal significance was determined using 
two-tailed Mann-Whitney test; α=0.05, * p<0.05, ** p<0.01, *** p<0.001. Genes were selected 
upon proven placental expression in literature or according to data from protein atlas 
(www.proteinatlas.org).  
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Figure 25: Expression changes iron homeostasis genes in placental tissue affected by gestational 
diabetes mellitus (GDM) on mRNA level. Transcript levels of Divalent metal transporter 1 (DMT1), 
Zrt- and Irt-like protein 8 (ZIP8), Ferroportin-1 (FPN1) and Transferrin receptor protein 1 (TfR1) 
were analyzed in placental tissues of GDM patients (orange) and term controls (blue). Expression 
results were determined in two independent experiments and normalized to the mean of the 
reference genes Tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein, 
zeta polypeptide (YWHAZ), Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and ubiquitin 
(UBC). Comparative transcript data are presented as mRNA abundance (ΔCt = Ctreference gene – Cttarget 
gene) from placental tissues from GDM (n=11) and control (n=11) patients using the mean of the 3 
reference genes YWHAZ, GAPDH and UBQ). Statistical significance was determined as described 
in Table 10 using two-tailed Mann-Whitney test, α=0.05, * p<0.05, ** p<0.01, *** p<0.001. Data 
are presented as mean (x), median (-) and Tukey whiskers (1.5 times the IQR). 
We analyzed the difference between male and female placentae for all 24 iron 
homeostasis genes. Since the data did not pass the normality tests, the nonparametric 
multiple T-test was used for statistical evaluation. There were no significant gender 
differences between male and female placentae within all 22 placentae (10   and 12  ) 
that would explain the detected difference between control and GDM for any of the 24 
genes (Figure 26A). There were no significant gender differences for any of the 24 
analyzed iron homeostasis genes using a nonparametric Mann-Whitney test. Of note, 
there were significant differences in the male-female comparison within the control 
cohort for Zp on mRNA and TfR1 on protein levels (Figure 26B/C).  
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Figure 26: Analysis of sex dimorphism of iron homeostasis genes expression in placentae from 
gestational diabetes mellitus (GDM) patients and controls. List of p values from 10 male and 12 
female placentae on mRNA (A, middle column) and protein data comparison (A, right column) by 
nonparametric Mann-Whitney test, α=0.05. Differential analysis of sex dimorphism separated in 
control and GDM for the ferroxidase zyklopen (Zp, HEPHL1) on mRNA (B) and for Transferrin 
receptor (TfR1) on protein level (C). A-C mRNA levels from male and female placentae of each 
gene was statistically compared using nonparametric Mann-Whitney test. # names of measured 
placental iron homeostasis genes. 
For the quantification on protein level the target genes TfR1 as sensitive indicator of 
changes in placental iron homeostasis and the three iron transporters DMT1, ZIP8 and 
FPN1 were selected. Since it was not possible to quantify the three iron-transporters by 
LC-MS/MS analysis in placental tissue lysates, we reduced the sample complexity by 
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isolating membrane proteins (TMI assay) for all 22 placentae. In collaboration with the 
FGCZ, we developed a method for LC-MS/MS-based protein quantification in TMI samples 
(see 2.2.2 on p.36 until 2.2.4 on p. 41ff). Figure 27 shows the results of all selected proteins 
(as defined in Table 3 on p.36) as raw values and after normalization with GAPDH allowing 
the comparison between GDM and control TMI samples. 
 
Figure 27: Placental membrane protein quantification in total membrane isolation (TMI) 
samples by mass spectrometry provided by the specialists from the Functional Genomics Center 
Zurich (FGCZ). The relative protein levels of 11 control and 11 GDM samples were normalized to 
GAPDH (G3P, dark gold color). Statistical significance determined by parametric t-test using the 
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Holm-Sidak method, α=0.05. Panel A is showing the protein level in a line plot for all individual 
samples in the x-axis and the relative protein levels as logarithmic 2-fold change in the y-axis. Panel 
B depicts the results of the comparison between the GDM versus control group as volcano plot. 
Here the mean logarithmic 2-fold changes are presented in x-axis and the p-values in y-axis. The 
red line indicates α=0.05 (-log10(α)= 1.3010). Therefore, all values above the red line were 
significantly different in GDM relative to the control group. In summary, ZIP8 (S39A8), 4F2hc (4F2), 
ABCA1, TfR1 (TFR1) and LAT2 were significantly (above red line) downregulated (negative log2 
fold change) in GDM total membrane samples. 
The MS/MS-based PRM quantification and the comparison of protein level in GDM and 
healthy control revealed a GDM-specific downregulation of the iron transporter ZIP8 and 
holo-Tf binding receptor TfR1, while the downregulation of DMT1 and FPN1 on mRNA 
level could not be confirmed in the proteomic approach (Figure 28). 
 
Figure 28 Expression changes of selected iron homeostasis genes in placental tissue from 
gestational diabetes mellitus (GDM) patients and controls on protein level. Altered expression 
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of iron homeostasis genes critical for transplacental iron transport, which were regulated in GDM 
either on mRNA Table 11 or protein level. Results of LC-MS/MS-based protein quantification in 
total membrane isolations of placental tissues from the same patient cohort and for the same 
targets as presented in Figure 25. Protein levels were calculated as fold changes relative to spiked 
peptides and subsequently relative to the reference gene GAPDH. A, protein data of 11 control 
and 11 GDM samples are comparatively presented as protein abundance fold changes relative to 
spiked peptides of target gene and normalized to GAPDH (abundance = reference gene – target 
gene). B, for easier comparison between GDM and control the same data are presented as delta-
delta FC values (ΔΔFC = fold changes (FC) relative to spiked peptides of target gene – FC relative 
to spiked peptides of GAPDH) and normalized to the mean of controls. Statistical significance was 
determined by two-tailed Student’s T-test, α=0.05. 
 
3.2.1.2 GDM-specific changes in placental DMT1 localization  
To follow up the discrepancy of significantly decreased DMT1 mRNA levels, but 
unchanged protein levels, blind semi-quantitative immunohistochemical analysis for 
DMT1 and FPN1 was performed in 22 placental tissues (Figure 29). Placental tissue 
samples from central localization (close to umbilical cord attachment) were stained for 
DMT1 and FPN1 and semi-quantitatively analyzed by an experienced external collaborator 
in a blinded trial (Figure 29C). The intense STB-specific staining mediated by the anti-FPN1 
antibody was restricted to basal/basolateral structures and did not show any differences 
between GDM and control (χ2 (2) =3.21, p=0.201, α<0.05). In contrary, the apically 
accentuated expression pattern of DMT1 in control was significantly shifted towards the 
cytoplasm of the STB in GDM (χ2 (2) =7.62, p=0.022, α<0.05).  
3.2.1.3 Unchanged iron levels in placental tissue from GDM pregnancies 
Based on the results showing GDM-specific downregulation and changes of expression 
patterns of iron transporters and the iron receptor TfR1, we measured and compared iron 
contents between GDM and control placentae. Although decreased iron levels were 
expected, the total iron contents measured by colorimetric ferrozine-based assay were 
similar between control and GDM placentae (Figure 30). 
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Figure 29: Effect of gestational diabetes mellitus (GDM) on the expression pattern of Divalent 
metal transporter 1 (DMT1, SLC11A2) and Ferroportin (FPN1, SLC40A1) in human term placenta 
detected by immunohistochemistry. A, In control tissues DMT1 was expressed exclusively in 
syncytiotrophoblasts (STB) and apically accentuated (A1), while GDM-tissue showed 
predominantly intracellular DMT1 expression (A2). FPN1 antibody-mediated staining was 
restricted to basal/basolateral structures of STB in both control (B1) and GDM tissues (B2). 
Negative controls are shown in the right panels (A3/B3). Arrows indicate the apical, i.e. maternal 
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blood-oriented side, arrowheads depict the basal membrane of the syncytiotrophoblasts. All 
images are displayed at 40 x magnification as indicated by the scale bar in B3. Abbreviations: IVS, 
intervillous space; STB, syncytiotrophoblast; VC, villous core. C, Results of the semi-quantitatively 
analysis of 22 placental tissues in a blinded trial performed by PD Dr. med. Meike Körner, an 
experienced external collaborator, and statistically assessed using Pearson's χ2 test, α<0.05.  
 
 
Figure 30: Placental iron content is not affected in gestational diabetes mellitus (GDM). Total 
iron contents in 22 placental tissue were measured by colorimetric ferrozine-based assay and 
normalized to the total protein concentration (A) and additionally to the placental weight (B). Iron 
content did not differ between control and GDM placentae. (A/B) Iron contents were compared 
using an unpaired T test, α = 0.05, and are presented as mean (+), median (-) and Tukey whiskers 
(1.5-times interquartile range). 
 
3.2.2 Establishment of an in vitro trophoblast cell model to study hyperglycemic iron 
homeostasis 
After adaption of conventionally cultured BeWo cells to physiological glucose 
concentration in the culture media for 28 passages as explained in 2.4, we investigated 
the effects of hyperglycemic and hyperlipidemic conditions mimicking the environment 
of trophoblasts during GDM with different grades of severity (as shown in Figure 31) 
during more than 30 days. Beside visualization of morphological changes, also the 
adaption of iron homeostasis gene expression was analyzed and compared to GDM-
specific expression patterns. 
3.2.2.1 BeWo cells alter cell morphology under hyperglycemic conditions 
From the first week of culturing onwards the BeWo cells under hyperglycemic (H) and 
hyperglycemic/hyperlipidemic conditions (HL) divided faster than under normoglycemic 
control conditions (N). During 30 days of culturing the cells adapted their morphology to 
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the increased availability of glucose in H by increasing nuclei and vacuoles size respectively 
glucose and fatty acids in HL additionally extensive intracellular lipid store (Figure 31).  
 
Figure 31: Cell biological visualization of time-dependent adaption of normoglycemic BeWo 
trophoblast cells to hyperglycemic and hyperglycemic/hyperlipidemic conditions. 
Representative images of Oil red O stained BeWo cells cultured on glass slides for 48 h after 
30 days of culture in normoglycemic (N; Dulbecco's Modified Eagle's Medium (DMEM)- 5.5 mM 
glucose)(A), hyperlipidemic (H; DMEM- 25 mM glucose)(B), and hyperglycemic combined with 
hyperlipidemic (HL; DMEM-25 mM glucose + 100 µM palmitic acid) (C) conditions. Cells were 
counterstained with hematoxylin. The BeWo-derived cell models H (orange) and HL (grey) showed 
altered cell morphology, including increased nuclei and vacuole size. In HL extensive intracellular 
lipid stores (red staining) were detected. N represents the healthy control condition, H mimicks 
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pre-diabetic and HL severe diabetic condition with increasing severity as depicted to the right of 
the pictures according to the expected condition in GDM placentae. A-C, the pictures are captured 
as represents for each cell model. 
3.2.2.2 Hyperglycemic adaptions in BeWo cell models reflect clinical observations in GDM 
The effect of GDM on iron homeostasis in the clinical specimens was characterized inter 
alia by downregulation of the key iron-transporters DMT1, FPN1 and ZIP8 and the iron-
uptake mediating TfR1 on either mRNA or protein level (3.2.1 on p. 89-96, Figure 25 and 
Figure 28). When monitoring the expression levels of the genes regulated in GDM during 
40 days of hyperglycemic/hyperlipidemic challenge in the BeWo cell models, there was an 
initial upregulation of DMT1 and ZIP8 after 3 days of stimulation and a stable 
downregulation of FPN1 and TfR1 after 20 days relative to normoglycemic conditions 
(Figure 32 A1). In the HL condition DMT1 was downregulated after 28 days of stimulation 
(Figure 32 B1). Moreover, the upregulation of the ferroxidase Zp in H and HL during the 
entire stimulation time (Figure 32 A2/B2) also mimicked the clinical results found in GDM 
placentae (3.2.1 on p. 89-96), and strongly underlines the suitability of the applied cell 
models. Interestingly, the constant downregulation of GLUT1 in H and HL confirmed the 
increased availability of glucose in H and HL (Figure 32 A2/B2).  
3.2.3 BeWo trophoblasts reduce iron uptake under hyperglycemic and hyperglycemic-
hyperlipidemic conditions 
Based on the high comparability between the developed hyperglycemic BeWo cell models 
(H and HL) and the GDM-specific changes of placental iron homeostasis gene expression 
found in the clinical setup, we extended our studies to the functional level. We performed 
Tf-mediated 55Fe3+ uptake assays to investigate the effect of hyperglycemia on placental 
iron transport function using the established BeWo cell models.  
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Figure 32: Expressional adaption of iron homeostasis genes during 40 days of hyperglycemic and 
hyperglycemic-hyperlipidemic stimulation on BeWo trophoblasts. Time-dependent adaption of 
mRNA levels of the iron transporters DMT1 (solid line), ZIP8 (dashed line), FPN1 (dotted line) and 
TfR1 (dash-dotted line) under hyperglycemic H (A1) and hyperglycemic-hyperlipidemic HL 
conditions (B1), but also of the iron transporter ZIP14 (dash-dotted line), the ferroxidase HEPHL 
(solid line), iron sensor IRP1 (dashed line) and of the glucose transporter GLUT1 (dotted line) under 
hyperglycemic H (A2) and hyperglycemic-hyperlipidemic HL conditions (B2). Error bars represent 
standard deviation (SD) of triplicate measurements (n=3). Transcript data are presented as 2-ΔΔCt 
values (ΔΔCt = Ct value of target gene – Ct value of the mean of YWHAZ, GAPDH and UBQ) and 
normalized to the mean of controls. Statistical significance was determined relative to 
normoglycemic conditions using two-tailed Mann-Whitney test, α=0.05, * p<0.05, ** p<0.01, *** 
p<0.001.  
 
Already after several days of stimulation the Tf-dependent Fe3+-uptake was significantly 
reduced in H and HL cell models independent of the cell differentiation stage (BeWo-CTB 
in Figure 33A / BeWo-STB in Figure 33B). Considering the total monitoring period of iron 
uptake, there was a consistent reduction of >40% in iron uptake in both H and HL (Figure 
33C). While an initial increase of iron uptake was detected after 1 day of stimulation in H, 
the iron uptake was significantly reduced in H and HL already after 5 days of stimulation 
(Figure 33C). All iron uptake assays were performed in unstimulated BeWo and in BeWo 
cells stimulated for 48 h with 100 µM Forskolin. There was no significant difference 
between Forskolin stimulated, differentiated BeWo cells and unstimulated cells (Figure 
33A/B).  
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Figure 33: Assessment of functional changes in iron homeostasis by measuring transferrin-
dependent radioactive 55Fe3+-uptake during adaption of BeWo trophoblasts to hyperglycemic 
and hyperglycemic-hyperlipidemic conditions. Normoglycemic BeWo cells (N, blue) were 
cultured under hyperglycemic (H, orange) and hyperglycemic-hyperlipidemic (HL, grey) conditions 
for 34 days. In parallel, functional changes in iron-transport were serially assessed by measuring 
transferrin (Tf)-dependent Fe3+-uptake in N, H and HL cell models. A/B, Representative iron uptake 
results of three independent experiments (n=3) after 5 days of adaption to hyperglycemic 
conditions. Alteration of iron-uptake was assessed in cytotrophoblast-stage (BeWo-CTB, 24 h after 
seeding) in A and in syncytiotrophoblast-stage (BeWo-STB, CTB with additional stimulation with 
100 µM forskolin for 48 h) in B. Iron uptake values are displayed as percentage of the applied total 
dose. Concentration of Tf-Fe3+ total dose in all experiments was 16.14 pmol/100 µL (161.4 nM). 
Reduction of iron uptake measured at 20 min (dotted square in panel A and B) was monitored 
over 34 days normalized to N (N=100%) in panel C. Error bars represent SD of 7 replicates. 
Statistical significance was determined using two-way ANOVA with Sidak’s multiple comparison 
post hoc analysis, α=0.05. The experiments were performed three times (n=3) with BeWo cells 
originating from the same normoglycemic BeWo line at different passage numbers. 
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3.2.4 Hyperglycemic conditions affect cellular death and oxidative stress pathways in 
trophoblasts  
To characterize the cellular mechanisms underlying the alteration of placental iron 
homeostasis under diabetic conditions, we sampled BeWo cells during 30 days of H and 
HL challenge and assessed the protein expression of stress response markers by 
immunoblotting. From day 3 onwards the expression of the autophagy markers p62 and 
LC3-II were downregulated (Figure 34A). No differences in protein expression of the 
endoplasmic reticulum (ER) stress marker BiP (Figure 34B) were detected when 
comparing H and HL to N at the respective time points after starting the stimulation. Thus, 
trophoblasts under hyperglycemic conditions showed reduced autophagy, but no effect 
on the ER-stress pathway.  
 
Figure 34: Trophoblasts under hyperglycemic conditions reduce autophagy but express no 
significant changes in the ER stress pathway. The expression of the autophagy markers p62 
(62 kDa) and LC3-II (14 kDa) (A) and ER stress marker BiP (75 kDa) (B) during 28 days of adaption 
to hyperglycemic (H) and hyperglycemic combined with hyperlipidemic conditions (HL) by 
immunoblotting (left panels). p62 and LC3-II expression visualized by immunoblotting at day 0, 3, 
14 and 28 was quantified by fluorescence detection analysis and presented relative to the 
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normoglycemic condition (N, blue bar) (right panels). Results of one representative experiment 
from three independent experimental setups are shown. 
Beside autophagy and ER-stress we quantified cellular damage caused by oxidative stress 
by measuring the production of MDA equivalents and carbonyl formation. After 30 days 
of adaption to hyperglycemic conditions, there was still significantly increased lipid 
peroxidation detectable in the supernatant of BeWo under H (Figure 35A). 
No change in protein carbonylation after 30 days of adaption to H and HL, respectively, 
was found (Figure 35B). 
We furthermore determined oxidative stress damage in association with hyperglycemia 
and altered placental iron homeostasis by analyzing the antioxidative potential (total-
GSH) in BeWo cell lysates cultured for 30 d in N, H and HL. The total-GSH levels were 
significantly reduced under HL (Figure 35C) reflecting increased GSH consumption for 
counteracting accelerated oxidative stress. 
Taken together, increased oxidative stress seems to play a predominant role in BeWo 
trophoblasts adapting to hyperglycemic and hyperlipidemic conditions.  
3.2.5 Antioxidant treatment - Rescue experiment 
To investigate whether oxidative stress is indeed the main mediator of the disturbed iron 
homeostasis in the placenta, we determined the effect of an experimentally induced 
oxidative stress challenge on trophoblast cells. Additionally, we studied whether the 
effect of hyperglycemic conditions on iron homeostasis gene expression reproduced by 
just increasing the oxidative stress levels independent of glucose and fatty acid 
availability, could be rescued by increasing the antioxidative potential. 
Therefore, we tested different chemicals such as Rotenone and tert-Butyl hydroperoxide. 
Rotenone is a mitochondrial toxin and a potent, reversible, and competitive inhibitor of 
complex I (NADH-CoQ reductase) of the respiratory chain leading to cellular ROS 
production. Oxidative stress induced by tert-BOOH was chosen because it was shown that 
tert-BOOH interferes with the placental transport of glucose in in vitro studies with BeWo 
cells (Araújo et al. 2013). Induced oxidative stress by tert-BOOH treatment led to clearly 
increased levels of MDA equivalents indicating increased lipid peroxidation, while the 
applied dose of rotenone just marginally induced lipid peroxidation compared to 
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untreated control (Figure 35D). Therefore, we choose tert-BOOH instead of Rotenone for 
oxidative stress induction. For antioxidative rescue, we tested additionally to NaSe, the 
flavonoid and dietary antioxidant quercetin (Bach et al. 2010) in our studies. Quercetin 
had a more pronounced rescue effect than NaSe (see Figure 35D). However, as quercetin 
has potential iron chelating properties (Morel et al. 1993) that would affect the 
interpretation of our results, we continued with NaSe instead of quercetin. In summary, 
the combination of the antioxidants NaSe with tert-BOOH as oxidative stress inducer 
showed suitable low dose rescue properties without iron chelation. 
Thus, we treated BeWo cells under normoglycemic conditions with the oxidant tert-BOOH 
for 24 h and compared the effects with the phenotypes found in GDM tissues. In 
agreement with the results found in GDM placentae (Figure 25), the induction of oxidative 
stress significantly reduced the mRNA abundance of the iron transporters DMT1 and FPN1 
(Figure 35D). The mRNA levels of ZIP8 and TfR1 were elevated whereas a profound 
decrease of GLUT1 mRNA was detected (Figure 35D).  
 
Figure 35: Trophoblasts under hyperglycemic conditions show increased oxidative stress 
damage and reduced antioxidative potential, while induced oxidative stress induce iron 
homeostasis gene alterations comparable to gestational diabetes mellitus (GDM). Increased 
oxidative stress in H and HL was detected in three independent experiments after 30 days of 
adaption time (n=3). A, Increased lipid peroxidation determined as the formation of 
malondialdehyde (MDA) equivalents in cell supernatants was found in H (orange) and HL (grey) 
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conditions. B, Protein carbonylation was measured by staining of cell lysates with 2,4-
Dinitrophenylhydrazine (DNP). C, Decreased antioxidative potential was assessed by measuring 
total glutathione (GSH) levels. Statistical significance was determined using two-way ANOVA with 
Dunnett’s multiple comparison test, α = 0.05, * p < 0.05, ** p < 0.01. D, Validation of effective 
agents to induce and reduce oxidative stress for the subsequent rescue experiments. BeWo cells 
were cultured in DMEM low glucose with 10% FBS, seeded in 6-well plates (350’000 cells/well 
resp. 36’500 cells/cm2) overnight and treated with the antioxidants 0.1 µM NaSe or 50 µM 
Quercentin for 24 h at 37°C without FBS, followed by oxidative stress challenge by either 0.8 µM 
Rotenone or 1000 µM tert-BOOH for 4 h at 37°C. Oxidative stress was measured by lipid 
peroxidation assay and represented as bar diagram with mean and SD. Treatment conditions are 
represented in the matrix below the x-axis. The combination of the antioxidants NaSe with tert-
BOOH as oxidative stress inducer showed low dose rescue properties without potential iron 
chelation. For statistical analysis parametric 2-way ANOVA test, α=0.05 was used; **p< 0.01, 
***p<0.001. E, mRNA abundances of the Divalent metal transporter 1 (DMT1), Zrt- and Irt-like 
protein 8 (ZIP8), Ferroportin-1 (FPN1), Transferrin receptor protein 1 (TfR1) and Glucose 
transporter 1 (GLUT1) were determined in untreated normoglycemic BeWo cells (N, blue) and in 
normoglycemic BeWo cells treated with tert-Butyl hydroperoxide (tert-BOOH; 100 µM; blue 
striped bars). Cycle threshold (Ct) values were determined by qRT-PCR and normalized to the 
mean of the reference genes Tyrosine 3-monooxygenase/tryptophan 5-monooxygenase 
activation protein, zeta polypeptide (YWHAZ), Glyceraldehyde-3-phosphate dehydrogenase 
(GAPDH) and ubiquitin (UBC). Statistical significance was determined using two-way ANOVA with 
Sidak's multiple comparison post hoc analysis, α = 0.05, ****p < 0.0001. 
 
3.2.6 Rescue of placental iron homeostasis by antioxidant supplementation 
To further investigate the association between oxidative stress, hyperglycemia and 
placental iron homeostasis, we performed rescue experiments assuming that the negative 
effects of hyperglycemia on the regulation of placental iron homeostasis genes in BeWo 
cell models can be counteracted by supplementation with an antioxidant. Thus N, H and 
HL BeWo cells were treated with Se and challenged the with additional oxidative stress by 
adding tert-BOOH for 24 h as for Figure 35D. The exposure to tert-BOOH aggravated the 
hyperglycemic/hyperlipidemic effects in the BeWo models and reduced the inter replicate 
variability in all performed assays. Focusing on the iron transporter DMT1, FPN1 and ZIP8, 
we observed significant downregulation of FPN1 under both hyperglycemic conditions 
and decreased ZIP8 under H. TfR1 was relative to N upregulated under H, but 
downregulated under HL. This typical pattern of gene regulation confirmed the results 
shown for GDM placentae in Figure 25, but also in the BeWo model treated with 
tert-BOOH in Figure 35D. Se supplementation reversed the hyperglycemic/hyperlipidemic 
effect at mRNA level almost completely (Figure 36A). Furthermore, Se supplementation 
reduced lipid peroxidation under HL (Figure 36B) and eliminated protein carbonylation 
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under both hyperglycemic conditions (Figure 36C). Importantly, Se supplementation 
increased the antioxidant potential and consequently rescued the hyperglycemic effect 
on gene expression by reducing oxidative damage in hyperglycemic trophoblasts. 
 
Figure 36: Effect of induced oxidative stress on mRNA abundances of iron homeostasis genes in 
trophoblasts and rescue of the hyperglycemic effects by selenium treatment. A, Oxidative stress 
was induced by tert-Butyl hydroperoxide (tert-BOOH; 100 µM) treatment in the three BeWo cell 
models (N, blue; H, orange; HL, grey) for 24 h (striped bars). In tert-BOOH treated cells 
supplementation with 400 nM sodium selenite (NaSe, +Se) significantly reduced the 
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hyperglycemic effect on iron homeostasis gene regulation. mRNA expression results were and 
normalized to the mean of the reference genes Tyrosine 3-monooxygenase/tryptophan 5-
monooxygenase activation protein, zeta polypeptide (YWHAZ), Glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH) and ubiquitin (UBC). Data are expressed as fold difference in relation to 
control cells for each condition, which were not treated with tert-BOOH. Samples treated with 
NaSe are displayed as striped bars in yellow boxes. Supplementation of 400 nM NaSe in the 
medium rescued the altered gene expression under hyperglycemic (H; orange) and 
hyperglycemic- and hyperlipidemic (HL; grey), conditions. B/C, In the three BeWo cell models (N, 
H, HL) oxidative stress was induced by tert-Butyl hydroperoxide (tert-BOOH; 100 µM) treatment 
for 24 h (striped bars). Supplementation with 400 nM sodium selenite significantly reduced the 
formation of malondialdehyde (MDA) equivalents (B) and protein carbonylation 2,4-
Dinitrophenylhydrazine (DNP) staining (C). Both parameters serve as indicators for oxidative 
stress. Statistical significance was determined in (A-C) using two-way ANOVA with Sidak’s multiple 
comparison post hoc analysis, α = 0.05. * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001. 
Results are shown as mean ± SD of triplicate measurements (n=3). In all panels black asterisks 
display significant differences between Se-treated and untreated cells, while red asterisks indicate 
significant differences between conditions H or HL compared to N. 
 
3.2.7 Effect of iron deficiency and iron overload on placental glucose transport 
During the studies outlined above the effect of hyperglycemic conditions on placental iron 
homeostasis was investigated and we found that increased oxidative stress is one factor 
contributing to changes in iron homeostasis gene regulation and function. In collaboration 
with Thuvaraga Kalakaran, who performed her master project in the Albrecht laboratory, 
we further investigated, whether iron deficiency and iron overload could affect placental 
glucose homeostasis. This approach complements the previous results and helps to shed 
light on the association between placental glucose and iron homeostasis.  
Initially, expressional changes of the glucose uniporter GLUT1 as consequence of iron 
deficiency and overload was studied. Therefore, normoglycemic BeWo cells were cultured 
under iron deficiency by treating the cells with the iron chelator DFO and under iron 
overload by supplementation with holo-transferrin (Tf-2Fe3+) during 24 h, 48 h and 72 h 
(Figure 37A). While GLUT1 mRNA levels were unaffected in the iron overload condition, 
there were 2.3-times increased GLUT1 transcript levels detected already after 24 h of 
stimulation with 30 µM DFO, followed by steady reduction of GLUT1 to 1.5-fold 
overexpression. The GLUT1 overexpression in the iron deficient condition was confirmed 
also on protein level (Figure 37C). In contrary to the reduction of GLUT1 overexpression 
from 24 h to 48 h after stimulation on mRNA level, GLUT1 protein expression was even 
more pronounced after two days of DFO treatment.  
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Based on these results, we further investigated the effect of different DFO concentrations 
on GLUT1 mRNA levels in a range of 3.75 – 30 µM DFO in normoglycemic BeWo cells for 
48 h (Figure 37B). Interestingly, within this experiment significant GLUT1 upregulation 
was observed at 15 µM DFO only. To reveal, whether DFO-mediated changes of GLUT1 
expression have a relevant effect for placental glucose uptake, we established a glucose 
uptake assay suitable to study GLUT1 function in BeWo cells. Hence, glucose uptake was 
measured using 2-DG that cannot undergo hexokinase-mediated glycolysis by 
trophoblasts (Figure 37D). Although there was rather high variation among the replicates 
in the glucose uptake assay, normoglycemic BeWo conveyed a significant glucose uptake 
increase after 80 min of 15 µM DFO treatment, while glucose uptake was reduced after 
100 min of 30 µM DFO treatment. Within the glucose uptake time course of 1 h 40 min 
glucose levels increased within the first 45 min almost linearly independent of the 
treatment. BeWo cells reached a maximal glucose uptake level of approx. 2.5 mM/well 
with 15 µM DFO treatment. Due to time restrictions the glucose uptake experiments 
following DFO treatment were done only once. 
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Figure 37: Iron deficiency leads to a temporal upregulation of the glucose transporter GLUT1 on 
mRNA and protein level, but partially reduced 2-Deoxy-D-glucose (2-DG) uptake function. A, 
Glucose transporter type 1 (GLUT1/SLC2A1) mRNA expression levels in normoglycemic BeWo cells 
were increased under iron deficiency induced by 30 µM deferoxamine (DFO) treatment (dark 
green) and unchanged with iron overload by 12.5 µM iron (Fe)-saturated holo-transferrin (Tf-Fe) 
supplementation (pink) during 72 h. B, GLUT1 mRNA levels were determined after iron depletion 
with a DFO concentration range of 3.75 – 30 µM. GLUT1 expression om mRNA level was 
significantly increased after application of 15 µM DFO for 48 h. GLUT1 mRNA levels were tested 
using a paired one-way ANOVA with Tukey’s multiple comparisons test, α=0.05, *p<0.05. mRNA 
levels are represented as mean ± standard deviation (SD) of two independent experiments (n=2) 
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and were normalized to the mean of the reference genes Tyrosine 3-monooxygenase/tryptophan 
5-monooxygenase activation protein, zeta polypeptide (YWHAZ), Glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH) and ubiquitin (UBC). Data are expressed as fold difference in relation to 
untreated control. C, GLUT1 protein levels were analyzed once (n=1) by immunoblotting after 
30 µM DFP treatment or 12.5 µM Tf-Fe supplementation at 24 h and 48 h of stimulation. GLUT1 
protein levels were increased after DFO treatment at both time points. D, Glucose uptake 
performance was measured using a total dose of 325 mM 2-Deoxy-D-glucose (2-DG) spiked with 
0.5 µCi/well 3H 2-DG during 100 min at 37°C. Glucose uptake was increased after 15 µM DFO 
treatment for 80 min, but reduced after 30 µM DFO treatment for 100 min. 2-DG uptake 
differences were determined in one experiment (n=1) and tested by 2 way ANOVA with Tukey's 
multiple comparisons test, α=0.05, *p<0.05.  
 
3.2.8 Obesogenic diet in mice provoke similar effects in placental iron homeostasis as 
human GDM 
In mice, a obesogenic high fat high sugar (HFHS) diet from the start of pregnancy 
compromised maternal glucose tolerance and insulin sensitivity in association with 
dysregulated lipid metabolism, thereby mimicking typical GDM symptoms (Sferruzzi-Perri 
et al. 2013; Musial et al. 2017). In collaboration with the Centre for Trophoblast Research, 
University of Cambridge, UK, we examined whether this mouse model of GDM shows 
similar changes in placental iron homeostasis as shown in human GDM before (3.2.1). At 
approx. 10 weeks of age, female C57Bl/6 mice without additional genetic modifications 
were time-mated to males and subsequently fed either standard (n=6) or HFHS (n=6) diet. 
Dams were sacrificed for tissue collection at day of pregnancy 16 or 19 (d16 or d19) and 
changes in the expression of iron homeostasis genes were determined in placental tissue 
by RT-qPCR (Figure 38).  
At d16, when maximal placental size and maternal glucose intolerance is reached in 
mouse gestation, placental expression of the iron transporter, Dmt1 was significantly 
upregulated in HFHS dams (Figure 38A). Such initial upregulation of DMT1 was also found 
after exposing human trophoblasts to hyperglycemic conditions in vitro (Figure 32A1). At 
d19, when fetal growth is maximal in mice, placental expression of the iron receptor, TfR1 
and iron transporters, Dmt1 and Zip14 were downregulated and the iron uptake regulator, 
Hepc and ferroxidase, Heph upregulated in HFHS dams (Figure 38B). Together, changes in 
placental iron homeostasis genes observed in HFHS mice nicely reflected the alterations 
observed in human GDM placentae (Figure 38C). 
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Figure 38: Expressional changes in mice with high fat and high sugar (HFHS) diet during 
pregnancy reflect regulation patterns found in human GDM placentae. RT-qPCR analyses 
revealed differential regulation of iron transporters Divalent metal transporter 1 
(DMT1/SLC11A2), Ferroportin-1 (FPN1/SLC40A1), Zrt- and Irt-like protein 8 (ZIP8/SLC39A8), the 
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iron receptor Transferrin receptor protein 1 (TfR1/TFRC), the iron sensor Iron regulatory protein 
1 (IRP1/ACO1), the iron homeostasis regulator Hepcidin (HEPC/HAMP) and the iron 
oxidoreductase Hephaestin (HEPH) and Zyklopen (Zp/HEPHL1) in mouse (A/B, blue background) 
and human (C, no background) placentae. A, mice were set on HFHS (n=6) or control (n=6) diet 
from day1 in pregnancy (d1) onwards. mRNA was isolated and quantified from mouse placentae 
at d16 (A) and d19 (B) and compared to human placentae affected by gestational diabetes mellitus 
(GDM, n=11) at term in panel C. A, There was upregulation of the iron transporter Dmt1 in mice 
at d16 only, while significant downregulation of the iron transporters Dmt1 and Zip14 was 
detected at d19. Furthermore, there was significant upregulation of the ferroxidase Heph and the 
iron uptake regulator hepcidin (Hepc). The human data is the same as shown in Figure 25. Taken 
together, expressional changes in HFHS mice (A/B) reflect the GDM-mediated regulation of 
placental iron homeostasis genes in human placentae (C). mRNA levels were statistically 
compared using nonparametric Mann-Whitney test, α=0.5, *p<0.05, **p<0.01. 
 
3.3 Establishment of knockout cell lines generated by CRISPR/Cas9 mutagenesis. 
In the framework of two parallel MSc projects co-supervised by the PhD candidate, we 
were targeting transporter genes crucial for leucine and iron transfer across the placenta. 
Martyna Kazimierczak was targeting the System L transporters LAT1(SLC7A5) and LAT2 
(SLC7A8), while Daniela Ramp was targeting DMT1 (SLC11A2) and ZIP8 (SLC39A8). 
Following the protocol explained in Figure 39, we first designed CRISPR/Cas9 target sites 
and validated them by sequencing the variant in the BeWo genome, optimized 
CRISPR/Cas9 transfection of either sgRNA+Cas9-GFP plasmid (Xfect) or sgRNA-Cas9-GFP 
RNP (jetCRISPR) into the trophoblast cell line BeWo using FACS for analysis of transfection 
rates, but also to collect GFP positive cells to grow knockout cell lines from single cells. 
The resulting CRISPR/Cas9-mutant candidates were characterized on expressional level 
using qPCR and immunoblotting and on functional level performing leucine and Tf-Fe 
uptake assays. Finally, we analyzed the target site for insertion or deletion (indel) 
mutation introduced by site-specific double strand break by sequencing. Although there 
were expressional and functional changes detected for several mutation candidates, final 
sequencing revealed unchanged target gene sequences for all of them. Despite the final 
negative outcome, the following chapter summarizes the procedures and results of our 
efforts to generate BeWo knockout cells for nutrient transporters. 
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Figure 39: Workflow diagram of reporter gene (Cas9-GFP) assisted sorting of transfected mutant 
candidates and subsequent identification of knockout candidate clones. A, 24-48 h after 
transfection of BeWo trophoblasts with Cas9-GFP plasmid or protein, the transfected cells were 
GFP-positive, visually identified and distributed into 96-well plates by FACS-assisted cell sorting 
(B). The surviving cells become knockout candidates and founders of potentially novel knockout 
BeWo cell lines, respectively. Knockout candidate clones were expressionally characterized by 
immunoblot staining (C) and functionally assessed by leucine or iron uptake assays. Finally, the 
knockout candidates showing loss of the targeted protein expression and a loss of function were 
sequenced by Sanger sequencing to determine the mutation leading to gene loss. D, Systematic 
characterization of emerging mutant variants will be done using CrispRVariant (Lindsay et al. 2016) 
and TIDE tool (Brinkman et al. 2014).  
 
3.3.1 Validation of genomic variants of the target sites in BeWo 
The target sites were carefully designed and determined in the intention to create 
devastating double-strand-breaks on the one hand, but no off-target effects on the other 
hand (Table 5 on p.45). To double check whether the sequences in BeWo genome were 
corresponding to the determined target site, we sequenced the region in proximity of the 
target site. Hence, single nucleotide polymorphism (SNP) were detected in the target 
sequence of ZIP8 as shown in Figure 40. After successful validation of all target sites and 
exclusion of any SNP disturbing sgRNA-mediated sequence recognition in the BeWo target 
gene variants, we continued with sgRNA synthesis.  
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Figure 40: Detection of a single nucleotide polymorphism (SNP) by target site sequencing. 
Sequencing data as fluorescent peak trace chromatogram of the ZIP8 target site “ZIP8_567_b”, 
which was finally excluded. Sequence is represented on the reverse strand right (5’) to left (3’) 
with the target site on blue and the PAM (NGG) on orange background. N at position 11 in 5’-3’ 
orientation indicates a G32A-mutation as indicated by two simultaneous upcoming peaks of A 
(Adenine, green) and G (Guanine, black). Such a SNP prevent gsRNA binding and therefore would 
lead to a reduction of knockout efficiency. 
 
3.3.2 Optimization of CRISPR/Cas9 transfection and cell sorting 
In a first step the transfection efficiency of BeWo cells with Cas9-GFP plasmid was tested 
and optimized before using 3 different transfection reagents: DharmafectDuo (Horizon), 
XtremeGENE 9 (Sigma) and Xfect plasmid (Takara Bio). Transfection efficiency and cell 
toxicity of these reagents were the main criteria for selecting the best reagent. HEK-293 
which are known to be easy-to-transfect (Thomas and Smart 2005) were chosen as 
reference cells. The transfection of BeWo and HEK-293 cells with the Cas9-GFP labeled 
plasmid by using the DharmaFECT™ Duo transfection reagent (Horizon) was not 
successful. No GFP signal was detected in both cell lines after various experiments with 
varying amounts of the DharmaFECT reagent and plasmid as suggested in the 
manufacturer’s protocol. At none of the different time points (24, 48 and 72 h post 
transfection) GFP was detectable by fluorescent microscopy. In contrast, by using the 
Xtreme Gene 9 (Roche) reagent the transfection procedure was more successful. The 
highest efficiency was obtained with 4:1 ratio of transfection reagent (in µL) to plasmid 
DNA (in µg), using 7.5 and 10 µL of the transfection complex and detected 48 and 72 h 
post transfection. As shown in Figure 41A-B, Xfect plasmid (TAKARA) transfection reagent 
led to the best transfection efficiencies and lowest toxicity, respectively (optimal 
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conditions see Table 12). Therefore, the Xfect plasmid (TAKARA) reagent was further used 
to transfect HEK-293 and BeWo cells with sgRNA targeting DMT1, ZIP8 and hCG genes and 
the Cas9-GFP plasmid reaching approx. 30% transfection efficiency in BeWo, 70% in HEK-
293 cells (Figure 41A-C). 
Table 12 Optimized Xfect plasmid transfection conditions 
Step Condition 
Preparation of target cells 40’000 cells/well overnight in complete growth 
medium 
Preparation of transfection reagent 3.75 µg plasmid DNA with Xfect plasmid 
Reaction Buffer to a final volume of 10 μL Add 
1.5 μL Xfect Polymer to the diluted plasmid DNA 
Nanoparticle complexes to formation Incubate for 10 min at room temperature 
Transfection Incubate the plate at 37°C for 8 h 
Determination of transfection rate Check for GFP expression after 48 h 
Next, the above optimized Cas9 plasmid-based transfection method was compared to the 
direct transfection of sgRNA-Cas9 protein RNP complexes using the jetCRISPR reagent 
from Polyplus. For this optimization experiment sgRNA targeting the hCG gene was 
additionally used, as knockout of this gene is expected to be less problematic for cell 
survival compared to targeting putative essential nutrient transporter genes (Malhotra, 
Suman, and Gupta 2015). The transfection efficiency was measured for BeWo and HEK-
293 by performing flow cytometry analysis 48 h after transfection (Figure 41D). 
Comparing the transfection efficiency between Cas9plasmid and the Cas9protein method 
(Figure 41D, left to right), Xfect sgRNA + Cas9plasmid - transfection reached in BeWo 
13.8% and 62.9% higher efficiency rates in the easier-to-transfect HEK-293 cells. 
Therefore, the consecutive transfection experiments targeting the nutrient transporters 
LAT1, LAT2, DMT1 and ZIP8 were performed in BeWo using the optimized Xfect plasmid 
method, that usually reached an efficiency of approx. 50% in later experiments (data not 
shown).  
Results - Establishment of knockout cell lines generated by CRISPR/Cas9 mutagenesis. 
  117 
 
Figure 41: Optimization of transfection conditions for BeWo using Xfect plasmid (Takara Bio) 
versus jetCRISPR (Polyplus). A, Representative images of cells 48 h post transfection using the 
optimized sgRNA + Cas9-GFP plasmid transfection protocol in a 96-well plate scale. Transfection 
efficiency in BeWo cells was approx. 30% applied at different cell densities (A-B) and 70% in the 
easier-to-transfect HEK-293 cells (C). The transfection experiment was performed in DMEM low 
glucose (BeWo) resp. DMEM (HEK-293) + 10% FBS + 1 x antibiotics in duplicates. Images were 
acquired by phase contrast and fluorescence cell imaging using InCellis cell imager (Bertin, USA) 
with a 20 x magnification. D, Comparison of the two transfection reagents Xfect plasmid (D, panels 
on the left) for transferring sgRNA together with Cas9-plasmid and jetCRISPR protein (D, panels 
on the right) for transferring sgRNA-Cas9-GFP ribonucleoprotein (RNP) complexes into BeWo cells 
(D, upper panels) and HEK-293 cells (D, lower panels) by flow cytometry analysis. For these 
experiments sgRNA targeting the hCG gene was used. The transfection efficiency of Xfect plasmid 
compared to the Cas9protein method was 13.8% higher if applied on BeWo and 62.9% higher on 
HEK-293 cells. FACS data was analyzed using FlowJo® data analysis software and is presented as 
scatter plots with of the fluorescence emission intensity (λem=488 nm) as area under the peak on 
the x-axis and side scatter (SSC) on the y-axis. 
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3.3.3 Cell recovery and expressional effects of CRISPR/Cas9 mutagenesis 
Following the optimization of sgRNA and Cas9 transfection, the newly established method 
was applied to target the nutrient transporters LAT1, LAT2, DMT1 and ZIP8 in BeWo cells. 
We intended to grow knockout candidate cell lines from a single founder cell as presented 
in Figure 42A, but most of the single sorted cells died within few days post transfection. 
Therefore, FACS was used to isolate successfully transfected, GFP-positive cells in 1, 100 
or 200 cells/well format. 
We further investigated the effect of ZIP8-knockout candidates in BeWo cells on the 
endogenous expression pattern of iron homeostasis genes such as the transporter DMT1, 
ZIP8 itself, ZIP14 and FPN1, but also the iron receptor TfR1, the iron sensor IRP1, the 
ferroxidase Zp and iron regulator HEPC. Figure 42B shows an overview on the expressional 
changes in the single-sorted C1 and 100/200-sorted D1, D2, D3, E1, E2, E3 and E4 ZIP8-
knockout candidates after putative ZIP8-mutagenesis. The expression of iron homeostasis 
genes was normalized to the no-sgRNA, but Cas9 plasmid transfected control cell line I1 
p8 (name l1; passage 8). Compared to I1 p8, the fold change of the non-transfected cell 
lines BeWo p28 and BeWo p29 were with +0.2 and -0.6 very low. Also 5 passages later 
only marginal changes in mRNA levels were observed as shown for l1 p13 as passage 
control. In general, all ZIP8-targeted BeWo cell lines showed a similar iron homeostasis 
gene expression pattern. The mRNA levels of Zp/HEPHL1 showed the strongest 
upregulation, followed by ZIP8 > ZIP14 > IRP1 > TfR1 > DMT1, while the iron exporter FPN1 
and regulator HEPC were downregulated (Figure 42B). Interestingly ZIP8 itself, which was 
targeted and expected to be knocked out, was in most of the samples even higher 
expressed than in controls.  
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Figure 42: A single cell as founder of a new knockout cell line and expressional changes due to 
CRISPR/Cas9 mutagenesis. After growing a single cell for 14 days after Xfect plasmid transfection 
targeting DMT1 and FACS-sorting, the cell has divided several times in a 96 well plate and formed 
a cell colony in culture (A, left panel). The cell knockout candidate clones in the founder colony 
were trypsinized and seeded again in a96-well plate to avoid spatial overgrowth and to expand 
the cell number (A, middle panel). 7 days later, the scattered cells adapted and became a slowly 
growing cell line (A, right panel). Magnification in left panel 50 x, in the middle and right panel 
20 x. B, Composition of expressional changes of iron homeostasis genes on mRNA level after 
CRISPR/Cas9-mediated ZIP8-mutagenesis. BeWo cells were targeted using ZIP8_567 sgRNA (Table 
5) and transfected using the optimized Xfect plasmid method (3.3.2). mRNA levels of candidate 
knockout cell lines were normalized to the no-sgRNA, Cas9plasmid transfected control cell line I1 
p8. The transfected cells were sorted as single cells and 100 or 200 cells/well (_100 resp. _200) 
and lysed for expression analysis in different passages (p6-8 passages after transfection / p28-29 
passages of original cell lines). L1, C1, D1, D2 and D3 were sorted 48 h post transfection and 
samples E1, E2, E3 and E4 were sorted 72 h post transfection. Expression levels were analyzed 
using the mean of reference genes YWHAZ and UBC. All mRNA levels are shown as the mean of 
duplicates from one experiment (n=1) and represented as fold change (2-ΔΔCt)). 
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In a next step, we analyzed the most promising knockout cell line candidates by 
immunoblotting. MVM and BM samples from membrane protein fractioning were loaded 
to confirm the transporter-specific expression ratio between apical MVM and basal BM 
expression. The exclusively MVM expression of LAT1 in Figure 43A and the MVM/BM 
expression of LAT2 Figure 43B, validate the immunoblot experiment. The untreated BeWo 
p27 in Figure 43A showed a very weak LAT1 band at 40 kDa. All clones transfected with 
anti-LAT1 sgRNA and Cas9 plasmid showed an increase in LAT1 expression by factor 3 or 
more compared to untreated BeWo p27 lysate (Figure 43A). The BeWo knockout 
candidate clones B1, B2 and B3 transfected with Xfect plasmid and anti-LAT2 sgRNA 
showed an increase in total LAT2 expression (50 kDa + 30 kDa band in Figure 43B) by a 
factor of 4-5, whereas for the clones B4, B5 and B8 there was only a slight increase of 10-
20% compared to the BeWo p27 control. In the B1, B2 and B3 clones, the upper 50 kDa 
band was 2.5-times more prominent compared to the lower 30 kDa signal. The total LAT2 
expression in deglycosylated BeWo wildtype cells p27 compared to untreated cells was 
slightly decreased but the intensity of the 30 kDa band did not get stronger after 
deglycosylation. For DMT1 quantification the bands between 150 and 75 kDa were 
selected according to (Tabuchi et al. 2000; Foot et al. 2016). All samples show increased 
DMT1 protein levels compared to the BeWo control (Figure 43C). In the immunoblots 
characterizing ZIP8-targeted knockout candidate clones sharp 65 kDa bands were 
quantified. Compared to the BeWo p25 control all samples have lower ZIP8 protein 
expression except sample C1 (Figure 43D). 
Against our expectations, increased levels of target protein expression were detected for 
7 LAT1-knockout candidates (Figure 43A), 6 LAT2-knockout candidates (Figure 43B) and 7 
DMT1-knockout candidates (Figure 43C). Only CRISPR/Cas9-mediated ZIP8-mutagenesis 
resulted in decreased expression levels of the targeted ZIP8 gene relative to the 
untransfected BeWo p25 control (Figure 43D). None of the candidates showed a complete 
loss of target gene expression on the immunoblots. As demonstrated in Figure 42B on 
mRNA level of iron homeostasis genes, the transfection itself led to various expressional 
changes.  
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Figure 43: Target gene expression after CRISPR/Cas9 mutagenesis quantified by 
immunoblotting. The most promising knockout candidates where analyzed on protein level for 
target gene loss through site directed mutagenesis after Xfect plasmid assisted CRISPR/Cas9 
transfection followed by the establishment of stable cell lines. The target gene expression was 
increased for all putative knockout candidates for LAT1 expression in LAT1 mutants #18-24 (A), 
LAT2 in LAT2 mutants #B1-8 and also DMT1 expression in DMT1 mutants #A6-12. In contrast, there 
was reduction of ZIP8 expression between 56% in clone D4 in passage (p) 9 to 86% in clone E3 p7. 
30 μg protein of total cell lysates of 7 LAT1-targeted (LAT1 MK1 sgRNA) BeWo cell lines (#18-24) 
were plotted on nitrocellulose membrane after SDS-Page and stained with the primary antibody 
rabbit anti-LAT1 (1:1000) overnight at 4°C and with secondary anti-rabbit (1:20'000) for 2 hours 
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at room temperature. Detection of β-actin as loading control was performed using primary mouse 
anti-β-actin (1:5000) and secondary anti-mouse (1:20’000) for 2 hours at room temperature each. 
B, Immunoblot analysis of 6 LAT2-targeted (LAT2 142 sgRNA) BeWo cell lines (#B1-B8) according 
to the description for panel A, but using primary rabbit anti-LAT2 (1:1000). For LAT2 an upper 
50 kDa and a lower 30 kDa band was quantified. C, Immunoblot analysis using 60μg total cell lysate 
from 7 DMT1-targeted BeWo cell lines (#A6-A12) with passage numbers between 7 and 9 using 
primary mouse anti-DMT1 (1:500) otherwise according to the description for panel A. D, 
Immunoblot analysis according to the description for panel C, but using rabbit anti-ZIP8 (1:1000). 
TMI: total membrane protein isolation sample; BM: basal membrane fraction; MVM: microvillous 
membrane fraction; BeWo p23-27 are non-transfected control samples with passage number (p); 
deg: deglycosylated sample after PNGase F treatment. All immunoblot experiments were 
repeated 2-times. 
3.3.4 Effects of CRISPR/Cas9 mutagenesis on functional nutrient uptake  
Despite of remaining expression of the targeted genes on protein level, we tested a 
selection of knockout candidate cell lines to investigate the CRISPR/Cas9 mutagenesis 
mediated effect on placental Leu and iron uptake. Furthermore, we established a strategy 
to characterize the knockout candidates by applying small molecule inhibitors bearing 
different specificities.  
Amino acid uptake 
In the case of targeting System L mediated leucine uptake, the LAT1-specific inhibitor 
JPH203 and the unspecific System L (mainly LAT1+LAT2) inhibitor JX009 was used. In LAT1 
knockout trophoblasts JPH203 inhibition was expected to have no effect on leucine 
uptake, while other transporter such as LAT2 would compensate for the essential 
acquisition of leucine. Therefore, only JX009 but not JPH203 could mediate leucine uptake 
inhibition in LAT1-targeted BeWo cells. On the other hand, JPH203 inhibition on LAT2 
knockout trophoblasts was expected to completely block leucine uptake, while inhibition 
trough JX009 would block leucine uptake similar as JPH203. Based on this expectations, 
the two LAT2-targeted BeWo cell lines B3 and B5 were investigated by leucine uptake 
assay in combination with JPH203 and JX009 inhibition (Figure 44A-C). The leucine uptake 
of untransfected control BeWo p27 cells was reduced by 10 µM JPH203 by about 50-60%, 
while leucine uptake inhibition by 10 µM JX009 reduced with approx. 85% almost 
completely. According to these expected JPH203 and JX009 inhibition pattern as 
characterized before in 3.1.4.1, the leucine uptake performance of B3 and B5 was 
experimentally assessed. There was 1.8-times increased leucine uptake efficiency of 
untreated B3 compared to control cells (Figure 44A/B). This increased leucine uptake was 
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unexpected but may be the result of adapted expression pattern of System L transporter 
in these CRISPR/Cas9-targeted cells. However, the expected similarity of JPH203 and 
JX009 inhibition in putative LAT2-knockout trophoblasts was observed for the B5, but not 
for the B3 clone.  
Iron uptake 
Through inhibition of Tf-mediated iron uptake by ferristatin II (also Chlorazol Black or 
NSC30611), which lead to the degradation of the TfR1, we expected to measure complete 
block of Tf-mediated and TfR1-dependent iron uptake. Hence, we expected to observe for 
the ZIP8-targeted candidate clones a reduction in Tf-Fe uptake during the iron uptake time 
course, e.g. a curve which is located between the untreated and ferristatin II treated cells. 
The iron uptake inhibition using ferristatin II in the Tf-dependent uptake setup has been 
measured with control BeWo p27 cells, C1 and D2 candidates (Figure 44D-F). Ferristatin II 
treatment led, as expected, to an almost complete inhibition of the iron uptake in all assay 
independent of testing transfected or control BeWo cells. Unfortunately, none of the 
tested ZIP8-knockout candidates conveyed a reduction of Tf-Fe uptake within the 
observed 2 h time course.  
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Figure 44: Functional characterization of CRISPR/Cas9-targeted BeWo cell lines by comparing 
leucine and iron uptake time courses of candidate knockout clones. In panel A, the inhibition of 
leucine (Leu) uptake of untransfected control BeWo passage number (p)27 cells by the LAT1-
specific small molecule compound JPH203 led to a Leu uptake reduction after 3 min (dashed box) 
of 48% (A, orange). Additionally, the System L (mainly LAT1+LAT2) inhibitor JX009 blocked 76% 
Leu uptake within 3 min compared to control BeWo cells (A, grey). The Leu uptake kinetics of the 
two promising LAT2-knockout candidates B3 (B) and B5 (C) were compared to the “wildtype” 
respectively untargeted control BeWo cell line in A. B3 showed a 1.8-times increased Leu uptake 
efficiency within 3 min (B, dashed box) compared to control BeWo cells in A, while untreated B5 
clones exhibited uptake levels similar to the control in A (C). Leu uptake of both B3 (B) and B5 (C) 
were reduced by JPH203 of 65% and 66% and by JX009 of 83% and 51%, respectively. There was 
clearly less difference between JX009 and JPH203 inhibition (difference between orange and grey 
curve) compared to control in A. B&C, A selection of LAT2_142 sgRNA and Cas9 plasmid 
transfected and FACS sorted cell lines, namely B2 and B5. The inhibitors JPH203 and JX009 were 
applied with a concentration of 10 µM during the 8 min of Leu uptake. Statistical significance 
between conditions was determined using the Holm-Sidak method, α=0.05, * p<0.05. In panel D, 
The inhibition of Transferrin-dependent iron uptake of untransfected control BeWo p27 cells by 
50 µM ferristatin-II (NSC30611) inducing Transferrin receptor 1 (TfR1) degradation led to an iron 
uptake reduction of 82% within 60 min (D, orange). The two selected ZIP8-targeted (ZIP8_567) 
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knockout cell lines C1 (E, single sorted) and D2 (F, 100 sorted cells) showed without inhibition very 
similar iron uptake kinetics as the untransfected control BeWo p27 cell line. Furthermore, 
ferristatin-II inhibition conveyed for C1 85% (E) and for D2 a reduction of iron uptake of 80% within 
60 min (F). There was no difference detectable between the two putative ZIP8-knockout candidate 
cell lines and the untransfected control BeWo p27. Ferristatin-II treatment was applied 4 h before 
and during the 120 min time course of the iron uptake assay. Statistical significance between 
conditions was determined using the Holm-Sidak method, α=0.05, * p<0.05. In general, all uptake 
results were normalized to the protein concentration. Data are expressed as mean of 3 replicates 
for each time point. 
 
3.3.5 Unsuccessful CRISPR/Cas9-mutagenesis in BeWo cells revealed by sequencing 
CRISPR/Cas9 mutagenesis is depending on cellular double-strand-break repair. Since 
CRISPR/Cas9-mediated mutations result often in in-frame indel mutation with remaining 
function or partially function (Burger et al. 2016), we performed target site sequencing of 
mutant candidates to the end of the workflow. The four most promising knockout 
candidates were further analyzed by target site sequencing. The LAT2-targeted clones B3 
and B5 were selected due to reduced difference comparing LAT1-specific inhibition by 
JPH203 and System L inhibition by JX009. ZIP8-targeted clones C1 and D2 were sent for 
sequencing due to characteristic regulation patterns in iron homeostasis gene expression 
on mRNA level (3.3.3) and promising changes on functional level (3.3.4). The sequences 
of all target sites perfectly matched the wildtype sequence (Figure 45) independent of 
which gene was targeted (B3/B5 compared to C1/D2) or whether the cells were single- or 
multi-sorted after transfection (C1 compared to D2).  
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Figure 45: Sequence trace chromatogram analysis of the four most promising knockout 
candidates revealing unsuccessful CRISPR/Cas9-mutagenesis. None of the sequenced target sites 
of the LAT2-targeted knockout candidates B3 (A) and B5 (B), nor the sequenced target sites of 
ZIP8-targeted candidates C1 (C) and D2 (D) showed any sign of an insertion or deletion (indel) 
mutation. There were no indels detected close to the planned and Cas9-mediated double strand 
break (red dashed line) nor up- or downstream of the sequenced target site region. In parallel to 
the sequence trace chromatogram the previously designed target sites (green) and the 
corresponding PAM-sites (red) are annotated. In theory most indel mutations were expected close 
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to the site of Cas9-mediated double strand break 3 nucleotides upstream of the PAM sequence 
marked with a yellow triangle. 
 
Nevertheless, to compare the mutagenesis efficiency between the two transfection 
methods based either on Cas9-plasmid (Xfect) or Cas9-protein (jetCRISPR) transfection 
and between different target sites, the CRISPR/Cas9-mutagenesis protocol used for BeWo 
targeting was applied on the easy-to-transfect HEK-293 cells. Unfortunately, no DNA 
shedding by T7-Endonuclease 1 and therefore no DNA mutagenesis was detected for any 
condition and target site analyzed (Figure 46). Of note, there was no difference in DNA 
shedding even when targeting a gene like hCG without expression in HEK-293.  
Another straightforward method to quantitatively assess genome editing using 
chromatogram sequencing trace data is based on the tracking of indels by decomposition 
(TIDE) algorithm (Brinkman et al. 2014). Therefore, we uploaded sequence trace data of 
two standard capillary sequencing reactions in the ab1-format as provided by Microsynth 
to the https://tide.nki.nl/ online platform. The TIDE software quantifies the editing 
efficacy and identifies the predominant types of insertions and deletions (indels) in the 
DNA of a targeted clone pool. Figure 46B shows a representative example of the TIDE 
results from the ZIP8 mutant candidate D2. The D2 was a clone pool that started originally 
with 100 sorted cells after transfection. In contrast to enzyme-based Cas9-editing 
detection method above, TIDE could detect a very low mutagenesis efficiency of 5.4%, 
which was below the detection limit of the T7-Endonuclease 1 assay.  
In summary, we designed target sites, established methods and strategies to analyze 
CRISPR/Cas9-mutant candidates on expressional and functional level. However, within 
the framework of this thesis we were finally not able to generate BeWo knockout cell lines 
for our nutrient transporter genes of interest. 
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Figure 46: Undetectable Cas9-nuclease activity in transfected HEK-293 cells by T7-Endonuclease 
1 assay, and low mutation efficiency detected by Tracking of insertion or deletion (indel)  by 
Decomposition (TIDE) analysis. Easy-to-transfect HEK-293 cell were treated with different 
transfection reagents together with either target site-specific sgRNA and Cas9-GFP plasmid or with 
sgRNA-Cas9-GFP protein ribonucleotide complexes. A, After transfection, the genomic DNA of 
unsorted cells was isolated, the target site amplified in a conventional PCR, digested by T7-
Endonuclease 1 and finally analyzed on a 1% agarose gel T7 Endonuclease 1 cleaves non-perfectly 
hybridized DNA. This would lead to a shedding of DNA, if there are different sequence variants 
after CRISPR/Cas9-mutagenesis. Different conditions were tested for efficient CRISPR/Cas9-
mutagenesis. The two transfection protocols sgRNA+Cas9-GFPplasmid (Xfect) and sgRNA-Cas9-
GFP RNP (jetCRISPR) were directly compared targeting different genes, such as LAT1, LAT2, DMT1, 
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ZIP8, but also hCG as silenced or unexpressed gene in HEK-293 cells. However, there was no DNA 
shedding detected independent of the transfection method or target gene (A). Expected amplicon 
sizes are given below the target gel labels: LAT1 MK1, 170 bp; LAT2 142, 305 bp; DMT1_1312, 
387 bp; ZIP8 567, 244 bp; hCGB3, 290 bp. B-C, Tracking of indels s by Decomposition (TIDE) 
analysis of ZIP8-targeted and Xfect plasmid transfected BeWo cells. The sequence trace 
chromatogram data were uploaded on https://tide.deskgen.com. The program detects indel 
mutations based on the Sanger sequencing information and analyzes not only the highest peak, 
but also the noisy peaks behind. It is possible to detect mutations within a mixture of differently 
mutated cells compared to the wildtype control. The indel spectrum shows 88.5% consistency 
with the control and deletions of 2, 4, 9 or 10 nucleotides (B)The lower panel aberrant sequence 
signal panel does not show any frame shifts at the expected cutting site 3 nucleotides upstream 
of the PAM sequence, which would lead to a chromatogram data decomposition by various 
insertions or deletions (C) There was decomposition detected, due to poor sequencing data 
quality after 220 bp. 
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4 Discussion 
This chapter includes the structured discussion of all key findings and results emerging 
from the experimental part of the PhD project. The previously defined specific aims (see 
1.6.1 on p.29 and 1.6.2 on p.30) are discussed in corresponding sequence in the two 
sections amino acid and iron transport. Beside these two clinically oriented parts, there is 
an additional methodological part discussing the current state of CRISPR/Cas9-mediated 
trophoblast mutagenesis in our research group. The hypotheses are discussed in the 
conclusion part.  
4.1 Amino acid transport 
Since studies in the 1970s have shown that concentrations of most proteogenic amino 
acids are higher in the fetal compared to the maternal circulation, there is the central 
dogma that most amino acids are actively transported across the placenta against a 
counter-directed gradient (Philipps et al. 1978). We hypothesized that counter-directed 
materno-fetal amino acid gradients have an impact on the function of amino acid 
transporters such as LAT1 and thereby affect transplacental amino acid supply. Thus, the 
maintenance of amino acid gradients between the maternal and fetal circulation is 
essential for a normal pregnancy and for adequate fetal growth.  
As only old and incomplete data on amino acid concentrations are found in literature, we 
first aimed to determine maternal and fetal concentrations of the 20 proteogenic amino 
acids in sera of healthy term pregnancies (aim A1). Subsequently, we performed 
correlation analyses between materno-fetal amino acid gradients as concentration 
differences of fetal and maternal compartments and parameters characterizing the 
maternal nutritional condition and fetal growth (A2). To test the resulting associations 
from a clinical and observational point of view with functional assays, we studied the 
effect of substrate concentrations on System L-mediated leucine uptake into trophoblasts 
and. Continuing, we determined the direct effect of a materno-fetal gradient on amino 
acid leucine transport across the placental barrier in vitro with BeWo cells using the 
Transwell® system (A3). 
In a second step, we investigated the influence of extracellular amino acid concentrations 
on the functional level by assessing exchanger-mediated Leu uptake in conventional cell 
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culture of HT-29 and BeWo cells at two differentiation stages, to characterize the effect 
of trophoblast differentiation on placental leucine transport (A4).  
In the third more transporter-oriented section of the amino acid part, we focused on the 
dissection of the single transporter by specific inhibition to elucidate the role of LAT1 and 
LAT2 in Na+-independent leucine transport across the placenta using small molecule 
inhibitors as tool compounds (A5).  
Each part of these three main sections of the amino acid project is separately discussed 
below (4.1.1-4.1.3). 
4.1.1 Materno-fetal amino acid gradients are crucial for transplacental amino acid 
transport and correlate with selected maternal and fetal parameters 
Variation of maternal and fetal amino acid concentrations 
In agreement with literature (Pohlandt 1978; Malinow et al. 1998; McIntosh, Rodeck, and 
Heath 1984; Irene Cetin et al. 1988; Karsdorp et al. 1994; Irene Cetin et al. 2005; Bajoria 
et al. 2001; Cockburn et al. 1971) we detected higher amino acid concentrations in the 
fetal as compared to the maternal circulation. Within our cohort we found in materno-
fetal paired analysis significant differences in the amino acid concentration especially for 
essential or conditionally essential amino acids such as Thr, Val, Trp, Lys, Gly and Tyr 
(Table 8 on p.64). Although there are 15 different amino acid transport systems 
characterized in the human placenta and several amino acids are transported by different 
systems (Thomas Jansson 2001), half of the amino acids showing significant differences 
are preferentially substrates for system L transporters, particularly LAT1 (see 
concentrations of selected LAT1 substrates schematically depicted in Figure 47C on 
p.144).  
The placenta is a metabolically active organ and interorgan exchange with fetal liver for 
non-essential amino acids like Gly to Ser and Gln to Glu was demonstrated in temporal 
amino acid interconversion characterization of sheep pregnancy using stable isotope 
methods (Marconi et al. 1989; Vaughn et al. 1995). Therefore, the comparison between 
maternal and fetal amino acid concentrations allows conclusions on materno-fetal 
transfer, but without including amino acid metabolism this can be misleading (I. Cetin 
2001). It has been shown that the nutritional stage of the mother affects the use of amino 
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acids as fuels by the placenta during pregnancy (Lemons, Reyman, and Schreiner 1984). 
Due to standardization of sampling and selection of patients that delivered exclusively by 
cesarean section, we did not expect significant effects of fasting in this study. For Cys 
unexpectedly low concentrations were detected (Figure 12 on p.63, Table 8 on p.64), and 
the reason for this phenomenon is unclear. Increased preanalytical degradation of amino 
acids or analytical problems with amino acid detection can be largely excluded, due to 
stable measurements of other amino acids, measurement repetitions and validity of 
internal controls. On the other side, there could be metabolic reasons for low Cys levels 
in late pregnancy. Sulfur-containing amino acids can be interconverted by transsulfuration 
(Met→Cys) or transmethyla on (Cys→Met). Due to the absence of transsulfura on 
activity in the fetal liver and high transmethylation activity for growth and cell 
proliferation, Cys consumption increases and becomes essential for the fetus in the 3rd 
trimester (Gaull, Sturman, and Räihä 1972; Sturman, Gaull, and Raiha 1970). Cys is also 
required for the synthesis of various proteins and glutathione. Therefore, high amounts 
of Cys are consumed and must be transported across the placenta particularly in the 3rd 
trimester, when fetal growth, amino acid metabolism and oxidative stress reach a 
maximum (Myatt and Cui 2004; Casasco et al. 1997). However, due to the discrepancies 
of our measured Cys concentrations with previously published data, Cys was excluded 
from the subsequent correlation studies. 
Fetal veno-arterial differences reveal different phases of placental amino acid homeostasis 
There is a high heterogeneity in the literature regarding the predominance of positive or 
negative veno-arterial differences in the fetal blood. Few studies showed positive FV-FA 
differences for most amino acids in healthy pregnancies (Irene Cetin et al. 1988), others 
larger or smaller proportions of negative FV-FA differences (Hayashi et al. 1978; Prenton 
and Young 1969; Velazquez et al. 1976; Steingrímsdóttir, Ronquist, and Ulmsten 1993; 
Irene Cetin et al. 2005; Tsuchiya et al. 2009). Cetin et al. found positive FV-FA amino acid 
concentration differences for most essential amino acids in normal fetuses, but less in 
intrauterine growth restriction (IUGR) (Irene Cetin et al. 1988). Furthermore, negative FV-
FA differences were also interpreted as sign for fetal maturation by comparing amino acid 
concentrations in term and preterm (Hayashi et al. 1978). Due to the paired analysis 
mode, veno-arterial (FV-FA) differences of the 22 patients in our study cohort (Table 7 on 
Discussion - Amino acid transport 
  133 
p.62) were individually analyzed. Although the means of FV-FA differences for all amino 
acids were negative, 45% of analyzed cases showed a clearly positive FV-FA difference for 
most amino acids (Figure 13 on p.65). Therefore, the negative mean FV-FA differences as 
listed in Table 8 (p.64) is based on a highly heterogenic group of placentae being either in 
accumulative (positive FV-FA difference) or secretory (negative FV-FA difference) mode. 
18 out of 22 placentae (82%) showed either accumulation or secretion of most amino 
acids into placenta towards the maternal circulation, while the remaining four placentae 
were showing a mixture of both modes (see ≈-marked placentae in Figure 13 on p.65). 
Since fetal growth is dependent on amino acid supply throughout the pregnancy, the 
placenta likely alternates throughout pregnancy between amino acid accumulation and 
secretion modes. Total amino acid concentrations in cattle are following a circadian 
rhythm depending on growth hormone levels and food intake (Ndibualonji et al. 1995). A 
circadian effect on amino acid concentrations has also been found in human young males 
where the concentrations of 16 amino acids varied throughout the day (Wurtman et al. 
1968). Another study reported that the circadian changes of amino acid concentrations in 
pregnant women were smaller than in non-pregnant women. Herein the authors 
observed changes of plasma glucose, free fatty acids and insulin levels suggesting a daily 
switching rhythm between anabolic and catabolic stages in pregnancy by (Phelps, 
Metzger, and Freinkel 1981). In summary, the different phases of placental amino acid 
homeostasis in individual pregnancies suggest a temporary switch between accumulation 
and secretion phases in placental amino acid transfer, which should be confirmed by in 
vivo determination of FV-FA differences. This could be achieved by using in utero 
cordocentesis allowing a relatively unstressed sampling unaffected by parturition and at 
different gestational ages (Irene Cetin et al. 1990; McIntosh, Rodeck, and Heath 1984). 
Association between maternal/fetal amino acid concentrations and anthropometric data 
To estimate the relevance of amino acid concentrations in different maternal and fetal 
compartments, and to investigate the importance of materno-fetal gradients, Spearman 
correlations with fetal and maternal anthropometric values were performed within our 
healthy study cohort. The results of our analyses complement data from a previous study 
that performed correlation analysis between amino acid concentrations among different 
maternal and fetal compartments (Holm et al. 2017). 
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Maternal amino acid concentrations correlate with maternal weight and BMI  
Exchanger-mediated amino acid transport, including the transfer of large neutral amino 
acid by system L transporters, depends on the availability of their exchange partner (Jane 
K. Cleal et al. 2007). The transfer of essential amino acids can be affected, if amino acid 
concentration gradients across the placental barrier are changed (Hill and Young 1973). 
To investigate the potential impact of maternal, fetal and placental parameters, amino 
acid concentrations were tested for correlations with all available anthropometric values 
(Table 7 on p.62). Remarkably, maternal (MV) and fetal (FA and FV) concentrations of 
essential amino acids such as the LAT1- substrates Val, Leu, Ile, Met, Phe, Tyr and His were 
positively correlated with maternal weights and BMI both before pregnancy and at 
partum (Figure 14 on p.69 and Table 9 on p.67). On the other side, the fetal amino acid 
levels of Val, Ile and Pro seem to be more dependent on the mother’s preconceptional 
weight rather than on the maternal weight at the end of pregnancy. Similarly, fetal amino 
acid concentrations of Val, Leu Ile, and Pro were correlated more often with 
preconceptional BMI than with BMI at partum. It has been shown that preconceptional 
body weight has a lasting impact on gestational weight gain, fetal growth and contribute 
to develop obesity postpartum (Gunderson and Abrams 2000). Obese women are 
predisposed to get babies that are large for gestational age, even when they show the 
same gestational weight gain as non-obese women (Niswander et al. 1969; Melzer and 
Schutz 2010). Therefore, high amino acid levels before pregnancy tend to stay high 
throughout gestation and influence fetal amino acid levels at term. These results are in 
line with observations during temporal maternal infusions with increasing amino acid 
concentrations. These infusions resulted in a temporal fast increase of maternal amino 
acid concentrations and enhanced umbilical amino acid uptake in humans (Ronzoni et al. 
1999) and sheep (Jozwik et al. 1999), but increased MV concentrations were ineffective 
after prolonged amino acid infusion in pregnant sheep (Jozwik et al. 1999). This inhibitory 
effect on fetal amino acid uptake were observed to a greater extent if large neutral amino 
acid were infused (Jóźwik et al. 2004). On the other hand, placental amino acid supply is 
highly vulnerable to maternal undernutrition. This was for instance detected as a 
consequence of the Dutch famine in the second world war, when newborns were growth 
restricted and showed an increased incidence of obesity and metabolic and cardiovascular 
disease in adulthood (Roseboom et al. 2011). 
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Amino acid gradients are associated with maternal and placental weight  
Materno-fetal amino acid gradients of Ile, Pro, Phe, Tyr, and His correlated with 
anthropometric data characterizing the weight and the nutritional stage of subjects, 
respectively (Table 9 on p.67). Of note, since amino acid levels are generally higher in the 
fetal as compared to the maternal circulation, those amino acid gradients are negative 
values and represent counter-directed materno-fetal gradients. The positive correlation 
between counter-directed materno-fetal gradients and anthropometric data indicates 
that increasing maternal amino acid levels lead to less-negative, smaller materno-fetal 
gradients. In other words, the heavier the mothers were before pregnancy or the more 
weight they gained, the smaller (more positive) the counter-directed gradients across the 
placental barrier were. Interestingly, the gradient of Gly was negatively correlated with 
gestational weight gain. Although there is a high Gly demand for fetal growth and 
consequently the Gly concentration in the fetal circulation is high, there is compared to 
Leu very low materno-fetal transport of Gly (Irene Cetin et al. 1995), probably due to Ser-
Gly transformation through hydroxymethyltransferase activity in the fetus (Rohan M. 
Lewis et al. 2005). The association between Gly gradients and weight gain values suggest 
an increased materno-fetal Gly transport or fetal Ser-Gly transformation, if the weight 
gain is high. Excess or lack of gestational weight gain was related to various pregnancy 
complications and cardiovascular diseases and obesity in the offspring (Gaillard 2015; 
Mamun, Mannan, and Doi 2014). Although a recent multi-cohort meta-analysis associated 
gestational weight gain with an increased risk for preeclampsia, gestational diabetes, 
preterm birth and other disorders, weight gain remains a multifactorial parameter 
depending on maternal fat accumulation, fluid expansion, and the growth of fetus, 
placenta and uterus (Voerman et al. 2019). Of note, both gestational weight gain and 
maternal weight represent a modifiable risk factors that are considered in prenatal 
counseling. Therefore, reducing the risk by diet adjustment and gestational counseling 
could help to prevent adverse outcome including gestational diabetes (Hedderson, 
Gunderson, and Ferrara 2010; Abrams and Laros 1986). 
Additionally, we found a relationship between placental weight and counter-directed 
amino acid gradients of the non-essential amino acids Gly, Ala, Asp and Glu (Figure 12 on 
p.63, Table 8 on p.64). While Gly and Ala are transported by different transport systems 
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such as system A, GLY or ASC, and are converted or metabolized by the placenta (F. C. 
Battaglia and Regnault 2001; Thomas Jansson 2001), the anionic amino acids Glu and Asp 
are synthesized by fetal tissue and have no net transfer across the perfused human 
placenta (H. Schneider et al. 1979; Moores et al. 1994). In a correlation study on small for 
gestational age babies, system A transporter activity was compared to a variety of 
anthropometric parameters. It was found that system A activity positively correlated with 
fetal proportions like skin-fold thicknesses and placental weight (Harrington et al. 1999). 
Therefore, the combination of system A transporter activity and smaller Gly and Ala 
gradients could represent a placental adaption to produce and supply more substrate 
towards the fetus (Harrington et al. 1999).  
Fetal amino acid concentrations and materno-fetal gradients affect maternal blood 
pressure 
Fetal concentrations of essential large neutral AA such as Met, Val, Leu and Phe, but also 
non-essential AA like Gly, Ala, Ser, Asn, Asp and Lys were negatively correlated with 
maternal blood pressure (Table 9 on p.67). Furthermore, materno-fetal gradients were 
positively associated with maternal blood pressure. Interestingly, smaller materno-fetal 
gradients as a result of lower fetal and higher maternal AA concentrations were associated 
with preeclampsia before (Cockburn et al. 1971; Evans et al. 2003). Offspring from 
hypertensive or preeclamptic pregnancy are often born with low birth weight, even more 
pronounced the earlier they were born (Xiong et al. 2002). Beside placental insufficiency 
to transfer nutrients into the fetal circulation through impaired placentation and reduced 
placental perfusion (Rana and Karumanchi 2017), it could be speculated that the failure 
to establish appropriate materno-fetal AA gradient contributes to diminished nutrient 
supply and hence reduced intrauterine growth.  
4.1.1.1 Counter-directed amino acid gradients in vivo affect leucine uptake into trophoblasts and 
transfer across the placental barrier 
Extracellular amino acid levels affect leucine uptake into differentiated trophoblasts  
In the placenta there are accumulative transporters, exchangers and facilitators forming 
a complex placental amino acid transport system, which is dependent of intracellular 
versus extracellular, maternal versus fetal, and fetal versus maternal substrate gradients. 
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The complex network of these transport systems enables an efficient materno-fetal 
transfer of essential amino acids against a counter-directed gradient (Jane K. Cleal and 
Lewis 2008; Thomas Jansson 2001). Extensive computational modeling suggests beside 
active transport also facilitated transport across the BM, which is highly dependent of 
amino acid gradients across the BM (Panitchob et al. 2015; Widdows et al. 2015; Rohan 
M Lewis, Cleal, and Sengers 2020). However, if and how counter-directed amino acid 
gradients affect the LAT1-dominated exchanger-mediated materno-fetal transfer of an 
essential amino acids like Leu, has not been investigated yet. In a first step, we examined 
whether the Leu uptake capacity in BeWo cells is sensitive to increased extracellular Leu 
levels. As expected, extracellular Leu levels in the upper clinical range (167 µM) increased 
Na+-independent uptake of Leu into the trophoblasts and into colon carcinoma cells (HT-
29). The choriocarcinoma cell line BeWo (clone b30) which differentiates upon cyclic 
adenosine monophosphate (cAMP) stimulation and further develops a polarized 
trophoblast monolayer (Orendi et al. 2010), has been validated with ex vivo placenta 
perfusion (Poulsen et al. 2009; H. Li et al. 2013) and selected to explore transport 
mechanisms in vitro before (Heaton et al. 2008).  
Next, we investigated, whether the differentiation stage of trophoblasts affects the 
uptake capacity for Leu. Indeed, differentiated BeWo-STB showed two times higher Leu 
uptake than undifferentiated BeWo-CTB or HT-29 cells (Figure 16A on p.73). Since all 
uptake assays were performed within 3 min, the increase of Leu uptake cannot be 
explained by expressional changes of Leu transporters. Furthermore, the inhibition 
experiment with the LAT1-specific inhibitor JPH203 (Endou et al. 2008) demonstrated that 
Leu uptake in trophoblasts is predominantly LAT1-dependent (Figure 16B on p.73). Meier 
et al. showed a 1:1 exchange stoichiometry of heteromeric LAT1 and LAT2 transporter and 
substrate selectivity allowing the exchange of one extracellular large neutral amino acid 
against a non-essential intracellular amino acid using the Xenopus expression system 
(Meier et al. 2002). The underlying mechanisms of trophoblasts to further increase Leu 
uptake upon differentiation without changing the concentrations of exchange partners 
are not clear yet. In human pregnancies, maternal-fetal transfer rates have been 
investigated in vivo by stable isotope infusions into the maternal circulation followed by 
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fetal blood sampling. The materno-fetal transfer rate of nonessential amino acids like Gly 
was significantly lower than for essential amino acids like Leu (Irene Cetin et al. 1995). 
Effect of counter-directed amino acid gradients on materno-fetal leucine transfer 
To test whether different extracellular amino acid concentrations have an effect on Leu 
transfer across the materno-fetal barrier, we conducted Leu transport experiments using 
the Transwell® system. Hereby we compared Leu transfer under equimolar Leu 
concentrations in the maternal and in the fetal compartment against a counter-directed 
Leu gradient (Figure 17 on p.75). To our knowledge this is the first time, that the effect of 
a physiological counter-directed amino acid gradient was functionally assessed in vitro. 
Although the applied gradient created a strong fetal to maternal directed transport 
pressure, we observed higher materno-fetal transfer rates in presence of the counter-
directed Leu gradient as compared equimolar Leu concentrations (Figure 47B on p.144). 
Additionally, the significant reduction of Leu transfer by the LAT1-specific inhibitor JPH203 
(Endou et al. 2008) underlines the importance of LAT1 in materno-fetal transport of Leu, 
but likely also affects placental transport of other LAT1 substrates like Ile, Phe, Met, Tyr, 
His, Trp, Val, Cys and Thr (Napolitano et al. 2017). At the end of the experiment no 
intracellular Leu retainment was detected, independent if the intracellular Leu content 
was calculated or measured, suggesting Leu uptake rather than efflux towards the fetal 
compartment as limiting step (Figure 17D on p.75). Intracellular Leu retainment would 
indicate fetal efflux as transfer limiting step, as shown in Leu uptake studies using 
LAT1/LAT2 small molecule inhibitors (Zaugg et al. in press). The asymmetry of the 
transplacental amino acid flux is favored by rapid uptake from the maternal circulation 
and transfer towards the fetus. It has been shown that amino acid transfer towards the 
fetal side is more rapid than in the reverse direction (H. Schneider et al. 1987). The 
importance of effective placental amino acid transport systems rather than maternal 
amino acid concentrations as crucial factor for fetal growth is supported by findings of 
Bajora and coworkers (Bajoria et al. 2001). They observed that in monochorionic twins 
from which one was growth retarded, the concentrations of Val, Leu, Ile, Phe, and Arg 
were only reduced in the growth restricted twin, but normal in the co-twin not suffering 
from IUGR (Bajoria et al. 2001). Furthermore, counter-directed amino acid gradients 
might play a crucial role after their establishment at the beginning of the second trimester 
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of human pregnancy and before starting the phase of biggest fetal growth (Jauniaux, 
Gulbis, and Gerloo 1999). Based on these results we suggest the incorporation of 
transplacental amino acid gradients relevant for fetal development in computational 
modeling based on placental perfusion studies (R. M. Lewis et al. 2013; Widdows et al. 
2015). 
4.1.2 Trophoblast differentiation affects placental amino acid uptake  
Induced trophoblast differentiation leads to expressional reorganization of System L 
transport 
The current understanding of transplacental leucine transport is based on the interplay 
between accumulative transporters such as members of the System A-family and 
exchangers such as System L-family members (Jane K. Cleal and Lewis 2008). System A-
family transporters like SNAT1, 2, and 4 are expressed at the MVM and accumulate small 
neutral amino acids against a concentration gradient in the STB in a Na+-dependent 
manner(Thomas Jansson 2001). The amino acids accumulated by System A-transporters 
can be used as substrates to exchange for essential large neutral amino acids such as 
leucine by the System L-exchangers LAT1 and LAT2 across the MVM into the STB. The 
principles of amino acid uptake at the MVM are largely characterized, but the contribution 
of single transporters in amino acid transfer across the BM to the fetus is less clear.  
Therefore, we investigated the expression and localization of LAT1 in the human placenta 
by immunohistochemistry of term placental tissue and by immunoblotting of MVM- and 
BM-enriched membrane preparations. We found an exclusive apical expression of LAT1 
at the MVM confirming previous reports (Gaccioli et al. 2015; Kudo and Boyd 2001).  
BeWo cells represent a suitable model comparable to primary trophoblasts 
So far most mechanistic studies are based on LAT1-overexpressing cell models like human 
colon cancer-derived HT-29 (Oda et al. 2010), mammary gland derived MCF-7 cells 
(Huttunen et al. 2016), Pichia pastoris(Costa et al. 2013) or reconstituted 4F2hc-LAT1 
proteoliposomes (Napolitano et al. 2015). Acquiring further detailed knowledge on the 
complex mechanisms regulating materno-fetal amino acid transport at the placenta level 
could be beneficial to clarify the relevance of LAT1 and LAT2 in gestational diseases such 
as IUGR and LGA (Lager and Powell 2012). To choose an appropriate physiological 
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placental cell model, we compared the BeWo cell line with isolated primary human 
trophoblasts at different stages of differentiation by analyzing LAT1/LAT2 mRNA and 
protein expression and leucine uptake. Spontaneous differentiation in primary 
trophoblasts and forskolin-mediated differentiation in BeWo cells provoked expressional 
changes of LAT1, LAT2 and 4F2hc on mRNA and protein level (Figure 20 on p.80). Our 
results demonstrated that the syncytialization process induced changes in the LAT1:LAT2 
ratio as well as in 4F2hc expression in both trophoblast models (Figure 20 on p.80) and 
resulted in an increased leucine uptake under Na+-free conditions (Figure 21 on p.82). 
These findings imply that differentiation induces a specialization process both in primary 
trophoblasts and BeWo cells, which results in an increased uptake, transport or transfer 
capacity as previously shown for the alanine-serine-cysteine-transporters and for alpha-
aminoisobutyric acid transport (Furesz, Smith, and Moe 1993; P. I. Karl, Alpy, and Fisher 
1992). This concept is in line with recent findings that differentiation processes such as 
syncytium formation resulted in an upregulation of MVM associated membrane proteins 
(Ohgaki et al. 2017). 
Based on the validation of expression in the two trophoblast cell models (Figure 20 on 
p.80) and comparable uptake behavior (Figure 21 on p.82), the BeWo cell line was chosen 
to test the effect of different SLC7-specific inhibitors. 
4.1.3 Specific inhibition of SLC7 transporters reveal the relevance of single solute carriers 
in placental nutrient acquisition 
The response to LAT1- and System L-specific inhibition reveals the relevance of single 
transporter in transplacental leucine uptake and transfer 
The low molecular weight inhibitors JPH203, JG336, JX009 and JX020 were assessed for 
their capacity to reduce leucine uptake into trophoblasts (Figure 22 on p.85) and leucine 
transfer across the placental barrier (Figure 24 on p.88). Due to the varying SLC7-
specificity, different inhibition patterns were expected. JPH203 was previously reported 
as potent, LAT1-specific inhibitor (Oda et al. 2010; Enomoto et al. 2019; Cormerais et al. 
2019; Muto et al. 2019; Häfliger et al. 2018; Yothaisong et al. 2017). JX009 has been 
described in the patent literature (Endo et al. 2008) to inhibit LAT1-mediated transport 
with similar efficacy as JPH203, albeit with significantly lower specificity, i.e. it is also a 
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potent LAT2 inhibitor. Beside the meta-tyrosine JX009 with a bulky side chain at the 
hydroxy group of the phenol, we additionally tested JX020 representing a bicyclic 
constrained meta-tyrosine (chemical structure is shown in Figure 22 on p.85). Within the 
NCCR TransCure network in collaboration with the group of Prof. Karl-Heinz Altmann, we 
found phenyl or benzyl side chains on the tyrosine or meta-tyrosine as the minimum to 
generate an inhibitor that cannot be transported by LAT1. Due to the bicyclic structure of 
JX020, the flexibility is limited and the conformation is predetermined. Therefore, JX020 
was more efficient inhibitor than JX009. Of note, similar bicyclic nitrogen mustards have 
already been described as system L inhibitors (Vistica 1983; Haines et al. 1987). As no 
other LAT2 inhibitors have been described in the literature, JX009 was considered the best 
available tool for the assessment of LAT2-related transport of leucine. JG336 was 
prepared based on a limited structure/activity relationship (SAR) study on JPH203 that 
investigated the effects of electron-donating (such as the methoxy group in JG336, see 
dashed red box in Figure 22B on p.85), electron-withdrawing and bulky substituents on 
the phenyl moiety at the 2-position of the benzoxazole ring on transport inhibition. The 
additional methoxy group in JG336 resulted in 3.8-times lower EC50 values in BeWo-CTB 
(Figure 22B on p.85) indicating that the inhibition efficiency of JPH203 was indeed 
increased by this modification.  
Leucine uptake 
Our results demonstrated that all four compounds are highly efficient LAT1 inhibitors, but 
JX009 and JX020 conveyed additionally LAT2 inhibition. Based on the complete leucine 
uptake inhibition of BeWo cells at the CTB stage, leucine uptake in undifferentiated 
trophoblasts seems to be completely dependent of LAT1 activity (Figure 22 on p.85). Since 
the LAT1:LAT2 ratio in BeWo-CTB compared to BeWo-STB is lower as shown in the 
expression studies (Figure 20 on p.80), JPH203 reduced leucine uptake in BeWo-STB by 
only 60%. This partial inhibition by JPH203 indicates that in BeWo-STB leucine uptake is 
mediated by alternative Na+-independent leucine transporters such as LAT2, LAT3 or 
LAT4. JX009 and JX020 reduced leucine uptake near 100% regardless of the trophoblast 
differentiation stage with a low EC50 in the range of JPH203, suggesting that both JX009 
and JX020 blocked most (if not all) Na+-independent leucine uptake transporters. Thus, 
JX009 and JX020 are the first characterized System L-specific leucine uptake inhibitors in 
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the low µM-range (EC50<4 µM; Figure 22 on p.85) for use in placental cell models. To date, 
the most widely used SLC7-specific inhibitor is the non-metabolizable leucine analog BCH 
which has been also tested in this study (Figure 23 on p.87) and other investigations 
(Otsuki et al. 2017; Kaji et al. 2010). In comparison to JX009 and JX020 this inhibitor is 
>100-times less effective and blocks System L-dependent amino acid transport with 
709 µM in BeWo-CTB and 442 µM in BeWo-STB in the high µM-range (Figure 23 on p.87). 
Nevertheless, further investigations of these small molecule compounds are needed to 
study viability, effects on amino acid metabolism and potential interactions with other 
transmembrane proteins such as System A-transporters.  
Leucine transfer 
To assess the functional importance of SLC7-transporters in leucine transfer across the 
placental barrier, the effect of the LAT1-specific inhibitors JPH203 and JG336 as well as 
the System L-inhibitor JX009 and JX020 were tested in the Transwell® system with 
polarized BeWo cells grown in a tight monolayer (Figure 24 on p.88). Treatment with 
JPH203 during 6 h reduced leucine transfer across the placental barrier by 58%. Assuming 
100% LAT1 inhibition after treatment with 10 µM JPH203 (approximately 5-times the EC50 
of JPH203), these results suggest that more than half of the leucine transfer across the 
differentiated trophoblast monolayer was LAT1-dependent. The 3.8-times more efficient 
inhibitor JG336 (60% reduction), and the less specific System L-inhibitor JX009 (55% 
reduction) and JX020 (48% reduction) showed similar inhibition capacities as JPH203. 
These results demonstrate a predominantly LAT1-dependent leucine transfer across the 
polarized trophoblast layer which mimicks the physiological materno-fetal barrier (Xiao 
Huang et al. 2016). In these transfer studies we also measured the intracellular leucine 
content at the end of the experiment. In this context, the intracellular accumulation of 
leucine suggests that the efflux activity at the BM, i.e. the transport towards the fetus, 
represents the rate limiting process in materno-fetal transfer. In contrast, a reduced 
intracellular leucine content predicts leucine transport across the MVM into the 
trophoblast monolayer as the rate-limiting step (J. K. Cleal et al. 2011). In our experiments 
only the two LAT1-specific inhibitors JPH203 and JG336 caused a reduction of the 
intracellular leucine content (Figure 24C on p.88), indicating that LAT1-mediated leucine 
transfer occurs at the apical MVM. In contrast, the unchanged intracellular leucine 
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content after JX009 treatment suggests System L-transporter dependent leucine efflux 
across the BM. This is in agreement with the hypothesis that LAT1 is the major leucine 
transporter at the MVM, while other placental Na+-independent System L-transporters 
such as LAT2, LAT3 or LAT4 mediate leucine efflux across the BM (see in introduction 
Figure 5 on p.18 ) as has been previously proposed (J. K. Cleal et al. 2011; Thomas Jansson 
2001; Kudo and Boyd 1990; Bodoy et al. 2005). Since the three tested inhibitors were 
applied at the maternal compartment, there is a certain membrane and cell layer 
permeability required to allow interactions with the transporters located at the BM. 
Permeability across the trophoblast barrier has not been investigated, but has been 
shown in Caco-2 cells for JPH203 (Wempe et al. 2012). Recently Lewis et al. demonstrated 
in a mathematical modelling approach of placental amino acid efflux based on placental 
perfusion data, that LAT2 allows the transport of a substrate across the BM without 
transport of another molecule in the other direction as normally expected from a classical 
exchanger (Rohan M Lewis, Cleal, and Sengers 2020). 
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Figure 47: Schematic representation of leucine transport across the placental barrier induced 
through a counter-directed gradient and maintained by asymmetric LAT1/LAT2 expression. A, 
The placental barrier formed mainly by syncytiotrophoblast (STB) and located at the fetal border 
in direct contact with the maternal circulation. Since the fetal leucine (Leu) concentration is higher 
than in the maternal blood, the placenta needs to overcome a counter-directed Leu gradient by 
energy demanding active transport mechanism (panel A right). B, The comparison of Na+-
independent Leu transfer across the placental barrier in vitro using the Transwell® technique 
demonstrated for the first time an increased materno-fetal Leu transfer when a counter-directed 
Leu gradient is applied. C, The Na+-independent uptake of the essential amino acid Leu from the 
maternal circulation (orange) across the microvillous membrane (MVM) into the STB (blue) 
represents the active step of placental Leu transport and is mediated by previously established 
intracellular co-substrate (e.g. glutamine, Gln) in the interplay with the amino acid exchangers 
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(LAT1/SLC7A5 in red, LAT2/SLC7A8 in yellow). LAT1 and LAT2, both expressed at the MVM, 
exchange one branched-chain amino acid amino acid (BCAA, like Leu) for another (in this case 
Gln), resulting in altered amino acid composition without changing the total intra-extracellular 
concentration. As indicated by the number of transporters (2 LAT1 versus 1 LAT2) LAT1 has been 
shown to be the major Leu uptake transporter at the maternal facing MVM. Under Na+-free 
conditions there is no possibility for the STB to build up a Na+-gradient driving System A amino 
acid uptake, hence only Na+-independent System L transport is active. Furthermore, Leu is 
transferred across the BM by facilitators like LAT3-, LAT4-mediated diffusion driven by the 
extracellularly directed concentration gradient on the fetal side. The relevance of LAT1 compared 
to the other System L transporter was revealed by SLC7-specific inhibition studies (JPH203 and 
JG336 as LAT1-, and JX009 and JX020 as System L-specific small molecule inhibitors). This study 
demonstrated that the temporal application of transporter-specific inhibitors allows studying 
transporter interrelations in trophoblast models by avoiding an impact on cell fusion. The font size 
of the amino acid in the 3-letter code represent an estimation of their relative concentration in 
the fetal (left in pink and red), intracellular (middle in blue) and maternal (right in orange) 
compartment. Intracellular amino acid concentrations were taken from (Philipps et al. 1978). 
4.2 Iron transport 
In the second part of this PhD project, we compared two clinically well-characterized 
cohorts with balanced distribution of maternal and gestational age at partum. As 
expected, the GDM-specific clinical parameters showed not only increased 
periconceptional BMI, but also the clear LGA symptomatology of the GDM newborns 
(Table 10 on p.90) verifying the suitability of our GDM cohort. Interestingly, also elevated 
maternal serum hemoglobin concentrations were detected which previously have been 
associated with increased risk for GDM (Afkhami-Ardekani and Rashidi 2009). However, 
the involved pathways linking iron homeostasis during pregnancy to disturbances in 
glucose handling and metabolism, as well as the role of the placenta in regulating 
materno-fetal iron transfer are largely unknown. To shed light on the involved pathways, 
we investigated the effects of hyperglycemic and hyperlipidemic conditions at distinct 
pathways controlling placental iron homeostasis in vitro using the BeWo cell model: at the 
level of uptake, transport, sensing and regulation of iron.  
To investigate the relation between gestational hyperglycemia like in GDM and altered 
placental iron homeostasis, we successively discuss the five postulated specific aims (B1-
5 on p.30). To challenge the hypothesis that the expression of placental iron-transporters 
and iron-regulatory proteins is altered in GDM, we characterized expressional changes of 
iron homeostasis genes in GDM-affected placental tissues (B1) and established and 
characterized trophoblast models mimicking human GDM conditions and investigated the 
effect of hyperglycemic and hyperlipidemic conditions on transplacental iron transfer 
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(B2). Furthermore, we used these hyperglycemic and hyperlipidemic models to identify 
cellular stress pathways responsible for altered placental iron homeostasis under 
hyperglycemic and hyperlipidemic conditions (B3) and to test whether increasing 
antioxidative potential rescues the hyperglycemic effect on placental iron homeostasis 
(B4). Finally, we discuss the suitability of an obesogenic mouse model developing GDM-
like symptoms based on the altered expression of placental iron homeostasis genes (B5). 
These five main sections of the iron transport project are separately discussed below 
(4.2.1-4.2.5). 
4.2.1 Gestational diabetes alters placental iron homeostasis gene expression 
To investigate if there is a functional relationship between GDM and disturbances in 
materno-fetal iron transport or placental iron homeostasis, we studied the expression of 
24 genes, known to be involved in iron homeostasis, in control and GDM placentae. These 
included beside iron transporters and oxidoreductases also iron regulators and sensors. 
As no pathway for fetal iron excretion has been identified (Sangkhae and Nemeth 2018), 
nonheme iron transport across the placenta to the fetus was defined to be unidirectional. 
Consequently, fetal iron homeostasis depends exclusively on placental iron absorption 
and transport. Contrary to its vital importance in fetal development, the mechanism of 
materno-fetal iron transport is only incompletely understood (C. Cao and Fleming 2016).  
In addition to DMT1, GDM placentae showed decreased mRNA levels of FPN1, and 
decreased protein levels for ZIP8 and TfR1. Despite downregulation of all these iron 
transport genes including FPN1, the only known transporter regulating iron export to the 
fetus, the total iron contents in GDM placental tissues were not increased in our cohort 
(Figure 30 on p.98). In contrast to our study, recently published Fe concentrations in a 
bigger cohort of GDM and control pregnancies (n=38 each) showed reduced iron levels in 
GDM placental tissue (11%) and umbilical cord blood (12%), but not in maternal whole 
blood (Roverso et al. 2019). These findings suggest that reduced iron concentrations in 
the placenta and fetal serum could result from downregulated placental iron uptake 
under hyperglycemia. Therefore, a reduction of placental iron uptake could be a 
physiological mechanism to protect the placenta and the fetus from excessive, harmful 
iron concentrations. In this context also the observed upregulation of the ferroxidases 
HEPH and Zp in GDM placentae could play an important role as protective mechanism of 
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the placenta. Beside facilitating the export of ferric iron by FPN1, they oxidize the 
potential toxic ferrous iron and thereby reduce the oxidative levels at the placental 
barrier. In addition, these ferroxidases have a crucial role in oxidizing exported ferrous 
iron to ferric iron to enable loading onto fetal Tf, although some redundancy seems to 
exist (Fuqua et al. 2018).   
Placental iron homeostasis depends on regulatory processes originating both from the 
mother, the fetus together with the placenta. Maternal, placental and fetal HEPC 
determine the rate of placental iron release to the fetal circulation through binding and 
degradation of placental FPN1 (Koenig et al. 2014). While HEPC is downregulated during 
normal pregnancy to ensure sufficient iron availability, we found increased placental HEPC 
levels in GDM. This indicates a placental mechanism to reduce systemic iron levels in the 
fetus by decreasing iron release towards the fetal circulation at the basolateral side of the 
STB by FPN1 degradation (Figure 48A). HEPC production is predominantly regulated at the 
transcriptional level, HEPC mRNA and protein levels show high correlation (Koenig et al. 
2014). Therefore, the increased placental mRNA levels of HEPC found in GDM are in line 
with the concomitant downregulation of FPN1.  
Beside the iron availability regulated by HEPC, the transfer of iron across the placental 
barrier depends mainly on the iron acquisition by activity of TfR1- and endosomal iron 
transport proteins like DMT1. Both, TfR1 and DMT1 are post-transcriptionally regulated 
by the iron-regulatory proteins IRP1 and IRP2. The IRPs bind at the stabilizing 3’-UTRs of 
TfR1 and DMT1 mRNA to the iron-responsive element (IRE) and further induce their 
translation (Wilkinson and Pantopoulos 2014). Thus, downregulation of IRP1 could be 
responsible for the decreased TfR1 protein levels detected in GDM as compared to 
healthy controls, despite similar mRNA levels. Hence TfR1, DMT1, ZIP8 and FPN1 were 
significantly downregulated in GDM placentae though mRNA and protein expression did 
not always correlate. For example, DMT1 was downregulated on transcriptional but not 
on protein level (Figure 28 on p.95). However, we observed a change in the intracellular 
localization of DMT1. This could be caused by altered subcellular trafficking, depending 
on the expression ratio between the two major splicing variants of DMT1 (+/-IRE) in 
trophoblasts (Lam-Yuk-Tseung and Gros 2006; Chong et al. 2005), or altered 
ubiquitination (Foot et al. 2016). These cellular processes can result in reduced DMT1 
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transport activity without affecting the protein level. In brief, subcellular trafficking in 
trophoblasts may depend on the expression ratio between the two major isoforms DMT1-
IRE and DMT1+IRE. DMT1-IRE undergoes clathrin-mediated endocytosis and is sorted to 
recycling endosomes, which allows Tf to release the two ferric iron molecules through 
acidification and creates the proton gradient required for DMT1-mediated iron transport 
(Lam-Yuk-Tseung and Gros 2006). As alternative to isoform-dependent trafficking, Foot et 
al. demonstrated a regulative interaction of NEDD4 family-interacting proteins (Ndfips) 
with both isoforms of DMT1 by acting as adaptors to recruit the ubiquitin ligase WWP2. 
Hence, ubiquitination of DMT1 and subsequent trafficking to the lysosome for 
degradation reduce the amount of DMT1 protein available to be transported to the cell 
membrane, reducing DMT1 activity and iron uptake (Foot et al. 2016).  
As schematically summarized in Figure 48A (in yellow) GDM alters iron homeostasis in 
placental tissue through specific regulation of iron homeostasis genes involved in uptake 
(TfR1), transport (DMT1, ZIP8, FPN1), oxidation (zyklopen, Zp) and regulation (IRP1; HEPC) 
on mRNA and/or protein level. The major changes on expressional level comprise reduced 
DMT1, FPN1, ZIP8, and TfR1 abundance, and alterations in DMT1 localization. In analogy, 
trophoblasts under hyperglycemic conditions decrease iron acquisition by reducing TfR1 
expression at the MVM, decrease transfer from the endosome into the cytoplasm through 
reduced expression of ZIP8 and mis-localization of DMT1 and diminish secretion of iron 
towards the fetal side through downregulation of FPN1.  
4.2.2 The hyperglycemic and hyperlipidemic BeWo models allow to study functional 
effects by mimicking GDM-like expression patterns 
To investigate the GDM-mediated effect on placental iron uptake on a functional level and 
to identify the underlying cellular mechanisms, we generated BeWo cell-derived 
hyperglycemic cell models. The BeWo cell line was chosen as primary trophoblasts freshly 
isolated from donated placentae do not proliferate and loose viability after a few days in 
culture (Xiao Huang et al. 2016). By examining BeWo cells cultured under N 
(normoglycemic), H (hyperglycemic) and HL (hyperglycemic and hyperlipidemic) 
conditions for 30 days, we were able to monitor and characterize the iron homeostasis-
related expressional and functional adaptions occurring in trophoblasts over time. 
Hyperlipidemia was achieved by adding palmitic acid to the cell culture medium as free 
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palmitic acid has been associated with induced insulin resistance in different cell models 
(Sinha et al. 2004) and in GDM patients (Stirm et al. 2018). During the adaption process to 
hyperglycemic/hyperlipidemic culture conditions, the BeWo cells changed their 
morphology, due to increased energy availability, and showed extensive lipids storage as 
indicated by Oil red O staining. Interestingly, the hyperglycemic stimulation in BeWo cells 
resulted in very similar changes in the expression pattern of placental iron homeostasis 
genes as found before in GDM placentae. This strongly underlined that the established 
BeWo models are suitable for the identification of cellular pathways underlying the effect 
of hyperglycemia on placental iron homeostasis. Furthermore, we found that these 
trophoblasts cultured under H and HL reduced their Tf-mediated iron uptake already after 
5 days of stimulation by more than 40% relative to N. The observed dramatic reduction of 
placental iron-uptake explains the inconspicuous iron-stores in placental tissue in 
combination with increased maternal hemoglobin levels. This is a clear indication for 
placental protection of fetal tissues from excessive iron-storage. Concomitantly, the 
observed alterations in placental iron-handling could promote increased iron-
concentrations found in maternal serum (Roverso et al. 2019). 
4.2.3 Autophagy and oxidative stress induce ferroptosis under hyperglycemic conditions 
and represent a potential target for treatment of altered iron homeostasis in GDM 
To identify the cellular pathways mainly mediating the effects of GDM on placental iron 
homeostasis we focused on mechanisms that have been implicated in both GDM and 
cellular iron imbalance: ER-stress (Yung et al. 2016; Vecchi et al. 2009), autophagy 
(Avagliano et al. 2017; Dixon et al. 2012) and oxidative stress (Peuchant et al. 2004). 
Despite reports of increased ER-stress in GDM patients, we did not find marked changes 
in placental BiP-expression by immunoblotting. However, we detected reduced p62 
protein and decreased LC3-II protein in H and HL compared to N. LC3-II is the lipidated, 
membrane-bound form of the widely used autophagic marker LC3 (Kabeya et al. 2000). 
Likewise, the downregulation of the p62 protein, also known as sequestosome or 
SQSTM1, indicates reduced autophagy, indicates reduced autophagy (Øvervatn et al. 
2010). Further extensive analyses revealed increased oxidative damage and reduced 
antioxidative capacity in both hyperglycemic cell models. Both GSH depletion and 
accumulation of oxygen activated lipids as shown in Figure 35A/C on p.105 are two of the 
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main characteristics of the distinct regulated cell death process called ferroptosis. The 
non-apoptotic cell death pathway ferroptosis is induced by disruption of GSH synthesis, 
depends on high intracellular iron levels and accumulation of lipid peroxides (J. Y. Cao and 
Dixon 2016). Although our results have limited depths in the analysis of the cellular 
pathways like ER-stress and autophagy, they strongly suggest oxidative stress-mediated 
ferroptosis as a hallmark of the disturbed placental iron homeostasis which should be 
further investigated. So far hyperglycemia is not characterized as known promotor of 
ferroptosis, however our results including reduced GSH levels, disturbed transcellular iron 
transport and increased lipid peroxidation indicate ferroptosis as mediator between 
hyperglycemia and altered placental iron homeostasis.  
To further confirm the concept that oxidative stress is a key pathway stimulated by 
hyperglycemia and a trigger for the placental regulation of iron-homeostasis, we 
performed rescue experiments by treating the cells with the antioxidant NaSe. Se-
supplementation has been shown to protect trophoblasts from both endogenously and 
exogenously applied oxidative stress (A. Khera, Vanderlelie, and Perkins 2013; Alisha 
Khera et al. 2017). Reduced selenoenzyme activity during pregnancy results in oxidative 
stress within tissues was associated with premature birth, miscarriage, preeclampsia, and 
intrauterine growth retardation (Zachara 2018). NaSe supplementation has been shown 
to protect trophoblast cells from both endogenously and exogenously applied oxidative 
stress (A. Khera, Vanderlelie, and Perkins 2013) as selenium is essential for the expression 
and activity of the endogenous antioxidant systems dependent on the selenoenzymes 
glutathione peroxidases (GSH-Pxs), thioredoxin reductases (TrxRs), and selenoprotein P 
(SePP) (Alisha Khera et al. 2017; Zachara 2018). There are 3 different Se-dependent 
glutathione peroxidases present in humans, and these are known to add two electrons to 
reduce peroxides by forming selenole (Se-OH) and the antioxidant properties of these 
selenoenzymes allow them to eliminate peroxides as potential substrates for the Fenton 
reaction. Selenium-dependent glutathione peroxidase acts in association with GSH, which 
exists in high concentrations in cells and catalyzes the conversion of hydrogen peroxide 
or organic peroxide to water or alcohol while simultaneously oxidizing GSH (Kurutas 
2016). Selenium supplementation strengthens the endogenous antioxidant potential of 
trophoblasts without disturbing the essential balance between oxidants and antioxidants 
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in living cells. Indeed, increasing the antioxidant potential in our experiments almost 
completely reverted the hyperglycemic effect on iron homeostasis genes. Additionally, Se 
supplementation protected BeWo cells under H and HL by reducing lipid peroxidation and 
eliminating protein carbonylation.  
These results suggest that antioxidant supplementation is beneficial for pregnant women 
with increased risk of GDM, e.g. due to obesity, high fat diet, or excessive weight gain in 
pregnancy by protecting the placenta and the fetus against oxidative stress caused by 
hyperglycemia, high iron status or both. Furthermore, these findings support potential 
concerns regarding the recommendation of routine iron supplementation among iron-
replete pregnant women (Rawal et al. 2017). 
Figure 48B summarizes the findings associating GDM with altered placental iron 
homeostasis. 
4.2.4 Iron deprivation affects glucose homeostasis in trophoblasts 
José Manuel Fernandez-Real and colleges suggested a bidirectional relationship between 
iron metabolism and type 2 diabetes, i.e. iron affects glucose metabolism and glucose 
metabolism affects iron metabolic pathways (Fernández-Real, López-Bermejo, and Ricart 
2002). As described before, oxidative stress seems to be a key factor in the effect of 
hyperglycemia and hyperlipidemia on placental iron homeostasis. However, there are 
contradictory publications about the relation between iron supplementation or maternal 
iron status and the increased the risk to develop GDM. While Afkhami-Ardekani et al. 
demonstrated in 34 women with diagnosed GDM and 34 non-GDM women an association 
between increased maternal iron status and GDM (Afkhami-Ardekani and Rashidi 2009), 
Chan et al. compared 565 women receiving 60 mg iron supplementation and 599 placebo 
controls and found that iron supplementation from early pregnancy onwards does not 
increase the risk of GDM (Chan et al. 2009). To our knowledge, there is no literature 
investigating whether different iron levels could have a direct effect on placental glucose 
uptake capability. Therefore, we challenged normoglycemic BeWo cells by inducing iron 
deficiency and iron overload and analyzed GLUT1 expression over time. GLUT1 expression 
and activity at the placental barrier and glucose concentration in the maternal blood are 
mainly responsible for the glucose transport during pregnancy (Baumann, Deborde, and 
Illsley 2002). Against our expectations iron deficiency, but not iron overload induced 
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GLUT1 expression and glucose uptake (Figure 37 on p.110). Interestingly, in this 
experiment GLUT1 upregulation and stimulation of glucose uptake was pronounced 
especially after 15 µM DFO treatment. However, it is difficult to explain this phenomenon. 
Estimating an iron concentration in the iron deprivation experiment of approx. 3.3 µM 
(0.3 µM Ferric Nitrate Fe(NO3)3 + 3.0 µM Fe3+ from 10% FBS à 30 µM Fe3+ = 3.3 µM Fe3+ in 
DMEM-lowG + 10% FBS) a DFO concentration of 15 µM is supposed to chelate 5-times 
more iron than theoretically available. Previously, GLUT1 expression at the BM has been 
shown to be rate-limiting in the materno-fetal transfer of glucose (Vardhana and Illsley 
2002), hence alterations in GLUT1 expression at the BM would have significant 
consequences for fetal glucose supply. Whether the DFO-mediated increase in GLUT1 
protein levels was affecting GLUT1 expression on BM or rather on MVM has not been 
investigated yet. Although GLUT1 expression at the BM was found elevated in GDM 
before, corresponding with a functional increase in glucose transfer (Gaither, Quraishi, 
and Illsley 1999), a better understanding and more experimental evidences are needed to 
estimate the presence and magnitude of a relationship between increased GLUT1 
expression under iron deprivation and GDM. Of note, whether oxidative stress or other 
ferroptosis-related mechanisms are sufficient to affect placental glucose homeostasis via 
GLUT1 expression need further experimental approaches (as indicated in Figure 48B on 
p.154). However, at the present stage we were able to demonstrate that DFO-mediated 
iron deprivation does not only result in increased GLUT1 expression on mRNA and protein 
level, but also in enhanced glucose uptake into BeWo trophoblasts. These findings confirm 
a bidirectional relationship between iron levels and placental glucose homeostasis via 
oxidative stress as previously suggested (Fernández-Real, López-Bermejo, and Ricart 
2002). 
The schematic model in Figure 48B summarizes the effects of GDM and hyperglycemic 
conditions on placental iron homeostasis and materno-fetal iron transfer. Our data 
indicate that impaired autophagy and increased oxidative stress under hyperglycemic and 
hyperglycemic combined with hyperlipidemic conditions alter the expression and partly 
also the localization of transporters and thereby affect placental iron transfer. The 
observed adaptations could be part of a protective mechanism preventing oxidative 
damage for both the fetus and the placenta caused by hyperglycemia, highly oxidative 
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iron and excessive iron levels. Treatment with antioxidants such as selenium helps to 
balance placental oxidative stress levels by increasing GSH levels or DFO to reduce 
putative harmful iron levels and could thereby counteract impaired iron homeostasis 
found in GDM patients. These results indicate fundamental changes in the organization of 
transplacental iron transport under hyperglycemic conditions. 
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Figure 48: Schematic representation of the mechanisms and regulation of materno-fetal iron 
transfer across the placenta and dysregulation under hyperglycemic conditions. A, Iron (Fe) is 
transferred from the mother to the fetus across the blood-placenta barrier (right to left). The 
placenta is in direct contact with the maternal blood circulation via a monolayer of syncytialized 
trophoblast cells (blue). After transferrin receptor (TfR1)-mediated iron uptake by clathrin-
dependent endocytosis at the maternal side of the syncytiotrophoblasts (villous membrane on the 
right side) into endosomes, divalent metal transporter 1 (DMT1) is supposed to release iron from 
endosomes into the cytosol. Cytosolic iron is transferred to the fetal circulation through the iron 
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exporter ferroportin (FPN1). The exact mechanisms as well as the role of other transporters such 
as the Zrt- and Irt-like proteins (ZIP) ZIP8 or ZIP14 in transplacental iron transfer are currently still 
unclear. (A, yellow) Gestational diabetes mellitus (GDM) alters iron homeostasis in placental tissue 
through specific regulation of iron homeostasis genes involved in uptake (TfR1), transport (DMT1, 
ZIP8, FPN1), oxidation (zyklopen, Zp) and regulation (iron regulatory protein 1, IRP1; Hepcidin, 
HEPC) on mRNA (highlighted dark red arrows) and/or protein level (highlighted blue arrows). The 
major changes on expressional level comprise reduced DMT1, FPN1, ZIP8, and TfR1 abundance, 
and alterations in DMT1 localization. The current study identified increased reactive oxygen 
species (ROS) and reduced autophagy as factors involved in altering iron homeostasis under 
hyperglycemic conditions. B, Schematic model summarizing the effects of GDM and 
hyperglycemic conditions on placental iron homeostasis and materno-fetal iron transfer. Our data 
indicate that impaired autophagy and increased oxidative stress under hyperglycemic and 
hyperglycemic combined with hyperlipidemic conditions alter the expression and partly also the 
localization of transporters and thereby affect placental iron transfer. Treatment with antioxidants 
such as selenium increasing glutathione levels or deferoxamine (DFO) reducing putative harmful 
iron levels could thereby counteract impaired iron homeostasis found in GDM patients.  
 
4.2.5 Mice under HFHS diet represent a suitable GDM model to study iron homeostasis 
Although the clinical parameters of our GDM cohort showed most of the typical 
characteristics described in literature (Rawal et al. 2017; Stirm et al. 2018), there are 
marked differences and variations concerning the time of diagnosis, optimal treatment 
and care during pregnancy and postpartum, making human GDM cohorts from clinical 
screenings highly heterogeneous (Nielsen et al. 2014). This was also found in our GDM 
cohort (Table 10 on p.90). For example, we included in our the GDM group patients who 
were either treated with insulin (n=8) or received recommendations for a diabetes diet 
(n=3). Under these circumstances it is difficult to define the grade of placental exposure 
to hyperglycemia (Nielsen et al. 2014). Therefore, we aimed to find a suitable mouse 
model in which we could further explore the association between GDM and altered 
placental iron homeostasis. Indeed, it was reported in literature that wildtype mice 
receiving a western diet or HFHS diet from the first day in pregnancy onwards showed 
compromised maternal glucose tolerance and insulin sensitivity in association with 
dysregulated lipid metabolism, thereby mimicking typical GDM symptoms (Sferruzzi-Perri 
et al. 2013; Musial et al. 2017). 
In collaboration with the University of Cambridge we made first steps in investigating this 
mouse model for the expression of iron related genes. Interestingly, analogous to human 
GDM, placentae from HFHS fed mice showed highly comparable expression patterns of 
iron homeostasis genes (Figure 38 on p.112). Similar to human GDM, the placentae from 
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HFHS mice also seem to protect the fetus and themselves from excessive oxidative iron 
levels. Therefore, mice under HFHS diet could serve as suitable model to further 
investigate the molecular and physiological relationships between GDM and altered 
placental iron homeostasis and to study the therapeutic effects of antioxidants. The 
access to a mouse model mimicking human GDM would further allow to assess the impact 
of disturbed iron and glucose homeostasis on embryonic development. Furthermore, the 
high similarity between the expression pattern of iron homeostasis genes in human GDM 
and HFHS mice confirm and strengthen the observations discussed and characterized 
before, despite of the prevalent heterogeneity in the human GDM cohort. 
4.3 Strategy for generation of SLC knockout trophoblast cell lines 
Similar to other sequence specific genome editing tools such as TALENs (transcription 
activator-like effector nucleases) or ZFNs (Zinc-finger nucleases), CRISPR/Cas9 is also able 
to produce double strand breaks on a specific locus, but it has higher mutation 
efficiencies, is rather easy to use and can be used for multiplex genome editing (Ran et al. 
2013). For example, it takes 3-4 days from the idea to target a certain gene until having 
the target site-specific sgRNA in hand (Bassett et al. 2013). This contrasts with the much 
more laborious re-engineering or selection of meganuclease, Zinc finger nuclease (ZFN) or 
Transcription activator-like effector nucleases (TALEN) proteins for each new genome 
target, which requires weeks or up to months (Robb 2019). This makes CRISPR/Cas9 
mutagenesis a powerful tool for all kind of applications based on gene sequence 
manipulation including multiplex targeting and knock-in genome editing. CRISPR/Cas9 has 
been shown to be an efficient tool in genome engineering of primary cells, using 
adenoviral CRISPR/Cas9 vector human lung fibroblasts and human bronchial epithelial 
cells (Voets et al. 2017). Furthermore, human T-cells were efficiently targeted by 
electroporation-mediated transfection of RNP (Schumann et al. 2015). Recently, the 
progress for targeted gene therapy was published to engineer patient derived induced 
pluripotent stem cells with CRISPR/Cas9 (Dannenmann et al. 2020). However, 
CRISPR/Cas9 mutagenesis as technical tool has been rarely used in the field of placental 
nutrient transport research. It was reported that it is feasible to generate knockout BeWo 
cell lines using the CRISPR/Cas9 technology (Msheik et al. 2019; Kovács et al. 2019). Kovács 
et al. were able to knock out the gene of interest by electroporation of RNP complexes 
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into BeWo cells. Also embryonic stem cells were successfully knocked out for the ETS 
domain-containing transcription factor (ERF) gene, coding for a transcription factor 
involved in the differentiation of trophoblasts (Si et al. 2019). Forbes et al. compared the 
transfection efficiency of BeWo to primary trophoblasts transfected with different 
cationic lipid-based reagents and electroporation method (Forbes et al. 2009). They found 
that transfection efficiency in BeWo cells (40-70 %) is generally lower or similar to those 
of primary cells (40-95%).  
Within this study, we aimed to generate stable knockout BeWo cell lines to study the 
relevance of single nutrient transporters in the complex placental amino acid and iron 
transfer across the human placenta. 
Targeting single gene sequence by CRISPR/Cas9-mutagenesis allows the assessment of 
the role of a specific transporter in complex nutrient transport pathways such as materno-
fetal amino acid or iron transport. Trophoblast cells lacking the function of single nutrient 
transporter by CRISPR/Cas9-mediated knockout, could help to reveal their role at the 
materno-fetal barrier in the human placenta. Novel findings in this context are important 
to unravel the causes and consequences associated with impaired transfer of nutrients in 
specific pregnancy diseases.  
There are only few published articles about CRISPR/Cas9-mutagenesis in placental 
research. Recently, knockout BeWo cell lines were generated using the CRISPR/Cas9 
technology for transcriptomic profiling to identify new target genes relevant for 
trophoblast fusion using BeWo and JEG-3 cells (Msheik et al. 2020). There were two major 
strategies to introduce sgRNA and functional Cas9 for mutagenesis via double-strand-
break by non-homologous end joining (NHEJ). We tested the transfection of Cas9-plasmid 
and sgRNA (target-specific ribonucleic acid generated by IVT or transfection of 
preassembled complexes of sgRNA and Cas9, also called RNP. As mentioned above, 
Kovács and colleges were able to knock out the gene of interest by electroporation of the 
RNP complex into the cells (Kovács et al. 2019).  
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4.3.1 Design of potential CRISPR/Cas9 target sites, sgRNA synthesis and optimization of 
BeWo transfection 
The design of the CRISPR/Cas9 target sites and corresponding primer pair for target site 
amplification and sequencing was performed with bioinformatic tools as previously 
described (Bassett et al. 2013; Gagnon et al. 2014; Burger et al. 2016). Target sites at the 
beginning of the gene and at positions essential for transcription are preferred because if 
an indel mutation happens, the frame shift would affect the whole gene and transcription 
would be blocked, respectively. We considered to choose one target site presumably 
inducing destructive effects in all isoforms of all target gene variants. In case of DMT1 
targeting, there are four human isoforms of DMT1 to be considered having all the same 
metal-ion transport efficiencies (Mackenzie et al. 2007). Candidate target sites were 
tested for uniqueness in the online BLAST tool from NCBI to avoid off-target effects. 
Additionally, we sequenced selected target sites of all target genes to make sure that the 
target site has 100% identity with the endogenous gene sequence in the BeWo cell batch 
that we use.  
To generate knockout BeWo cell lines by CRISPR/Cas9 mutagenesis for LAT1, LAT2, DMT1 
and ZIP8, two approaches based on either Cas9 plasmid or Cas9 protein delivery and 2-3 
different transfection reagents per approach were tested. The transfection methods were 
optimized for Cas9 plasmid together with target-specific sgRNA using Xfect transfection 
reagent (TAKARA). For transfection of pre-assembled Cas9 protein sgRNA (RNP) the 
jetCRISPR (Polyplus) reagent reached the highest transfection rate and GFP-signal 
induction in BeWo cells, respectively.  
Finally, the transfection of the Cas9 plasmid by Xfect transfection was optimized up to an 
efficiency of approx. 49% in BeWo cells. This result was almost comparable to the 
efficiency in the easy to transfect cell line HEK-293 with approx. 76% efficiency. The 
plasmid is with the size of 9271 bp quite big and might have a negative impact on the 
transfection efficiency. A comparable efficiency of 50% using Lipofectamin 2000 for siRNA 
transfection in BeWo has been reported (Forbes et al. 2009) and also the non-liposomal 
reagent FuGENE6 led to successful transfection in BeWo (Kudo et al. 2003). Of note, the 
Xfect transfection reagent has been designed to transfect plasmids only. In our approach 
we used it to transfect the plasmid together with the single-stranded sgRNA. There is no 
Discussion - Strategy for generation of SLC knockout trophoblast cell lines 
  159 
protocol for this kind of application and no literature for successful CRISPR/Cas9 
transfection with this reagent. Therefore, it is possible that the sgRNA has not been 
transfected or the 2:1 molar ratio of sgRNA : plasmid as described in other similar 
protocols was not appropriate.  
However, the Cas9-sgRNA RNP approach was promising due to maximal mutagenesis 
efficiency of up to 100% by targeting GFP in ubiquitously GFP expressing zebrafish embryo 
(Burger et al. 2016). Also Kim et al. 2014 and Liang et al. 2015 showed that the delivery of 
RNP complexes have the advantage of fewer off-targets and higher editing rate. The 
transfection protocol using Xfect Protein was not designed for this kind of transfection, 
but it was adapted to the jetCRISPR protocol, which was optimized for RNP transfection. 
After unsuccessful transfection and sorting procedures additional assays with the Xfect 
Protein reagent, were omitted and instead the jetCRISPR reagent was further used for 
knockout generation. The sorting procedure turned out to be difficult because of the weak 
GFP signal after Cas9 protein transfection. It was not clear, if the Cas9-GFP was already 
degraded 48 h post transfection when FACS analyses were performed or whether the GFP 
signal on the Cas9 protein was not strong enough. Another reason for low transfection 
efficiencies could be the labeling of the Cas9 protein with GFP. This increases the cargo 
size of the RNP and therefore affect the delivery efficiency (Schubert et al. 2017). 
Overall, the generation of LAT1, LAT2, DMT1 and ZIP8 transporter knockout in BeWo cell 
lines was despite different approaches not successful as demonstrated by the final target 
site sequencing analysis (see Figure 45 on p.126 and in Figure 46 on p.128). The reason 
for this could not be conclusively clarified. As the design of the target sites was performed 
as previously described in the literature and with the help of widely used online tools, 
sequence errors in the target site can be largely excluded. The chosen transfection 
reagents Xfect and Xfect Protein were originally not designed for combined Cas9 and 
sgRNA applications. Although GFP signal was detected after application of our optimized 
protocols (Figure 41 on p.117), it was not clear whether also the sgRNA as well as the Cas9 
plasmid and the Cas9 protein, respectively, was delivered into the cell. Furthermore, it 
has been demonstrated that CRISPR/Cas9 applications could be blocked for the access of 
repair enzymes by a persistent binding of the Cas9 protein to the DNA at the cutting site, 
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which occurred in 15% of CRISPR/Cas9 transfections before (Clarke et al. 2019). Hence, if 
the double strand break cannot be repaired, no mutations occur. 
The sgRNA was produce by T7-MAXIscript® IVT according to previously optimized and 
published protocol (Burger et al. 2016). The bioanalyzer analysis revealed that there was 
no RNA shedding and further gave an estimation of the RNA concentration. There were 
two bands at 100 and 200 bp detected in the bioanalyzer analysis representing both 
sgRNA. It is a common phenomenon that the T7 polymerase can accept the former 
template and extend this RNA if the 3’end is not folded into a stable secondary structure 
(Triana-Alonso et al. 1995). Since the RNA concentration is calculated subsequentially to 
the bioanalyzer according to 28s/18s ribosomal RNA analysis, which was not present in 
the sgRNA after IVT, these concentration estimations were not reliable. Therefore, 
concentrations determined by Nanodrop were considered for further calculations for 
transfection.  
4.3.2 Characterization of CRISPR/Cas9 mutant cell candidates 
Immunoblotting of the obtained cell lines lysates with antibodies against LAT1, LAT2, ZIP8 
and DMT1 protein after transfection and FACS sorting procedure was successful, but 
revealed, despite of CRISPR/Cas9 targeting, target gene expression. Most of the candidate 
clones generated from the transfection with Xfect plasmid and sgRNA showed even higher 
expression compared to untransfected BeWo cells. The mRNA upregulation of the 
transporter ZIP14 and the slightly increased levels of DMT1 mRNA could be the result of 
compensation, while the overexpression of HEPHL1 could be interpreted as cellular 
protection mechanism against an excess of toxic ferrous iron. Furthermore, the 
downregulation of FPN1 mRNA could be to keep iron levels in the cells by reduction of 
iron export. The down regulation of the iron regulator HEPC would lead increased iron 
acquisition in vivo via increasing FPN1 expression in maternal enterocytes. These 
expressional changes seemed to follow a certain pattern, that could suggest a molecular 
reorganization on transcriptional level to maintain iron homeostasis duet to a putative 
transporter loss. However, there were few clones showing a downregulation on protein 
level of approximately 50% (e.g. LAT2) compared to the no-sgRNA transfected control. 
However, eight out of eleven quantified DMT1 knockout candidates showed increased 
protein levels compared to BeWo control cells as well (see Figure 43 on p.121). ZIP8 
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knockout candidates were more promising in immunoblot analysis because most of them 
showed downregulation. Because 100 or 200 cells were sorted in one well, a knockdown 
phenotype was regarded due as possible. In this case, it is possible that not all alleles of 
every cell were mutated.  
For future investigations, independent whether expressional of functional measurements 
are performed, a specific control undergoing the whole transfection and sorting 
procedure without being transfected with sgRNA should be included in every BeWo cell 
targeting series and in all follow-up analyses. However, we have measured so far only 
untransfected BeWo control cells and not an appropriate no-sgRNA control. The sorting 
procedure to single, 100 or 200 cells/well might be an additional stress factor for the cells 
and may disrupt the gene expression pattern directly after sorting (Richardson, Lannigan, 
and Macara 2015). However, in our experiment the protein lysates were taken several 
weeks after sorting, adaption and sufficient proliferation. Another factor is the 
transfection procedure which apparently resulted in increased protein expression of the 
cells.  
While the functional characterization of CRISPR/Cas9-mediated DMT1, ZIP8 and LAT1 
knockout candidates resulted in an iron and leucine uptake capacity comparable to the 
untransfected control cells, the LAT2 targeted clone B5 showed reduced leucine uptake 
during 8 min (Figure 44 on p.124). Furthermore, the leucine uptake time course of clone 
B5 was reduced independent of JPH203-mediated LAT1 or JX009-mediated System L 
transport inhibition. Such characteristic inhibition patterns would be typical for successful 
LAT1 loss of function mutation, but clone B5 was LAT2-targeted and anyway not mutated 
as demonstrated later by target site sequencing (Figure 45 on p.126). Desforges and 
Westwood showed that upon transfection with lipid-based reagents ligand-independent 
activation of insulin/IGF-1 receptor can be triggered (M Desforges and Westwood 2011). 
This leads to a stimulation of System A and ASC transporters like SNAT1/SLC38A1 or 
ASCT2/SLC1A5. Both transporters are relevant for Na+-dependent glutamine uptake 
enabling glutaminolysis within the cells, which is an important energy source for 
proliferation of cancer cells like BeWo (A. Bröer, Rahimi, and Bröer 2016). This effect could 
additionally influence leucine uptake behavior of targeted cells.  
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Sanger sequencing combined with TIDE analyses finally revealed that no genetic 
modification in the CRISPR/Cas9 targeted cell lines compared to BeWo control cells has 
occurred. Considering this result, we assume that the decreased protein levels detected 
in the immunoblot analyses and the altered leucine and iron uptake of the CRISPR/Cas9 
targeted cells were side effects of the transfection and FACS sorting procedures. For these 
two analyses we have measured so far only untransfected BeWo control cells and not an 
appropriate no-sgRNA control which underwent the entire mutagenesis procedure. 
We finally also considered the possibility, that CRISPR/Cas9-targeting of the nutrient 
transporters LAT1, LAT2, DMT1 and ZIP8 resulted in severe impairments and cellular 
lethality. If this hypothesis would be correct, we might have successfully targeted the 
respective transporters, but the cells died upon knockout. To test these concerns, we 
additionally targeted hCG with the same experimental approach. hCG is exclusively 
expressed by trophoblasts, but not in HEK-293 cells. Thus CRISPR/Cas9 mutagenesis in 
HEK-293 cells are expected to introduce indel mutations without causing a major 
phenotype or being lethal. Furthermore, hCG has already been successfully silenced in 
BeWo cells before and caused a phenotype at the STB-stage during and after 
differentiation (Malhotra, Suman, and Gupta 2015). For further analysis, the Cas9 plasmid 
and Cas9-RNP transfection and sorting procedure was performed according to our 
optimized protocol, followed by target site amplification of targeted and untargeted no-
sgRNA control cells. Finally, the T7 endonuclease I assay demonstrated that also with this 
approach there were no mutations introduced neither with the Cas9 plasmid nor with the 
RNP transfection method. This finding strongly suggests a problem with the sgRNA 
availability in the cell leading to an unsuccessful transduction of CRISPR/Cas9 
mutagenesis.  
In summary, based on our obtained results, further optimization procedures are needed 
for the CRSPR/Cas9 approach. For our future CRISPR/Cas9 experiments with sgRNA we 
will also test specialized commercially available kits for their efficiency in CRSPR/Cas9 
modulated knockout of nutrient transporters.  
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5 Conclusion 
5.1 Amino acid transport 
Accumulative transporters, exchangers and facilitators form complex placental amino acid 
transport systems, which are dependent of intra-extracellular and materno-fetal 
substrate gradients enabling an efficient materno-fetal transfer of essential amino acid 
such as leucine against a counter-directed gradient.  
Based on prospectively analyzed amino acid concentrations in the serum of mothers and 
their newborns, we found associations with clinical and anthropometric values. First, 
there were significant relations between maternal amino acid concentrations of LAT1-
specific substrates and maternal weights both before pregnancy and at term. These 
findings allow conclusions regarding the dependence of the maternal nutritional stage 
and the formation of transplacental gradients throughout gestation. Secondly, we could 
show for the first time that there is a relation between materno-fetal gradients of various 
LAT1 substrates and clinically relevant parameters such as maternal weight, gestational 
weight gain, BMI, blood pressure, but also placental growth. These statistical correlations 
confirm the hypothesis: “Materno-fetal amino acid gradients are crucial for transplacental 
amino acid transport and correlate with selected maternal and fetal parameters.” 
Moreover, these observations suggest that factors such as the maternal nutrition 
influence the formation of materno-fetal amino acid gradients and thereby might have an 
impact on reduced intrauterine growth in hypertensive gestational diseases like 
preeclampsia. 
Beside these observational studies, we could also demonstrate in functional in vitro 
studies that leucine transfer across the materno-fetal barrier is increased against a 
counter-directed gradient. These results confirmed the second hypothesis: “Counter-
directed amino acid gradients in vivo affect leucine uptake into trophoblasts and transfer 
across the placental barrier.” These findings also revealed a so far underestimated 
relevance of transplacental amino acid gradients in human pregnancy which could affect 
pregnancy outcome and may play a role in fetal development. 
In a more cell biology-oriented approach, we confirmed that high and asymmetric 
expression of SLC7-family members makes the placental leucine uptake sensitive to LAT1- 
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and LAT2-inhibition. Based on this, we compared the choriocarcinoma cell line BeWo to 
primary trophoblasts and demonstrated that BeWo could serve as useful model system 
to test putative LAT1 inhibitors and characterize their effects at an active amino acid 
transporting and physiologically relevant cell barrier. Furthermore, we could show that 
the application of compounds like the LAT1-specific small molecule inhibitor JPH203 or 
the less specific System L transport inhibitor JX009, allows for distinguishing the 
contribution of single leucine transporters across the placental barrier. The combined 
application of the LAT1-specific inhibitor JPH203 and the System L-inhibitor JX009 in 
Transwell® studies identified LAT1 as major leucine transporter having an essential role in 
the materno-fetal supply of essential amino acids at the MVM and demonstrated the 
usefulness of applying small-compound inhibitors bearing different specificities. The 
identification of new lead structures or the further advancement of existing inhibitors 
targeting System L-facilitators such as LAT3 and LAT4 could be valuable tools for assessing 
the relevance of single transporters in materno-fetal amino acid transfer. From a 
pharmacological point of view, a better understanding of the SLC7 transporter-mediated 
supply of amino acids and its impact on pregnancy diseases including IUGR and GDM could 
be a first step towards the optimization of fetal growth and its effect on fetal programming 
in future. Due to the successful application of SLC7-specific small molecule inhibitors, we 
could partially confirm the third and last hypothesis in the amino acid transport part: 
“Specific inhibition of SLC7 transporters or knockout of single transporter genes can reveal 
the relevance of single solute carriers in placental nutrient acquisition.” Of note, the short-
term treatment with small molecule inhibitors exhibiting different specificities also 
reduces the risk of impacting trophoblast fusion and differentiation as for example with 
long-term gene silencing or constitutive knockout. 
5.2 Iron transport 
The findings outlined in this thesis explain clinical observations associating GDM with 
dysregulated placental iron homeostasis on a cellular and mechanistic level. Our study 
was based on a well-characterized clinical cohort, and combines clinical observations, 
analysis of clinical samples with complementary investigations using in vitro cell models. 
The newly established hyperglycemic cell models showed expressional changes which 
closely resembled the alterations observed in GDM tissues allowing novel mechanistic 
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insights. Due to the study design, we were not able to analyze additional iron-related 
blood parameters such as ferritin levels, Tf saturation or blood status of the newborns. 
We found in GDM significant differences in the expression, trafficking and function of 
proteins involved in the uptake, transport, sensing, and regulation of iron, which clearly 
confirmed the first hypothesis of the iron transport part: “The expression of placental 
iron-transporters and iron-regulatory proteins is altered in GDM.” Newly established 
trophoblast cell models exposed to hyperglycemic culture conditions, but also obesogenic 
HFHS diet in wildtype mice, mimicked to a great extent the expression patterns found in 
the clinical specimens of GDM patients at term. This strengthens the validity of our results 
and demonstrates the significance of our findings. Cellular adaption to GDM-like 
conditions reduced placental iron uptake by mechanisms involving alterations in 
autophagy and oxidative stress pathways. These adaptations could be part of a protective 
mechanism preventing oxidative damage for both the fetus and the placenta caused by 
hyperglycemia and highly oxidative iron. Hence, a putative and clinically relevant relation 
between hyperglycemia and altered iron transport in trophoblast was functionally 
characterized, confirming the second iron transport hypothesis; “Simulation of 
hyperglycemic and hyperlipidemic conditions in trophoblasts induces cellular stress and 
affects iron uptake.” The almost complete reversion of hyperglycemic effects on placental 
iron homeostasis gene expression in trophoblasts after antioxidant treatment suggests 
beneficial effects of antioxidant supplementation in pregnant women with increased risk 
to develop GDM. Taken together these results confirm the last hypothesis: “The reduction 
of cellular stress levels recues placental iron homeostasis.” Such antioxidant treatment 
could and should be further investigated using the HFHS mouse model spontaneously 
developing GDM-like changes in iron homeostasis gene expression patterns. 
The herein identified adaptive processes of the placenta in GDM are presumably part of a 
protective mechanism preventing oxidative damage for both the fetus and the placenta 
caused by hyperglycemia and highly oxidative iron. On the other side, these findings also 
raise potential concerns regarding the recommendation of routine iron-supplementation 
among iron-replete pregnant women. Importantly, our results suggest that antioxidant 
supplementation could be beneficial for pregnant women with increased risk to develop 
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GDM by protecting the placenta and fetus against oxidative stress caused by 
hyperglycemia, high iron status or both.  
5.3 CRISPR/Cas9-mutagenesis of placental SLC transporter 
Within this smaller and more methodologically oriented part of the PhD thesis, we aimed 
to target single genes relevant for leucine and iron transport across the placenta by 
CRISPR/Cas9-mutagenesis. Trophoblast cells lacking the function of single nutrient 
transporter by specifically and CRISPR/Cas9-mediated knockout, would reveal their role 
at the materno-fetal barrier in the placenta. The generation of such SLC-knockout 
trophoblast cell lines could have helped to unravel the causes and consequences 
associated with impaired transfer of nutrients in specific pregnancy diseases. Probably 
due to failed introduction of functionally active sgRNA into BeWo cells, we were 
unfortunately not yet able to generate knockout cell lines. However, extensive 
optimization of target site validation, the establishment of transfection and 
characterization procedures of potential CRISPR/Cas9-mutant candidates on expressional 
and functional level set the stage for successful future studies in this context. In fact, we 
have created an advanced toolbox for a successful continuation of nutrient transporter 
characterization by CRISPR/Cas9-mediated mutagenesis in human trophoblasts. This may 
help to delineate the role of single placental nutrient transporters in a cell biological 
context. 
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6 Perspectives 
The work presented in this thesis has shed light on specific molecular mechanisms related 
to transplacental transfer of amino acids and iron, but it has also raised several questions 
which should be addressed in future investigations. In the first part of this thesis, amino 
acid concentrations in fetal and maternal blood from uncomplicated pregnancies were 
measured and investigated by correlation analysis. To complement the amino acid 
concentrations measurement, LC-MS/MS-based quantification of cysteine and its 
metabolic products in serum should be intensified to provide additional information 
about the unexpectedly low cysteine concentrations in all analyzed samples. Moreover, 
LC-MS/MS-based amino acid quantification would further allow the assessment of the full 
amino acid spectra in the fetal and maternal compartments of a Transwell® experiment 
without depending on radio-labeled amino acid derivates as detectable substrate after 
placental transfer. With this analytical advancement the monitoring of amino acid fluxes 
and their metabolism would be feasible. In this system the clinically relevant System L-
mediated transport across the placenta could be investigated under physiological or even 
pathophysiological conditions. Additionally, it could be tested whether an in vitro 
placental barrier is able to create amino acid gradients which has never been 
demonstrated before.  
In our amino acid studies we identified two states into which healthy human term 
placentae could be categorized, namely either an accumulative (positive FV-FA difference) 
or a secretory (negative FV-FA difference) mode suggesting a temporary switch between 
accumulation and secretion phases in placental amino acid transfer. This should be 
confirmed by in vivo determination of FV-FA differences during pregnancy which could be 
achieved by using in utero cordocentesis at different gestational stages (Irene Cetin et al. 
1990; McIntosh, Rodeck, and Heath 1984). Within the correlation studies, we found, 
beside associations between materno-fetal gradients and maternal pregnancy weights, 
also strong positive correlations with maternal systolic blood pressure at term. Based on 
this finding, it would be interesting to compare materno-fetal amino acid gradients 
between preeclampsia patients and a healthy control group within a prospective study. 
This would allow to assess at an early stage of pregnancy, whether materno-fetal amino 
Perspectives - CRISPR/Cas9-mutagenesis of placental SLC transporter 
168 
acid gradients are altered in pregnancies that subsequently develop hypertension and 
become preeclamptic later in pregnancy (Sibai 2012).  
In the last chapter of the amino acid part, we demonstrated the benefit of applying small 
molecule inhibitors bearing different nutrient transporter specificities. Of note, there are 
currently new inhibitor lead compounds, and, interestingly, also new SLC7 transport 
activators in the pipeline of the SLC7 project of NCCR TransCure (https://www.nccr-
transcure.ch/research/projects/slc7-family-amino-acid-transporters/). These compounds 
are currently being studied by other investigators in the context of cancer therapy 
strategies. These newly developed compounds could be valuable tools for the 
transporter-specific investigation of placental amino acid transfer as shown for inhibitors 
within this project. Moreover, potent and safe activators of System L transporters should 
be investigated in the context of placental biology since such compounds could be 
interesting future drug candidates for the treatment of reduced fetal growth in IUGR.  
In the second part of this PhD thesis, we investigated the relation between GDM and 
dysregulated placental iron homeostasis by analyzing human placentae. Due to the 
retrospective study design, we were not able to measure additional iron-related blood 
parameters such as ferritin levels, Tf saturation or blood status of the newborns. These 
parameters, however, would give valuable important additional information and could 
support the current findings of altered placental iron homeostasis suggested in this study. 
In this context, it would be beneficial to organize a prospective clinical study in 
collaboration with the collaborating hospitals in Bern. Herein glucose tolerance tests and 
the collection of maternal / fetal blood for the determination of systemic iron status 
should be performed. These parameters should be combined with the expressional and 
functional assessment of the corresponding placentae and isolated primary trophoblasts 
cells as well as iron transport studies in villous explants and placental dual-perfusion. The 
combination of all these ex vivo methods, that are already established in the Albrecht 
laboratory, could shed more light on the molecular pathways disturbed in GDM. 
Moreover, these in vitro and ex vivo model systems would allow to investigate iron 
transporter expressional changes and/or functional transport time courses in 
combination with the application of exogenous stress such as oxidative stress, hypoxia, 
hyperglycemia or hyperlipidemia. Additionally, the effects of iron depletion by DFO 
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treatment or increased antioxidative potential by NaSe supplementation could be further 
elaborated. Another approach which should be followed-up is to design experiments with 
mice developing GDM during pregnancy. The further establishment of diets, such as HFHS 
to induce GDM in wildtype mice or to test antioxidative treatments in these mice would 
allow to characterize effects on fetal growth and could provide deeper insights into the 
relationship between placental glucose and iron homeostasis. Within future studies to 
investigate the association between placental glucose and iron homeostasis, there should 
be a special focus on the ferroptosis pathway. To date hyperglycemia is not characterized 
as known promotor of ferroptosis, but our results strongly suggest disturbed 
transplacental iron transport, GSH depletion and increased lipid peroxidation as mediator 
between hyperglycemia and altered placental iron homeostasis.  
There are also open questions concerning the placental iron transfer on a cellular level. 
As emphasized in the introduction section of this thesis, a systematic approach to localize 
all proteins potentially involved in placental iron uptake and transfer across the placental 
barrier including alternative heme- and non-heme-iron transporter, receptors, 
chaperones, storage proteins, reductases and oxidases, would inspire the whole field of 
placental nutrient transport research. Isolation of different plasma and endosomal 
membranes for expressional studies, confocal microscopy on placental tissue and 
trophoblasts in the Transwell® system, preferentially with experts for correlative light and 
electron microscopy such as Prof. Wanda Kukulski, who recently joined our institute, 
would be a promising strategy of to achieve these goals. 
Different technical approaches or the refinement and optimization of the current 
methodology is also needed for the generation of knockout cell lines for nutrient 
transporters by CRISPR/Cas9 mutagenesis. Although we adapted and optimized the 
strategy and corresponding protocols to generate SLC transporter-specific trophoblast 
knockout cell lines by CRISPR/Cas9 mutagenesis, we were not able to produce stable 
BeWo cells bearing loss-of-function mutations. Our results in this context suggest a 
problem with the transfection and/or the activity of the in vitro synthesized sgRNA. To 
overcome this problem, we need to guarantee the introduction of functional sgRNA into 
the cell. As a first approach, we recommend to further optimize the transfection by using 
plasmids expressing both guide RNA and Cas9-GFP. Alternatively, commercially available 
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kits should be carefully selected and tested for successful CRISPR/Cas9 mutagenesis of 
nutrient transporters.  
In parallel to the CRISPR/Cas9 approach in this PhD project, the Albrecht laboratory 
started to establish placenta specific knockout mouse models targeting DMT1 and ZIP8 
with support from Prof. Willy Hofstetter, University of Bern, and Prof. Mitchell D. Knutson, 
University of Florida. To generate placenta specific DMT1-/- and Zip8-/- mice, we utilize 
mice expressing cre recombinase under the control of the mouse glial cells missing 
homolog 1 promoter (Tg(Gcm1-cre)1Chrn/J), which specifically expresses the Cre 
recombinase in syncytiotrophoblast layer II cells of the labyrinth in mouse placenta (V. 
Nadeau et al. 2009; Valérie Nadeau and Charron 2014). Gcm1-cre mice (Zip8+/+; 
Gcm1Cretg/+) will be crossed with Zip8flox/flox (Zip8flox/flox;Gcm1Cre+/+) to finally generate 
female mice that produce Zip8flox/flox;Cretg/+ embryos under time controlled mating. Using 
this approach, we lose Dmt1 or Zip8 expression only in trophoblasts, that are responsible 
for nutrient transfer in mice. Importantly, this time-controlled mating approach allows the 
investigation of mouse embryos at defined developmental stages. The fetuses will be 
thoroughly characterized for changes in glucose and iron homeostasis. This will 
complement our data generated in humans and will eventually provide new insights into 
the role of the placenta in materno-fetal iron transfer. 
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